

# Cancer

PRESENTED BY AMERICA'S BIOPHARMACEUTICAL RESEARCH COMPANIES

## Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer

Few things cause patients more fear and apprehension than a cancer diagnosis. But today—because of early detection and a steady stream of new and improved treatments—cancer increasingly can be managed and even beaten. President Obama has called for a cancer cure in our lifetime, patients and their families are looking for more and better treatments, and America's pharmaceutical research and biotechnology companies are responding.

Biopharmaceutical researchers are now working on 887 medicines for cancer. Many are high-tech weapons to fight the disease, while some involve innovative research into using existing medicines in new ways.


The medicines in development—all in either clinical trials or under Food and Drug Administration review—include among others 98 for lung cancer, the leading cause of cancer death in the United States, and 91 for breast cancer, which is expected to strike more than 200,000 American women each year. The medicines in development also include 80 for prostate cancer, which is expected to kill more than 32,000 American men each year, and 55 for colorectal cancer, the third most common cancer in both men and women in this country.

A deep commitment to patients and research is at the core of the remarkable progress made in fighting cancer that has led to declines in cancer deaths. According to the National Cancer Institute, cancer deaths in the United States decreased 1.6 percent per year from 2001-2006. Meanwhile, the number of cancer survivors living in the United States has increased from 3 million in 1971 to 11.7 million in 2007. The increase in survivors is attributed in large measure to earlier diagnosis and detection and better treatments and follow-up care.

America's pharmaceutical research companies are working on many new cutting edge approaches to fight cancer. They include:

- A medicine that interferes with the metabolism of cancer cells by depriving them of energy from glucose.
- A medicine designed to induce a powerful immune response to melanoma.
- A potential first-line treatment (meaning it's given to patients before any other treatment) and first-in-class

### MEDICINES IN DEVELOPMENT FOR CANCER\*



\*Some medicines are listed in more than one category.

medicine designed to target specific cancer cells and kill them, then activate the patient's general immune system to destroy any remaining cancer cells.

- A therapy that uses new nanotechnology that enhances the delivery of medicine to the patient, overcoming obstacles in existing treatments.

Despite progress, cancer remains the second leading cause of death by disease in the United States, exceeded only by heart disease. In 2010, some 569,490 Americans were expected to die of cancer—more than 1,500 people a day. The hundreds of new medicines to treat cancer now being developed by the biopharmaceutical research industry demonstrate our commitment to meeting patient needs. They are our best hope for lessening the burden of cancer to patients, their families and society.

John Castellani  
President and CEO  
PhRMA

# Medicines in Development for Cancer

## BLADDER CANCER

Product Name	Sponsor	Indication	Development Status*
<b>Abraxane®</b> albumin-bound paclitaxel	Celgene <i>Summit, NJ</i>	(see also lung, ovarian, pancreatic, skin)	Phase II (908) 673-9000
AEZS-108	AEterna-Zentaris <i>Warren, NJ</i>	(see also prostate)	Phase I/II (908) 626-5428
apaziquone	Allergan <i>Irvine, CA</i> Spectrum Pharmaceuticals <i>Irvine, CA</i>	non-invasive bladder cancer (Fast Track)	Phase III (949) 788-6700
BC-819	BioCancell Therapeutics <i>Jerusalem, Israel</i>	(see also ovarian, pancreatic)	Phase II <a href="http://www.biocancell.com">www.biocancell.com</a>
CDX-1307	Celldex Therapeutics <i>Needham, MA</i>	first-line bladder cancer	Phase II (781) 433-0771
<b>Chemophase™</b> hyaluronidase	Halozyne Therapeutics <i>San Diego, CA</i>	superficial bladder cancer	Phase I/II completed (858) 794-8889
EN3348	Endo Pharmaceuticals <i>Chadds Ford, PA</i>	(Fast Track)	Phase III (610) 558-9800
<b>Erbix®</b> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also breast, head/neck, lung)	Phase II (212) 546-4000 (800) 545-5979 (212) 645-1405
eribulin (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	(see also lung, prostate, sarcoma)	Phase II (888) 422-4743
<b>Foloty®</b> pralatrexate (Orphan Drug)	Allos Therapeutics <i>Westminster, CO</i>	(see also breast, lung, lymphoma)	Phase II (303) 426-6262
OGX-427	Oncogenex Pharmaceuticals <i>Bothell, WA</i>	(see also breast, lung, ovarian, prostate)	Phase I (425) 686-1500
<b>Tarceva®</b> erlotinib	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	(see also brain, breast, colorectal, head/neck, leukemia, liver, lung, other)	Phase II (650) 224-1000 (800) 572-1932
tesetaxel	Genta <i>Berkeley Heights, NJ</i>	advanced bladder cancer (see also breast, prostate, skin, stomach)	Phase II (908) 286-9800
VB4-845	Viventia Biotechnologies <i>Mississauga, Canada</i>	(see also head/neck)	Phase II (905) 362-2973

\* For more information about a specific medicine in this report, please call the telephone number listed.

## BRAIN CANCER

Product Name	Sponsor	Indication	Development Status
8H9 mAb	United Therapeutics <i>Silver Spring, MD</i>	(see also sarcoma, other)	Phase I (301) 608-9292
ABT-888 (veliparib)	Abbott Laboratories <i>Abbott Park, IL</i>	(see also breast, colorectal, ovarian, prostate, skin, other)	Phase I (847) 937-6100
AC480	Ambit Biosciences <i>San Diego, CA</i>	glioma (see also solid tumors)	Phase I (858) 334-2100
AAE788	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	glioblastoma multiforme	Phase I/II (888) 669-6682
antineoplaston- AS2-1 IV <b>(Orphan Drug)</b>	Burzynski Research Institute <i>Houston, TX</i>	glioma	Phase II (713) 335-5697
APN301 (hu14.18-IL2)	Apeiron Biologics <i>Vienna, Austria</i>	neuroblastoma (see also skin)	Phase II completed <a href="http://www.apeiron-biologics.com">www.apeiron-biologics.com</a>
AR-67	Arno Therapeutics <i>Parsippany, NJ</i>	glioblastoma (see also other)	Phase I (862) 703-7170
ARC-100	Archer Biosciences <i>New York, NY</i>	glioblastoma, medulloblastoma, neuroblastoma (see also pancreatic, prostate, skin)	Phase II (616) 747-9090
AT-101	Ascenta Therapeutics <i>Malvern, PA</i>	glioblastoma (see also leukemia, lung, lymphoma, prostate, stomach)	Phase II (610) 408-0313
AV-299 (ficlatuzumab)	AVEO Pharmaceuticals <i>Cambridge, MA</i>	recurrent glioblastoma (see also lymphoma, multiple myeloma, solid tumors)	Phase I (617) 299-5000
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	first-line glioblastoma multiforme (see also breast, colorectal, lung, ovarian, other)	Phase III (650) 225-1000
<b>Azedra™</b> iodine-labeled metaiodobenzyl- guanidine	Molecular Insight Pharmaceuticals <i>Cambridge, MA</i>	neuroblastoma in children (Fast Track) (see also other)	Phase II completed (617) 492-5554
<b>Azixa™</b> verubulin	Myrexix <i>Salt Lake City, UT</i>	glioblastoma, metastatic brain cancer (Fast Track) (see also skin)	Phase II (801) 214-7800
berubicin <b>(Orphan Drug)</b>	Reata Pharmaceuticals <i>Dallas, TX</i>	brain metastases, recurrent primary brain cancer	Phase II (972) 865-2200
		glioma	Phase I (972) 865-2200
BIBW 2992 (afatinib)	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	glioblastoma (see also breast, head/neck, lung)	Phase I/II (800) 243-0127
BMS-844203 (VEGF R-2 adnectin)	Bristol-Myers Squibb <i>Princeton, NJ</i>	recurrent glioblastoma (see also colorectal, lung)	Phase II (212) 546-4000
		newly-diagnosed glioblastoma	Phase I (212) 546-4000

## BRAIN CANCER

Product Name	Sponsor	Indication	Development Status
ch14.18 mAb	United Therapeutics <i>Silver Spring, MD</i>	neuroblastoma in children	Phase III (301) 608-9292
cilengitide (Orphan Drug)	EMD Serono <i>Rockland, MA</i>	newly diagnosed glioblastoma (see also lymphoma, prostate)	Phase III (800) 283-8088
		recurrent glioblastoma	Phase II (800) 283-8088
cintredekin besudotox (Orphan Drug)	NeoPharm <i>Lake Bluff, IL</i>	glioma (Fast Track)	Phase I (847) 887-0800
<b>Cotara®</b> mAb TNT-1 (Orphan Drug)	Peregrine Pharmaceuticals <i>Tustin, CA</i>	recurrent glioblastoma (Fast Track)	Phase II (714) 508-6000
CPP-1X (eflornithine)	Cancer Prevention Pharmaceuticals <i>Tucson, AZ</i>	neuroblastoma	Phase I (520) 908-7774
<b>DCVax®-Brain®</b> brain cancer vaccine (Orphan Drug)	Northwest Biotherapeutics <i>Bothell, WA</i>	glioblastoma	Phase II (425) 608-3000
dendritic cell cancer vaccine	TriMed Biotech <i>Vienna, Austria</i>	glioblastoma	Phase II <a href="http://www.trimed-biotech.com">www.trimed-biotech.com</a>
<b>GliAtak™</b> gene therapy (Orphan Drug)	Advantagene <i>Auburndale, MA</i>		Phase I/II (617) 916-5445
GRN 1005	Geron <i>Menlo Park, CA</i>	glioma, metastatic brain cancer	Phase I/II (650) 473-7700
<b>Hiltonol®</b> poly-ICIC (Orphan Drug)	Oncovir <i>Washington, DC</i>	anaplastic astrocytoma, glioblastoma in adolescents and children	Phase II <a href="http://www.oncovir.com">www.oncovir.com</a>
<b>Hycamtin®</b> topotecan	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	metastatic brain cancer	Phase III (888) 825-5249
ICT-107 (cancer vaccine) (Orphan Drug)	ImmunoCellular Therapeutics <i>Woodland Hills, CA</i>	glioblastoma	Phase II (818) 992-2907
lenvatinib (E7080)	Eisai <i>Woodcliff Lake, NJ</i>	glioma (see also kidney, liver, ovarian, skin, other)	Phase II (888) 422-4743
<b>Levulan® Kerastick®</b> aminolevulinic acid	DUSA Pharmaceuticals <i>Wilmington, MA</i>	(see also skin)	Phase II (978) 657-7500
<b>Lucanix®</b> belagenpumatucel-L	NovaRx <i>San Diego, CA</i>	glioma (see also lung)	Phase I (858) 552-8600
motexafin gadolinium	Pharmacyclics <i>Sunnyvale, CA</i>	glioblastoma (combination therapy)	Phase II (408) 774-0330
nimotuzumab (Orphan Drug)	YM Biosciences USA <i>Lehigh Valley, PA</i>	brain metastases from non-small-cell lung cancer (NSCLC), recurrent glioma (see also breast, prostate)	Phase II (610) 560-0600

# BRAIN CANCER

Product Name	Sponsor	Indication	Development Status
patupilone (EPO906)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also liver)	Phase II (888) 669-6682
PD-0332991	Pfizer <i>New York, NY</i>	recurrent Rb-positive glioblastoma (see also breast, lymphoma, multiple myeloma, sarcoma)	Phase II (860) 732-5156
perifosine (KRX-0401)	AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i>	glioma (see also colorectal, kidney, leukemia, lymphoma, multiple myeloma, ovarian, sarcoma, stomach)	Phase II (212) 531-5965
prophage (vitespen) <b>(Orphan Drug)</b>	Agenus <i>Lexington, MA</i>	glioma (see also kidney, skin)	Phase II (781) 674-4400
Reolysin® reovirus	Oncolytics Biotech <i>Calgary, Canada</i>	glioma (see also colorectal, head/neck, lung, pancreatic, sarcoma, skin)	Phase I/II (403) 670-7377
rilotumumab	Amgen <i>Thousand Oaks, CA</i>	recurrent glioma (see also colorectal, lung, prostate, stomach)	Phase II (800) 772-6436
rindopepimut <b>(Orphan Drug)</b>	Celldex Therapeutics <i>Needham, MA</i>	newly diagnosed glioblastoma (Fast Track) (see also solid tumors)	Phase II (860) 732-5156
sagopilone	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	(see also breast, ovarian, prostate)	Phase II (888) 842-2937
SB-313-xTZ	Sangamo Biosciences <i>Richmond, CA</i>	glioblastoma	Phase I (510) 970-6000
SBG and cancer vaccine	Biotec Pharmacon <i>Tromsø, Norway</i>	neuroblastoma (pediatric)	Phase I/II www.biotec.no
SL-701 vaccine	Stemline Therapeutics <i>New York, NY</i>		Phase I/II completed (212) 831-1111
Sprycel® dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	glioblastoma (see also breast, colorectal, leukemia, lung, lymphoma, multiple myeloma, prostate, skin)	Phase I/II (212) 546-4000
tandutinib (MLN518)	Millennium Pharmaceuticals <i>Cambridge, MA</i>	glioblastoma, glioma	Phase II (800) 390-5663
Tarceva® erlotinib <b>(Orphan Drug)</b>	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	ependymoma, glioblastoma, late-stage brain metastases (see also bladder, breast, colorectal, head/neck, leukemia, liver, lung, other)	Phase II (650) 225-1000 (800) 572-1932
terameprocol (intravenous)	Erimos Pharmaceuticals <i>Houston, TX</i>	glioma (see also cervical, head/neck, solid tumors, other)	Phase I/II (713) 541-2000
Toca-511 (cytosine deaminase gene therapy)	Tocagen <i>San Diego, CA</i>	glioblastoma	Phase I/II (858) 412-8400

## BRAIN CANCER

Product Name	Sponsor	Indication	Development Status
<b>Trisenox®</b> arsenic trioxide	Cephalon <i>Frazer, PA</i>	glioma (see also leukemia, multiple myeloma)	Phase I (610) 344-0200
VB-111	VBL Therapeutics <i>Or Yehuda, Israel</i>	glioblastoma (see also other)	Phase I/II www.vblrx.com
<b>Xeloda®</b> capecitabine	Roche <i>Nutley, NJ</i>	newly-diagnosed glioma	Phase I (973) 235-5000

## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
18F-fluorothymidine	Merck <i>Whitehouse Station, NJ</i>	diagnosis of breast cancer	Phase II (800) 672-6372
abiraterone acetate (CB7630)	Cougar Biotechnology <i>Raritan, NJ</i>	(see also prostate)	Phase I/II (800) 817-5286
ABT-869 (linifarib)	Abbott Laboratories <i>Abbott Park, IL</i>	(see also colorectal, kidney, liver, lung)	Phase II (847) 937-6100
ABT-888 (veliparib)	Abbott Laboratories <i>Abbott Park, IL</i>	(see also brain, colorectal, ovarian, prostate, skin, other)	Phase II (847) 937-6100
acolibifene	EndoCeutics <i>Quebec City, Canada</i>	prevention of breast cancer	Phase II (418) 653-0033
aderbasib (INCB7839)	Incyte <i>Wilmington, DE</i>		Phase II (302) 498-6700
AE-37	Antigen Express <i>Worcester, MA</i>	(see also ovarian)	Phase II (508) 852-8783
afimoxifene	ASCEND Therapeutics <i>Herndon, VA</i>	breast cancer prevention	Phase II (703) 471-4744
<b>Afinitor®</b> everolimus	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also kidney, liver, lymphoma, stomach, other)	Phase III (888) 669-6682
AMG 386	Amgen <i>Thousand Oaks, CA</i>	(see also colorectal, kidney, liver, ovarian, stomach, other)	Phase II (800) 772-6436
AMG 479 (ganitumab)	Amgen <i>Thousand Oaks, CA</i>	(see also colorectal, lung, pancreatic, sarcoma, other)	Phase II (800) 772-6436
anti-CD3 anti-HER/neu activated T-cells	TransTarget <i>Hillsborough, CA</i>	metastatic breast cancer	Phase II
ARRY-380	Array BioPharma <i>Boulder, CO</i>		Phase I (303) 381-6600
AUY922	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also colorectal, lung, multiple myeloma, stomach)	Phase II (888) 669-6682
AV-951 (tivozanib)	AVEO Pharmaceuticals <i>Cambridge, MA</i>	(see also kidney, lung, stomach)	Phase I/II (617) 299-5000

# BREAST CANCER

Product Name	Sponsor	Indication	Development Status
Avastin® bevacizumab	Genentech <i>South San Francisco, CA</i>	first-line metastatic breast cancer (with <b>Xeloda</b> ®) (see also brain, colorectal, lung, other)	Phase III (650) 225-1000
		HER2-positive breast cancer (adjuvant therapy), triple-negative breast cancer (adjuvant therapy), HER2-negative breast cancer (adjuvant therapy)	Phase III (650) 225-1000
		first-line HER2-positive metastatic breast cancer (with <b>Herceptin</b> ®)	Phase III (650) 225-1000
AZD8931 (erbB kinase inhibitor)	AstraZeneca <i>Wilmington, DE</i>	breast cancer (see also solid tumors)	Phase II (800) 236-9933
BIBW 2992 (afatinib)	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	metastatic breast cancer (see also brain, head/neck, lung)	Phase III (800) 243-0127
BKM120	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also solid tumors)	Phase I/II (888) 669-6682
BMS-690514 (HER/VEGFR2 inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>	metastatic breast cancer (see also lung)	Phase II (212) 546-4000
BMS-754807 (IGF-1R antagonist)	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also solid tumors)	Phase II (212) 546-4000
breast cancer vaccine	Quantum Immunologics <i>Tampa, FL</i>		Phase I/II (866) 213-4594
BTSCAN	Molecular Targeting Technologies <i>West Chester, PA</i>	diagnosis of breast cancer	Phase I (610) 738-7938
BZL-101	Bionovo <i>Emeryville, CA</i>		Phase I (510) 601-2000
CDX-011	Celldex Therapeutics <i>Needham, MA</i>	(Fast Track) (see also skin)	Phase II (781) 433-0771
CNF-2024	Biogen Idec <i>Weston, MA</i>	(see also stomach)	Phase II (781) 464-2000
dalotuzumab	Merck <i>Whitehouse Station, NJ</i>	(see also colorectal, lung, pancreatic, other)	Phase I/II (800) 672-6372
dinaciclib	Merck <i>Whitehouse Station, NJ</i>	(see also leukemia, lung, lymphoma)	Phase II (800) 672-6372
DPX-0907	Immunovaccine <i>Halifax, Canada</i>	(see also ovarian, prostate)	Phase I (902) 492-1819



## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
<b>Erbix<sup>®</sup></b> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also bladder, head/neck, lung)	Phase II (212) 546-4000 (800) 545-5979 (212) 645-1405
EVO 022	Evolve Oncology <i>New York, NY</i>		in clinical trials (646) 723-8941
EVO 033	Evolve Oncology <i>New York, NY</i>		in clinical trials (646) 723-8941
<b>Exelbine<sup>™</sup></b> vinorelbine emulsion	ADVENTRX Pharmaceuticals <i>San Diego, CA</i>	(see also lung, lymphoma)	application submitted (858) 552-0866
EZN-2208	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	metastatic breast cancer (see also colorectal, solid tumors)	Phase II (908) 541-8600
<b>Foloty<sup>®</sup></b> pralatrexate	Allos Therapeutics <i>Westminster, CO</i>	(see also bladder, lung, lymphoma)	Phase II (303) 426-6262
ganetespib	Synta Pharmaceuticals <i>Lexington, MA</i>	(see also colorectal, lung, stomach, other)	Phase II (781) 274-8200
GDC-0941 (PI3 kinase inhibitor)	Genentech <i>South San Francisco, CA</i>	metastatic breast cancer (see also lung, lymphoma, solid tumors)	Phase I (650) 224-1000
GDC-0980 (PI3 kinase/mTOR dual inhibitor)	Genentech <i>South San Francisco, CA</i>	late-stage breast cancer (see also lymphoma, solid tumors)	Phase I (650) 224-1000
GRN-163L (imetelstat)	Geron <i>Menlo Park, CA</i>	(see also leukemia, lung, multiple myeloma)	Phase II (650) 473-7700
<b>GVAX<sup>®</sup> Breast</b>	BioSante Pharmaceuticals <i>Lincolnshire, IL</i>	(see also colorectal, leukemia, multiple myeloma, pancreatic)	Phase I (847) 478-0500
<b>Herceptin<sup>®</sup> SC</b> rHuPH20/ trastuzumab	Halozyne <i>San Diego, CA</i> Roche <i>Nutley, NJ</i>	HER2-positive breast cancer	Phase III (858) 794-8889 (973) 235-5000
IMT-1012 (immunotherapeutic vaccine)	Immunotope <i>Doylestown, PA</i>	(see also ovarian)	Phase I (215) 253-4180
iniparib (BSI-201)	BiPar Sciences <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i>	metastatic triple negative breast cancer (see also lung, ovarian)	Phase III (800) 633-1810
		neoadjuvant breast cancer	Phase II (800) 633-1810
<b>Ixempra<sup>®</sup></b> ixabepilone	Bristol-Myers Squibb <i>Princeton, NJ</i>	early-stage breast cancer (see also lung, stomach, other)	Phase II/III (212) 546-4000
KW-2450	Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i>		Phase I/II (609) 919-1100



## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
LEP-ETU	NeoPharm <i>Lake Bluff, IL</i>		Phase II (847) 887-0800
LOR-2040	Lorus Therapeutics <i>Toronto, Canada</i>	metastatic breast cancer (see also colorectal, kidney, leukemia)	Phase II (416) 798-1200
<b>Lymphoseek™</b>	Neoprobe <i>Dublin, OH</i>	diagnosis of breast cancer (see also head/neck, skin)	Phase III (800) 793-0079
MK-0752	Merck <i>Whitehouse Station, NJ</i>	(see also solid tumors)	Phase I (800) 672-6372
MK-2206	Merck <i>Whitehouse Station, NJ</i>	(see also colorectal, other)	Phase I (800) 672-6372
MM-111	Merrimack Pharmaceuticals <i>Cambridge, MA</i>	(see also solid tumors)	Phase I/II (617) 441-1000
motesanib (AMG 708)	Amgen <i>Thousand Oaks, CA</i> Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also lung)	Phase II (800) 772-6436 (800) 390-5663
<b>Myocet™</b> doxorubicin liposomal	Spherion Therapeutics <i>Princeton, NJ</i>	(Fast Track)	Phase III (609) 986-2021
neratinib (HKI272)	Pfizer <i>New York, NY</i>	early-stage breast cancer, late-stage breast cancer	Phase III (860) 732-5156
<b>NeuVax™</b> E75 cancer vaccine	Apthera <i>Scottsdale, AZ</i>	(see also prostate)	Phase II <a href="http://www.apthera.com">www.apthera.com</a>
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i>	(see also colorectal, kidney, liver, lung, ovarian, other)	Phase II (888) 842-2937 (510) 597-6500
nimotuzumab	YM Biosciences USA <i>Lehigh Valley, PA</i>	(see also brain, prostate)	Phase I completed (610) 560-0600
NK-012	Nippon Kayaku <i>Tokyo, Japan</i>	(see also lung)	Phase II
NKTR-102	Nektar Therapeutics <i>San Francisco, CA</i>	(see also colorectal, ovarian)	Phase II (415) 482-5300
NOV-002	Novelos Therapeutics <i>Newton, MA</i>	early-stage breast cancer (see also ovarian)	Phase II (617) 244-1616
OBP-301	Oncolys Biopharma <i>Tokyo, Japan</i>	(see also head/neck, lung)	Phase I <a href="http://www.oncolys.com">www.oncolys.com</a>
OGX-427	Oncogenex Pharmaceuticals <i>Bothell, WA</i>	(see also bladder, lung, ovarian, prostate)	Phase I (425) 686-1500
OPT-822/OPT-821	Optimer Pharmaceuticals <i>San Diego, CA</i>		Phase I (858) 909-0736

## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
PD-0332991	Pfizer New York, NY	(see also brain, lymphoma, multiple myeloma, sarcoma)	Phase I/II (860) 732-5156
pertuzumab (RG 1273)	Roche Nutley, NJ	first-line metastatic HER2-positive breast cancer	Phase III (973) 235-5000
		early HER2-positive breast cancer, metastatic breast cancer	Phase II (973) 235-5000
PF-01367338	Pfizer New York, NY	(see also ovarian, skin)	Phase II (860) 732-5156
<b>Pixuvri™</b> pixantrone	Cell Therapeutics Seattle, WA	metastatic breast cancer (see also lymphoma)	Phase II (800) 215-2355
PTC299	PTC Therapeutics South Plainfield, NJ	(see also skin, solid tumors, other)	Phase I/II (908) 222-7000
PX-1032 (HER2 breast cancer vaccine)	BN ImmunoTherapeutics Mountain View, CA		Phase I (650) 681-4660
<b>Quinamed®</b> amonafile	ChemGenex Pharmaceuticals Menlo Park, CA	(see also ovarian, prostate)	Phase II (650) 474-9800
ramucirumab (IMC-1121B)	Eli Lilly Indianapolis, IN ImClone Systems New York, NY	(see also colorectal, liver, lung, stomach)	Phase III (800) 545-5979 (212) 645-1405
<b>Reximmune-C™</b> personalized cancer vaccine	Epeius Biotechnologies San Marino, CA		Phase I/II (626) 441-6695
<b>Rexin-G™</b> tumor-targeted gene therapy	Epeius Biotechnologies San Marino, CA	recurrent, refractory metastatic breast cancer (see also pancreatic, sarcoma)	Phase I/II (626) 441-6695
ridaforolimus	Merck Whitehouse Station, NJ	(see also lung, sarcoma)	Phase II (800) 672-6372
sagopilone	Bayer HealthCare Pharmaceuticals Wayne, NJ	(see also brain, ovarian, prostate)	Phase II completed (888) 842-2937
SAR256212 (MM-121)	Merrimack Pharmaceuticals Cambridge, MA sanofi-aventis Bridgewater, NJ	(see also ovarian, solid tumors)	Phase II (617) 441-1000 (800) 633-1810
SF1 (sonodynamic therapy)	SonneMed Boston, MA	advanced breast cancer	Phase I/II www.sonnemed.com
SNDX-275 (entinostat)	Syndax Pharmaceuticals Waltham, MA	(see also colorectal, leukemia, lymphoma, lung)	Phase II (781) 419-1400
<b>Sprycel®</b> dasatinib	Bristol-Myers Squibb Princeton, NJ	(see also brain, colorectal, leukemia, lung, lymphoma, multiple myeloma, prostate, skin)	Phase II (212) 546-4000

## BREAST CANCER

Product Name	Sponsor	Indication	Development Status
<b>Tarceva</b> <sup>®</sup> erlotinib	Genentech South San Francisco, CA OSI Pharmaceuticals Melville, NY	(see also bladder, brain, colorectal, head/neck, leukemia, liver, lung, other)	Phase II (650) 224-1000 (800) 572-1932
TAS-108	Taiho Pharma USA Princeton, NJ		Phase II (609) 750-5300
tesetaxel	Genta Berkeley Heights, NJ	advanced breast cancer (see also bladder, prostate, skin, stomach)	Phase II (908) 286-9800
<b>ThermoDox</b> <sup>®</sup> LTSDEL	Celsion Columbia, MD	recurrent breast cancer (see also liver)	Phase I/II (410) 290-5390
trabectedin	Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ	metastatic breast cancer (see also ovarian, prostate, sarcoma)	Phase III (800) 817-5286
trastuzumab-DM1	Roche Nutley, NJ	advanced metastatic HER2-positive breast cancer, metastatic HER2-positive breast cancer	Phase III (973) 235-5000
		early HER2-positive breast cancer	Phase II (973) 235-5000
<b>Tykerb</b> <sup>®</sup> lapatinib	GlaxoSmithKline Rsch. Triangle Park, NC	breast cancer (adjuvant therapy) (see also head/neck, stomach)	Phase III (888) 825-5249
<b>Votrient</b> <sup>®</sup> pazopanib and <b>Tykerb</b> <sup>®</sup> lapatinib	GlaxoSmithKline Rsch. Triangle Park, NC	inflammatory breast cancer (see also kidney, ovarian, sarcoma)	Phase III (888) 825-5249
WX-671	Wilex Munich, Germany	metastatic breast cancer	Phase II www.wilex.com
YM-155	Astellas Pharma US Deerfield, IL	(see also lymphoma)	Phase II (800) 727-7003
ZIO-301 (indibulin)	ZIOPHARM Oncology New York, NY	late-stage breast cancer	Phase I/II (646) 214-0700
<b>Zolinza</b> <sup>®</sup> vorinostat	Merck Whitehouse Station, NJ	(see also multiple myeloma, other)	Phase II (800) 672-6372

## CERVICAL CANCER

Product Name	Sponsor	Indication	Development Status
ADXS-11001	Advaxis North Brunswick, NJ	cervical intraepithelial neoplasia	Phase II (732) 545-1590
interferon alpha-2b topical	Helix BioPharma Aurora, Canada	cervical dysplasia	Phase II completed (905) 841-2300
PM-00104	PharmaMar USA Cambridge, MA	(see also other)	Phase II (617) 868-3797

## CERVICAL CANCER

Product Name	Sponsor	Indication	Development Status
PV701	Wellstat Biologics <i>Gaithersburg, MD</i>	(see also colorectal)	Phase II (240) 631-2500
terameprocol (intravaginal)	Erimos Pharmaceuticals <i>Houston, TX</i>	cervical intraepithelial neoplasia (see also brain, head/neck, solid tumors, other)	Phase II (713) 541-2000
TG4001	Transgene <i>Kensington, MD</i>	cervical intraepithelial neoplasia	Phase II (301) 816-5404
V503	Merck <i>Whitehouse Station, NJ</i>	cervical cancer prevention (see also other)	Phase III (800) 672-6372
V505	Merck <i>Whitehouse Station, NJ</i>	cervical cancer prevention	Phase II (800) 672-6372
VGX-3100	Inovio Pharmaceuticals <i>Blue Bell, PA</i>	cervical intraepithelial neoplasia	Phase II (267) 440-4200

## COLORECTAL CANCER

Product Name	Sponsor	Indication	Development Status
ABT-869 (linifanib)	Abbott Laboratories <i>Abbott Park, IL</i>	(see also breast, kidney, liver, lung)	Phase II (847) 937-6100
ABT-888 (veliparib)	Abbott Laboratories <i>Abbott Park, IL</i>	(see also brain, breast, ovarian, prostate, skin, other)	Phase II (847) 937-6100
aflibercept (VEGF-trap)	sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i>	second-line metastatic colorectal cancer (see also lung, prostate)	Phase III (800) 633-1610 (914) 345-7400
		first-line colorectal cancer	Phase II (800) 633-1610 (914) 345-7400
AMG 386	Amgen <i>Thousand Oaks, CA</i>	metastatic colorectal cancer (see also breast, kidney, liver, ovarian, stomach, other)	Phase II (800) 772-6436
AMG 479 (ganitumab)	Amgen <i>Thousand Oaks, CA</i>	(see also breast, lung, pancreatic, sarcoma, other)	Phase II (800) 772-6436
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	(see also kidney, liver, lung, pancreatic, sarcoma, other)	Phase II (781) 994-0300 (973) 944-2600
AUY922	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also breast, lung, multiple myeloma, stomach)	Phase I (888) 669-6682
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	metastatic colorectal cancer (see also brain, lung, ovarian, other)	Phase III (650) 225-1000
AVX701	AlphaVax <i>Rsch. Triangle Park, NC</i>	colorectal cancer prevention in patients with CEA-expressing malignancies	Phase I/II (919) 595-0400

## COLORECTAL CANCER

Product Name	Sponsor	Indication	Development Status
BAY 73-4506 (regorafenib)	Bayer HealthCare Pharmaceuticals Wayne, NJ	metastatic colorectal cancer (see also kidney, lung, stomach)	Phase III (888) 842-2937
BMS-844203 (VEGF R-2 adnectin)	Bristol-Myers Squibb Princeton, NJ	(see also brain, lung)	Phase II (212) 546-4000
BMS-908662 (RAF kinase inhibitor)	Bristol-Myers Squibb Princeton, NJ Exelixis South San Francisco, CA	(see also skin)	Phase I/II (212) 546-4000
conatumumab	Amgen Thousand Oaks, CA	(see also lung, pancreatic, sarcoma)	Phase II (800) 772-6436
CPX-1	Celator Pharmaceuticals Princeton, NJ		Phase II completed (609) 243-0123
CS-7017 (efatutazone)	Daiichi Sankyo Parsippany, NJ	(see also lung, other)	Phase II (973) 944-2600
CT-011	CureTech Yavne, Israel	(see also leukemia, lymphoma)	Phase II www.curetechbio.com
dalotuzumab	Merck Whitehouse Station, NJ	(see also breast, lung, pancreatic, other)	Phase II (800) 672-6372
<b>Davanat®</b> galactomannan C	Pro-Pharmaceuticals Newton, MA	(see also liver)	Phase II (617) 559-0033
dulanermin (rhApo2L/TRAIL)	Amgen Thousand Oaks, CA Genentech South San Francisco, CA	(see also lymphoma)	Phase I (800) 772-6436 (650) 225-1000
E7820	Eisai Woodcliff Lake, NJ		Phase I/II (888) 422-4743
EMD 525797 (DI17E6)	EMD Serono Rockland, MA		Phase II (800) 283-8088
encapsulated cell therapy (macrobeads)	Rogosin Institute New York, NY	refractory metastatic colorectal cancer (see also pancreatic, prostate)	Phase II (212) 746-1225
ensituximab	Neogenix Oncology Great Neck, NY	metastatic colorectal cancer (see also pancreatic)	Phase I (516) 482-1200
EZN-2208	Enzon Pharmaceuticals Bridgewater, NJ	metastatic colorectal cancer (see also breast, solid tumors)	Phase II (908) 541-8600
<b>Fusilev™</b> levoleucovorin (ready-to-use formulation)	Spectrum Pharmaceuticals Irvine, CA		application submitted (949) 788-6700
ganetespib	Synta Pharmaceuticals Lexington, MA	refractory metastatic colorectal cancer (see also breast, lung, stomach, other)	Phase II (781) 274-8200
GI-4000	GlobeImmune Louisville, CO	(see also lung, pancreatic)	Phase I (303) 625-2700

## COLORECTAL CANCER

Product Name	Sponsor	Indication	Development Status
<b>GVAX® Colorectal</b>	BioSante Pharmaceuticals <i>Lincolnshire, IL</i>	(see also breast, leukemia, multiple myeloma, pancreatic)	Phase I (847) 478-0500
IMO-2055 (EMD-1201081)	EMD Serono <i>Rockland, MA</i> Idera Pharmaceuticals <i>Cambridge, MA</i>	(see also head/neck, lung)	Phase I (800) 283-8088 (617) 679-5500
<b>Imprime PGG®</b>	Biothera <i>Eagan, MN</i>	(see also leukemia, lung, skin)	Phase III (651) 675-0300
JX-594	Jennerex Biotherapeutics <i>San Francisco, CA</i>	(see also liver)	Phase II (415) 281-8886
KRN-330	Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i>		Phase I/II (609) 919-1100
<b>Litx™</b> talaporfin	Light Sciences Oncology <i>Bellevue, WA</i>	metastatic colorectal cancer	Phase III (425) 957-8900
LOR-2040	Lorus Therapeutics <i>Toronto, Canada</i>	metastatic colorectal cancer (see also breast, kidney, leukemia)	Phase II (416) 798-1200
MK-2206	Merck <i>Whitehouse Station, NJ</i>	(see also breast, other)	Phase II (800) 672-6372
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i>	(see also breast, kidney, liver, lung, ovarian, other)	Phase II (888) 842-2837 (510) 597-6500
NKTR-102	Nektar Therapeutics <i>San Francisco, CA</i>	(see also breast, ovarian)	Phase II/III (415) 482-5300
<b>OncoVAX®</b> cancer vaccine	Vaccinogen <i>Frederick, MD</i>	stage II colorectal cancer (Fast Track)	Phase III (301) 668-8400
perifosine (KRX-1401)	Aeterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i>	refractory, metastatic colorectal cancer (Fast Track) (see also brain, kidney, leukemia, lymphoma, multiple myeloma, ovarian, sarcoma, stomach)	Phase III (212) 531-5965
picoplatin intravenous	Poniard Pharmaceuticals <i>San Francisco, CA</i>	(see also lung, ovarian, prostate)	Phase II (650) 583-3774
polyclonal antibody stimulator	Cancer Advances <i>Durham, NC</i>	(see also pancreatic, stomach)	Phase II (919) 361-2162
PV701	Wellstat Biologics <i>Gaithersburg, MD</i>	(see also cervical)	Phase II (240) 631-2500
ramucirumab (IMC-1121B)	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also breast, liver, lung, stomach)	Phase III (800) 545-5979 (212) 645-1405
<b>Reolysin®</b> reovirus	Oncolytics Biotech <i>Calgary, Canada</i>	(see also brain, head/neck, lung, pancreatic, sarcoma, skin)	Phase I (403) 670-7377
<b>RIGScan® CR49</b> radiodiagnostic agent	Neoprobe <i>Dublin, OH</i>	diagnosis of metastatic colorectal cancer	application submitted (800) 793-0079

## COLORECTAL CANCER

Product Name	Sponsor	Indication	Development Status
rilotumumab	Amgen <i>Thousand Oaks, CA</i>	metastatic colorectal cancer (see also brain, lung, prostate, stomach)	Phase II (800) 772-6436
SNDX-275 (entinostat)	Syndax Pharmaceuticals <i>Waltham, MA</i>	(see also breast, leukemia, lymphoma, lung)	Phase II (781) 419-1400
<b>Sprycel</b> <sup>®</sup> dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also brain, breast, leukemia, lung, lymphoma, multiple myeloma, prostate, skin)	Phase I (212) 546-4000
<b>Tarceva</b> <sup>®</sup> erlotinib	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	(see also bladder, brain, breast, head/neck, leukemia, liver, lung, other)	Phase II (650) 224-1000 (800) 572-1932
TAS-102	Taiho Pharma USA <i>Princeton, NJ</i>		Phase II (609) 750-5300
telatinib	ACT Biotech <i>San Francisco, CA</i>	(see also stomach)	Phase I (415) 230-3900
TF2	Immunomedics <i>Morris Plains, NJ</i>	diagnosis of colorectal cancer	Phase I (973) 605-8200
tigatuzumab	Daiichi Sankyo <i>Parsippany, NJ</i>	(see also liver, lymphoma, ovarian, pancreatic)	Phase I (973) 359-2600
<b>TNFrade</b> <sup>™</sup> golnerminogene pradenovec	GenVec <i>Gaithersburg, MD</i>	(see also head/neck, skin, stomach)	Phase II (877) 943-6832
<b>Vectibix</b> <sup>®</sup> panitumumab	Amgen <i>Thousand Oaks, CA</i>	first-line colorectal cancer, second-line colorectal cancer (see also head/neck)	Phase III (800) 772-6436

## HEAD/NECK CANCER

Product Name	Sponsor	Indication	Development Status
<b>Alimta</b> <sup>®</sup> pemetrexed	Eli Lilly <i>Indianapolis, IN</i>		Phase III (800) 545-5979
BIBW 2992 (afatinib)	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	(see also brain, breast, lung)	Phase II (800) 243-0127
<b>Erbitux</b> <sup>®</sup> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also bladder, breast, lung)	Phase II (212) 546-4000 (800) 545-5979 (212) 645-1405
foretinib	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also kidney)	Phase II (888) 825-5249
HF10	Takara Bio <i>Shiga, Japan</i>		Phase I www.takara-bio.com



## HEAD/NECK CANCER

Product Name	Sponsor	Indication	Development Status
IMO-2055 (EMD-1201081)	EMD Serono Rockland, MA Idera Pharmaceuticals Cambridge, MA	(see also colorectal, lung)	Phase II (800) 283-8088 (617) 679-5500
IRX-2	IRX Therapeutics New York, NY	(Fast Track)	Phase II (212) 582-1199
<b>LymphoSeek™</b>	Neoprobe Dublin, OH	diagnosis of head/neck cancer (see also breast, skin)	Phase III (800) 793-0079
<b>Multikine®</b> leukocyte interleukin	CEL-SCI Vienna, VA		Phase III (703) 506-9460
OBP-301	Oncolys Biopharma Tokyo, Japan	(see also breast, lung)	Phase I www.oncolys.com
OncoVEX <sup>GM-CSF</sup>	BioVex Woburn, MA	(see also skin)	Phase III (781) 376-4900
<b>ProLindac™</b> polymer-DACH platinum conjugate	Access Pharmaceuticals Dallas, TX		Phase II (214) 905-5100
<b>Reolysin®</b> reovirus	Oncolytics Biotech Calgary, Canada	(see also brain, colorectal, lung, pancreatic, sarcoma, skin)	Phase III (403) 670-7377
<b>Tarceva®</b> erlotinib	Genentech South San Francisco, CA OSI Pharmaceuticals Melville, NY	(see also bladder, brain, breast, colorectal, leukemia, liver, lung, other)	Phase II (650) 224-1000 (800) 572-1932
TAS-106	Taiho Pharma USA Princeton, NJ		Phase II (609) 750-5300
terameprocol (intravaginal)	Erimos Pharmaceuticals Houston, TX	(see also brain, cervical, solid tumors, other)	Phase I (713) 541-2000
<b>TNFERade™</b>	GenVec Gaithersburg, MD	(see also colorectal, pancreatic, skin, stomach)	Phase I/II (240) 632-0740
<b>Tykerb®</b> lapatinib	GlaxoSmithKline Rsch. Triangle Park, NC	(see also brain, stomach)	Phase III (888) 825-5249
VB4-845 <b>(Orphan Drug)</b>	Viventia Biotechnologies Mississauga, Canada	(Fast Track) (see also bladder)	Phase II (905) 362-2973
<b>Vectibix®</b> panitumumab	Amgen Thousand Oaks, CA	locally advanced head/neck cancer (see also colorectal)	Phase II (800) 772-6436
zalutumumab	Genmab Princeton, NJ	(Fast Track)	Phase II (609) 430-2481

## KIDNEY CANCER

Product Name	Sponsor	Indication	Development Status
ABT-869 (linifarib)	Abbott Laboratories Abbott Park, IL	(see also breast, colorectal, liver, lung)	Phase II (847) 937-6100 (650) 225-1000

## KIDNEY CANCER

Product Name	Sponsor	Indication	Development Status
<b>Afinitor®</b> everolimus	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	tuberous sclerosis complex angiomyolipomas (see also breast, liver, lymphoma, stomach, other)	Phase II (888) 669-6682
AGS-003	Argos Therapeutics <i>Durham, NC</i>		Phase II (919) 287-6300
AGS-16M8F	Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i>		Phase I (800) 695-4321
AMG 386	Amgen <i>Thousand Oaks, CA</i>	(see also breast, colorectal, liver, ovarian, stomach, other)	Phase II (800) 772-6436
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	(see also colorectal, liver, lung, pancreatic, sarcoma, other)	Phase II (781) 994-0300 (973) 944-2600
AV-951 (tivozanib)	AVEO Pharmaceuticals <i>Cambridge, MA</i>	(see also breast, lung, stomach)	Phase III (617) 299-5000
axitinib	Pfizer <i>New York, NY</i>	(see also lung, other)	Phase III (860) 732-5156
BAY 73-4506 (regorafenib)	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	(see also colorectal, lung, stomach)	Phase II (888) 842-2937
BNC 105	Bionomics <i>Thebarton, Australia</i>		Phase II <a href="http://www.bionomics.com.au">www.bionomics.com.au</a>
CA9-SCAN	Wilex <i>Munich, Germany</i>	diagnosis of kidney cancer	Phase III completed <a href="http://www.wilex.com">www.wilex.com</a>
CYT-107	Cytheris <i>Rockville, MD</i>	(see also leukemia, skin, solid tumors)	Phase I (301) 231-0450
EC-17	Endocyte <i>West Lafayette, IN</i>		Phase II (765) 463-7175
foretinib	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	papillary renal cell carcinoma (see also head/neck)	Phase II (888) 825-5249
GC-1008 (fresolimumab)	Genzyme <i>Cambridge, MA</i>	(see also skin)	Phase I (617) 252-7000
lenvatinib (E7080)	Eisai <i>Woodcliff Lake, NJ</i>	renal cell carcinoma (see also brain, liver, ovarian, skin, other)	Phase I/II (888) 422-4743
LOR-2040 <b>(Orphan Drug)</b>	Lorus Therapeutics <i>Toronto, Canada</i>	metastatic kidney cancer (see also breast, colorectal, leukemia)	Phase II (416) 798-1200
MDX-1203 (anti-CD70 ADC)	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also lymphoma)	Phase I (212) 546-4000
naptumomab estafenatox	Active Biotech <i>Lund, Sweden</i>	(see also lung, pancreatic)	Phase I completed <a href="http://www.activebiotech.com">www.activebiotech.com</a>

## KIDNEY CANCER

Product Name	Sponsor	Indication	Development Status
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals Wayne, NJ Onyx Pharmaceuticals Emeryville, CA	adjuvant therapy (see also breast, colorectal, liver, lung, ovarian, other)	Phase III (888) 842-2837 (510) 597-6500
OSI-027	OSI Pharmaceuticals Melville, NY	(see also lymphoma)	Phase II (800) 572-1932
perifosine (KRX-0401)	AEterna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY	(see also brain, colorectal, leukemia, lymphoma, multiple myeloma, ovarian, sarcoma, stomach)	Phase II (212) 531-5965
prophage (vitespen) <b>(Orphan Drug)</b>	Agenus Lexington, MA	(Fast Track) (see also brain, skin)	Phase II (781) 674-4400
<b>Rencarex®</b> girentuximab <b>(Orphan Drug)</b>	Wilex Munich, Germany	non-metastatic, clear cell renal cell carcinoma	Phase III www.wilex.com
SGN-75	Seattle Genetics Bothell, WA	renal cell carcinoma (see also lymphoma)	Phase I (425) 527-4000
<b>Sutent®</b> sunitinib	Pfizer New York, NY	adjuvant therapy (see also pancreatic)	Phase III (860) 732-5156
talactoferrin <b>(Orphan Drug)</b>	Agennix Houston, TX	(Fast Track) (see also lung)	Phase II (713) 552-1091
<b>Torisel®</b> temsirolimus <b>(Orphan Drug)</b>	Pfizer New York, NY	combination therapy	Phase III (860) 732-5156
tremelimumab (CP-675206)	Pfizer New York, NY	(see also pancreatic, skin, stomach, other)	Phase II (860) 732-5156
veglin (VEGF antisense)	VasGene Therapeutics Los Angeles, CA	(see also lung, skin)	Phase I (323) 221-7818
<b>Votrient®</b> pazopanib	GlaxoSmithKline Rsch. Triangle Park, NC	(see also breast, ovarian, sarcoma)	Phase III (888) 825-5249

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
ABIO05/01 (TALL-104)	Abiogen Pharma Pisa, Italy	chronic myeloid leukemia (CML)	Phase II
AC430	Ambit Biosciences San Diego, CA		Phase I (858) 334-2100
AEG-35156	Aegera Therapeutics Montreal, Canada	acute myeloid leukemia (AML) (see also lymphoma)	Phase II (514) 288-5532
		chronic lymphocytic leukemia (CLL)	Phase I/II (514) 288-5532

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
<b>Aezea®</b> cenersen (Orphan Drug)	Eleos Omaha, NE	AML	Phase II completed (402) 393-3034
afutuzumab (GA101/RG7159)	Biogen Idec Cambridge, MA Roche Nutley, NJ	CLL (see also lymphoma)	Phase III (617) 679-2000 (973) 235-5000
AFX-9154	Afecta Pharmaceuticals Irvine, CA		in clinical trials (949) 253-4688
ALD-151	Aldagen Durham, NC		Phase I (919) 484-2571
ALXN-6000 (samalizumab)	Alexion Pharmaceuticals Cheshire, CT	CLL (see also multiple myeloma)	Phase I/II (203) 272-2596
aminopterin	Syntrix Biosystems Auburn, WA	acute lymphoblastic leukemia (ALL)	Phase II completed (253) 833-8009
anti-CD22 ADC	Genentech South San Francisco, CA	recurrent CLL (see also lymphoma)	Phase I (650) 225-1000
anti-CD22/CD19 mAb-toxin conjugate	Abiogen Pharma Pisa, Italy University of Texas Southwestern Medical Center Dallas, TX	ALL	Phase I www.abiogen.com
AR-42	Arno Therapeutics Parsippany, NJ	CLL (see also lymphoma, multiple myeloma)	Phase I/II (862) 703-7170
ARRY-520	Array BioPharma Boulder, CO	AML (see also multiple myeloma, solid tumors)	Phase I/II (303) 381-6600
ARRY-614	Array BioPharma Boulder, CO	myelodysplastic syndromes	Phase I (303) 381-6600
<b>Arzerra®</b> ofatumumab (Orphan Drug)	GlaxoSmithKline Rsch. Triangle Park, NC	first-line CLL (see also lymphoma)	Phase III (888) 825-5249
AS-1411	Antisoma Cambridge, MA	AML	Phase II (617) 252-6100
AT-101	Ascenta Therapeutics Malvern, PA	CLL (see also brain, lung, lymphoma, prostate, stomach)	Phase II completed (610) 408-0313
AT9283	Astex Therapeutics Cambridge, United Kingdom	AML (see also solid tumors)	Phase I/II www.astex.therapeutics. com
bafetinib (Orphan Drug)	CytRx Los Angeles, CA	CLL (see also prostate)	Phase II (310) 826-5648
		ALL, CML	Phase I (310) 826-5648

# LEUKEMIA

Product Name	Sponsor	Indication	Development Status
BI 811283	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	AML (see also solid tumors)	Phase II (800) 243-0127
blinatumomab	Micromet <i>Bethesda, MD</i>	ALL (see also lymphoma)	Phase II (240) 752-1420
BMS-936564 (anti-CXCR4)	Bristol-Myers Squibb <i>Princeton, NJ</i>	AML	Phase I (212) 546-4000
bosutinib	Pfizer <i>New York, NY</i>	CML	Phase III (860) 732-5156
CAL-101	Calistoga Pharmaceuticals <i>Seattle, WA</i>	CLL (see also lymphoma, multiple myeloma)	Phase II (206) 728-4700
		AML	Phase I (206) 728-4700
<b>Campath®</b> alemtuzumab (intravenous) <b>(Orphan Drug)</b>	Genzyme <i>Cambridge, MA</i>	CLL combination therapy (see also cancer/chemotherapy)	Phase III (617) 252-7500
<b>Campath®</b> alemtuzumab (subcutaneous)	Genzyme <i>Cambridge, MA</i>	CLL	Phase II (617) 252-7500
cell permeation therapeutic vaccine	MaxCyte <i>Gaithersburg, MD</i>	CLL	Phase I/II (301) 944-1700
<b>Ceplene™</b> histamine dehydrochloride injection <b>(Orphan Drug)</b>	EpiCept <i>Tarrytown, NY</i>	AML	application submitted (914) 606-3500
<b>Clolar®</b> clofarabine	Genzyme <i>Cambridge, MA</i>	AML in elderly (monotherapy)	application submitted (617) 252-7500
		AML in elderly (combination therapy)	Phase III (617) 252-7500
		AML in children, myelodysplastic syndromes	Phase II (617) 252-7500
CNDO-109	Coronado Biosciences <i>New York, NY</i>	AML	Phase I/II (212) 332-1665
CPX-351	Celator Pharmaceuticals <i>Princeton, NJ</i>	AML	Phase II (609) 243-0123
CST-101	ConKwest <i>Del Mar, CA</i>	AML (see also lung, lymphoma, skin)	Phase I (858) 380-1999
CT-011	CureTech <i>Yavne, Israel</i>	AML (see also colorectal, lymphoma)	Phase II <a href="http://www.curetechbio.com">www.curetechbio.com</a>
CYT-107	Cytheris <i>Rockville, MD</i>	myeloid leukemia (see also kidney, skin, solid tumors)	Phase I (301) 231-0450

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
dacetuzumab (anti-CD40) <b>(Orphan Drug)</b>	Seattle Genetics <i>Bothell, WA</i>	CLL (see also lymphoma, multiple myeloma)	Phase I/II (425) 527-4000
danusertib	Nerviano Medical Sciences <i>Nerviano, Italy</i>	CML	Phase II www.nervianoms.com
DCC-2036	Deciphera Pharmaceuticals <i>Lawrence, KS</i>	ALL, CML	Phase I/II (785) 838-3767
dinaciclib	Merck <i>Whitehouse Station, NJ</i>	(see also breast, lung, lymphoma)	Phase II (800) 672-6372
<b>Elacyt™</b> elacytarabine <b>(Orphan Drug)</b>	Clavis Pharma <i>Oslo, Norway</i>	AML (Fast Track)	Phase III www.clavispharma.com
elesclomol	Synta Pharmaceuticals <i>Lexington, MA</i>	AML	Phase I (781) 274-8200
epratuzumab <b>(Orphan Drug)</b>	Immunomedics <i>Morris Plains, NJ</i>	ALL in children (see also lymphoma)	Phase II (973) 605-8200
<b>Erwinaze®</b> crisantaspase <b>(Orphan Drug)</b>	EUSA Pharma <i>Langhorne, PA</i>	ALL (Fast Track)	application submitted (800) 833-3533
EZN-3042	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	ALL in children (see also lymphoma, solid tumors)	Phase I (908) 541-8600
<b>Fodosine™</b> forodesine	BioCryst Pharmaceuticals <i>Birmingham, AL</i>	CLL (see also lymphoma)	Phase II (205) 444-4600
<b>Genasense®</b> oblimersen <b>(Orphan Drug)</b>	Genta <i>Berkeley Heights, NJ</i>	CLL (Fast Track) (see also lymphoma, skin)	application submitted (908) 286-9800
GNKG-68	SBI Biotech <i>Tokyo, Japan</i>	CLL	Phase I www.sbibiotech.jp
GRN-163L (imetelstat)	Geron <i>Menlo Park, CA</i>	CLL (see also breast, lung, multiple myeloma)	Phase I/II (650) 473-7700
GRNVAC1	Geron <i>Menlo Park, CA</i>	AML (see also prostate)	Phase II (650) 473-7700
<b>GVAX® Leukemia</b> <b>(Orphan Drug)</b>	BioSante Pharmaceuticals <i>Lincolnshire, IL</i>	AML, CML (see also breast, colorectal, multiple myeloma, pancreatic)	Phase II (847) 478-0500
HuM195-Ac-225	Actinium Pharmaceuticals <i>Newark, NJ</i>	AML	Phase I (973) 344-6500
HuM195-Bi-213	Actinium Pharmaceuticals <i>Newark, NJ</i>	AML	Phase I/II (973) 344-6500
HuM195/rGel (lintuzumab-gelonin conjugate)	Targa Therapeutics <i>San Diego, CA</i>	AML, CML, myelodysplastic syndromes	Phase I (858) 483-6600
<b>Imprime PGG®</b>	Biothera <i>Eagan, MN</i>	CLL (see also colorectal, lung, skin)	Phase I/II (651) 675-0300

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
ISF35	Memgen <i>Dallas, TX</i>	CLL (see also lymphoma)	Phase II (214) 731-3141
JNJ-26481585	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	refractory metastatic leukemia, refractory metastatic myelodysplastic syndromes	Phase I (800) 817-5286
JVRS-100 immunotherapeutic	Juvaris BioTherapeutics <i>Burlingame, CA</i>		Phase I (650) 259-1800
L-annamycin (liposomal annamycin) <b>(Orphan Drug)</b>	Callisto Pharmaceuticals <i>New York, NY</i>	ALL, AML	Phase I/II (212) 297-0010
LC-1	Leuchemix <i>Redwood City, CA</i>	AML	Phase I (650) 851-9925
lestaurtinib	Cephalon <i>Frazer, PA</i>	AML	Phase II (610) 344-0200
LG740	Lentigen <i>Gaithersburg, MD</i> University of Pennsylvania <i>Philadelphia, PA</i>	ALL, B-cell prolymphocytic leukemia, CLL (see also lymphoma)	Phase I (301) 527-4200
LOR-2040 <b>(Orphan Drug)</b>	Lorus Therapeutics <i>Toronto, Canada</i>	AML (see also breast, colorectal, kidney)	Phase II (416) 798-1200
		CML, myelodysplastic syndromes	Phase I (416) 798-1200
<b>Marqibo®</b> vincristine liposomal <b>(Orphan Drug)</b>	Talon Therapeutics <i>South San Francisco, CA</i>	ALL (Fast Track) (see also skin)	Phase II (650) 588-6404
masitinib	AB Science USA <i>Short Hills, NJ</i>	mastocytosis (see also pancreatic, stomach)	Phase III (973) 218-2437
MGCD-0103	MethylGene <i>Montreal, Canada</i>	CLL (see also lymphoma, solid tumors)	Phase II completed (514) 337-3333
midostaurin (PKC412) <b>(Orphan Drug)</b>	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	AML	Phase III (888) 669-6682
		aggressive systemic mastocytosis	Phase II (888) 669-6682
milatuzumab (IMMU-115) <b>(Orphan Drug)</b>	Immunomedics <i>Morris Plains, NJ</i>	CLL (see lymphoma, multiple myeloma)	Phase I/II (973) 605-8200
<b>Mozobil™</b> plerixafor	Genzyme <i>Cambridge, MA</i>	AML, CLL	Phase I/II (617) 252-7500
navitoclax (ABT-263/RG7433)	Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i>	CLL (see also lung, lymphoma)	Phase II (847) 937-6100 (650) 225-1000



## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
<b>Nplate™</b> romiplostim	Amgen Thousand Oaks, CA	myelodysplastic syndromes (see also cancer/chemotherapy)	Phase II (800) 772-6436
obatoclox (Orphan Drug)	Gemin X Biotechnologies Montreal, Canada	CLL (see also lung, lymphoma, multiple myeloma)	Phase I/II completed (514) 281-8989
<b>Omapro™</b> omacetaxine mepesuccinate (Orphan Drug)	ChemGenex Pharmaceuticals Menlo Park, CA	second-line CML (Fast Track)	application submitted (650) 474-9800
		AML, CML, myelodysplastic syndromes	Phase II (650) 474-9800
ON-01910 (Orphan Drug)	Onconova Therapeutics Princeton, NJ	myelodysplastic syndromes (see also lymphoma, ovarian, solid tumors)	Phase III (609) 844-7735
		AML, CLL	Phase II (609) 844-7735
ON-013105	Onconova Therapeutics Princeton, NJ	ALL (see also lymphoma)	Phase I (609) 844-7735
OXi4503	OXiGENE South San Francisco, CA	AML (see also solid tumors)	Phase I (650) 635-7000
PCI-32765 (BTK inhibitor)	Pharmacyclics Sunnyvale, CA	CLL (see also lymphoma)	Phase I (408) 774-0330
perifosine (KRX-1401)	Aeterna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY	refractory metastatic CLL (see also brain, colorectal, kidney, lymphoma, multiple myeloma, ovarian, sarcoma, stomach)	Phase II (212) 531-5965
polyphenon E (Orphan Drug)	Polyphenon Pharma New York, NY	CLL (see also prostate)	Phase I/II (212) 661-0578
ponatinib (AP24534)	ARIAD Pharmaceuticals Cambridge, MA	ALL, CML	Phase II (617) 494-0400
PR1 cancer vaccine	Vaccine Company South San Francisco, CA	AML	Phase III (650) 244-4100
		CML, myelodysplastic syndromes	Phase II (650) 244-4100
PR104	Proacta Therapeutics San Diego, CA	AML	Phase I/II (858) 642-0386
quizartinib	Ambit Biosciences San Diego, CA Astellas Pharma US Deerfield, IL	AML (see also solid tumors)	Phase II (858) 334-2100 (800) 727-7003
sapacitabine	Cyclacel Pharmaceuticals Short Hills, NJ	AML in elderly patients (see also lung)	Phase III (973) 847-5955
SAR103168 (multikinase inhibitor)	sanofi-aventis Bridgewater, NJ	AML	Phase I (800) 633-1810
SB939	S*Bio Redwood City, CA	AML (see also solid tumors)	Phase II (650) 730-2860

# LEUKEMIA

Product Name	Sponsor	Indication	Development Status
SB1518	S*Bio <i>Redwood City, CA</i>	myeloid leukemia (see also lymphoma)	Phase I/II (650) 730-2860
SCH-900776	Merck <i>Whitehouse Station, NJ</i>	(see also lymphoma)	Phase I (800) 672-6372
SF1126 <b>(Orphan Drug)</b>	Semafore Pharmaceuticals <i>Indianapolis, IN</i>	CLL (see also multiple myeloma, solid tumors)	Phase I (317) 876-3075
SGI-110	SuperGen <i>Dublin, CA</i>	AML	Phase I/II (925) 560-0100
SL-401	Stemline Therapeutics <i>New York, NY</i>	AML	Phase I/II (212) 831-1111
SNDX-275 (entinostat)	Syndax Pharmaceuticals <i>Waltham, MA</i>	(see also breast, leukemia, lung, lymphoma)	Phase II (781) 419-1400
<b>Sprycel®</b> dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	myelodysplastic syndromes (see also brain, breast, colorectal, lung, lymphoma, multiple myeloma, prostate, skin)	Phase II (212) 546-4000
tamibarotene <b>(Orphan Drug)</b>	CytRx <i>Los Angeles, CA</i>	acute promyelocytic leukemia (APL) (Fast Track) (see also lung)	Phase II (310) 826-5648
<b>Tarceva®</b> erlotinib	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	myelodysplastic syndromes (see also bladder, brain, breast, colorectal, head/neck, liver, lung, other)	Phase II (650) 224-1000 (800) 572-1932
<b>Tasigna®</b> nilotinib <b>(Orphan Drug)</b>	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	CML in adolescents and children (see also skin, stomach)	Phase II (888) 669-6682
<b>Telintra®</b> ezatiostat	Telik <i>Palo Alto, CA</i>	myelodysplastic syndromes	Phase II (650) 845-7700
<b>Temodar®</b> temozolomide	Merck <i>Whitehouse Station, NJ</i>	AML (see also lung, skin)	Phase II (800) 672-6372
TH-302	Threshold Pharmaceuticals <i>Redwood City, CA</i>	advanced leukemia (see also pancreatic, sarcoma, solid tumors)	Phase I (650) 474-8200
thiarabine	Access Pharmaceuticals <i>Dallas, TX</i>	(see also lymphoma)	Phase I/II (214) 905-5100
tosedostat <b>(Orphan Drug)</b>	Chroma Therapeutics <i>Oxford, United Kingdom</i>	AML	Phase II www.chroma therapeutics.com
treosulfan	medac <i>Wedel, Germany</i>	ALL, AML, myelodysplastic syndromes	Phase II www.medac.de
<b>Trisenox®</b> arsenic trioxide	Cephalon <i>Frazer, PA</i>	AML in elderly patients (see also brain, multiple myeloma)	Phase III (610) 344-0200
TRU-016 (anti-CD37)	Emergent Biosolutions <i>Rockville, MD</i>	CLL (see also lymphoma)	Phase I/II (301) 795-1800

## LEUKEMIA

Product Name	Sponsor	Indication	Development Status
veltuzumab (IMMU-106)	Immunomedics <i>Morris Plains, NJ</i>	CLL (see also lymphoma)	Phase I/II completed (973) 605-8200
<b>Vidaza®</b> azacitidine <b>(Orphan Drug)</b>	Celgene <i>Summit, NJ</i>	AML	Phase III (908) 673-9000
vosaroxin (SNS-595) <b>(Orphan Drug)</b>	Sunesis Pharmaceuticals <i>South San Francisco, CA</i>	AML (Fast Track) (see also ovarian)	Phase III (650) 266-3500
		AML in the elderly	Phase II (650) 266-3500
WT1 recombinant vaccine (antigen specific cancer immunotherapy)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	AML	Phase II (888) 825-5249
XmAb®5574 (MOR-208)	Xencor <i>Monrovia, CA</i> MorphoSys <i>Munich, Germany</i>	CLL	Phase I (626) 305-5900
zosuquidar <b>(Orphan Drug)</b>	Kanisa Pharmaceuticals <i>San Diego, CA</i>	newly-diagnosed AML in elderly patients	Phase I/II (858) 436-1800

## LIVER CANCER

Product Name	Sponsor	Indication	Development Status
ABT-869 (linifarib)	Abbott Laboratories <i>Abbott Park, IL</i>	(see also breast, colorectal, kidney, lung)	Phase III (847) 937-6100
ADI-PEG 20 <b>(Orphan Drug)</b>	Polaris Pharmaceuticals <i>San Diego, CA</i>	(see also lung, skin)	Phase II (858) 452-6688
<b>Afinitor®</b> everolimus	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	advanced hepatocellular carcinoma (see also breast, liver, lymphoma, stomach, other)	Phase III (888) 669-6682
ALN-VSP	Alnylam Pharmaceuticals <i>Cambridge, MA</i>		Phase I (617) 551-8200
AMG 386	Amgen <i>Thousand Oaks, CA</i>	(see also breast, colorectal, kidney, ovarian, stomach, other)	Phase II (800) 772-6436
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	hepatocellular carcinoma (see also colorectal, kidney, lung, pancreatic, sarcoma, solid tumors, other)	Phase II (781) 994-0300 (973) 944-2600
bavituximab	Peregrine Pharmaceuticals <i>Tustin, CA</i>	(see also breast, pancreatic)	Phase I/II (714) 508-6000
BAY 86-9766	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>		Phase II (888) 842-2937

## LIVER CANCER

Product Name	Sponsor	Indication	Development Status
BIIB 022	Biogen Idec <i>Cambridge, MA</i>	(see also lung)	Phase I (617) 679-2000
brivanib (VEGFR/FGFR kinase inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>	hepatocellular carcinoma (see also stomach)	Phase III (212) 546-4000
CRS-100	Aduro BioTech <i>Berkeley, CA</i>		Phase I (510) 848-4400
darinaparsin (ZIO-101)	ZIOPHARM Oncology <i>New York, NY</i>	(see also lymphoma, multiple myeloma, solid tumors)	Phase II completed (646) 214-0700
<b>Davanat™</b> galactomannan C	Pro-Pharmaceuticals <i>Newton, MA</i>	biliary cancer (see also colorectal)	Phase II (617) 559-0033
E7050	Eisai <i>Woodcliff Lake, NJ</i>	hepatocellular carcinoma (see also stomach, other)	Phase I/II (888) 422-4743
GC-33/RG7686	Chugai Pharma USA <i>Berkeley Heights, NJ</i> Roche <i>Nutley, NJ</i>		Phase I (908) 516-1350 (973) 235-5000
irinotecan eluting beads	Biocompatibles International <i>Surrey, United Kingdom</i>	liver metastases from colorectal cancer	Phase II www.biocompatibles.com
JX-594	Jennerex Biotherapeutics <i>San Francisco, CA</i>	(see also colorectal)	Phase II (415) 281-8886
lenvatinib (E7080)	Eisai <i>Woodcliff Lake, NJ</i>	hepatocellular carcinoma (see also brain, kidney, ovarian, skin, other)	Phase I/II (888) 422-4743
mapatumumab	Human Genome Sciences <i>Rockville, MD</i>	(see also lung, multiple myeloma)	Phase I/II (301) 309-8504
MB-07133 <b>(Orphan Drug)</b>	Ligand Pharmaceuticals <i>La Jolla, CA</i>	inoperable, unresectable liver cancer	Phase I/II completed (858) 550-7500
melphalan drug delivery system	Delcath Systems <i>New York, NY</i>	secondary liver cancer arising from metastatic ocular or cutaneous melanoma	application submitted (212) 489-2100
muparfostat (PI-88)	Progen Pharmaceuticals <i>Redwood City, CA</i>	(Fast Track) (see also skin)	Phase III (650) 610-7080
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i>	adjuvant therapy (see also breast, colorectal, kidney, lung, ovarian, other)	Phase III (888) 842-2837 (510) 597-6500
NV1020	Catherex <i>Arlington, VA</i>		Phase I/II completed (703) 786-3790
patupilone (EPO906)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also brain)	Phase II (888) 669-6682
<b>PrevOnco™</b> lansoprazole <b>(Orphan Drug)</b>	Apricus Biosciences <i>San Diego, CA</i>		Phase II (858) 222-8041

## LIVER CANCER

Product Name	Sponsor	Indication	Development Status
PV-10	Provectis Pharmaceuticals <i>Knoxville, TN</i>	liver metastases (see also skin)	Phase I (866) 594-5999
ramucirumab (IMC-1121B)	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	(see also breast, colorectal, lung, stomach)	Phase III (800) 545-5979 (212) 645-1405
<b>Tarceva®</b> erlotinib	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	inoperable, unresectable liver cancer (see also bladder, brain, breast, colorectal, head/neck, leukemia, lung, other)	Phase III (650) 224-1000 (800) 572-1932
<b>ThermoDox®</b> LTSDEL (Orphan Drug)	Celsion <i>Columbia, MD</i>	inoperable, unresectable liver cancer (Fast Track) (see also breast)	Phase III (410) 290-5390
tigatuzumab	Daiichi Sankyo <i>Parsippany, NJ</i>	(see also colorectal, lymphoma, ovarian, pancreatic)	Phase II (973) 359-2600

## LUNG CANCER

Product Name	Sponsor	Indication	Development Status
<b>Abraxane®</b> albumin-bound paclitaxel	Celgene <i>Summit, NJ</i>	advanced non-small-cell lung cancer (NSCLC) (see also bladder, ovarian, pancreatic, skin)	Phase III (908) 673-9000
ABT-869 (linifarib)	Abbott Laboratories <i>Abbott Park, IL</i>	NSCLC (see also breast, kidney, liver)	Phase II (847) 937-6100
ADI-PEG 20 (Orphan Drug)	Polaris Pharmaceuticals <i>San Diego, CA</i>	small-cell lung cancer (SCLC) (see also liver, skin)	Phase II (858) 452-6688
		mesothelioma	Phase I (858) 452-6688
aflibercept (VEGF-trap)	sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i>	second-line NSCLC (see also colorectal, prostate)	Phase III (800) 633-1610 (914) 345-7400
AMG 479 (gunitumab)	Amgen <i>Thousand Oaks, CA</i>	SCLC (see also breast, colorectal, pancreatic, sarcoma, other)	Phase I/II (800) 772-6436
amrubicin (Orphan Drug)	Celgene <i>Summit, NJ</i>	second-line SCLC (Fast Track)	Phase III (908) 673-9000
		first-line SCLC	Phase II (908) 673-9000
apricoxib	Tragara Pharmaceuticals <i>San Diego, CA</i>	NSCLC (see also pancreatic)	Phase II (858) 350-6900

## LUNG CANCER

Product Name	Sponsor	Indication	Development Status
ARQ-197	ArQule Woburn, MA Daiichi Sankyo Parsippany, NJ	NSCLC (see also colorectal, kidney, liver, pancreatic, sarcoma, solid tumors, other)	Phase III (781) 994-0300 (973) 944-2600
AT-101	Ascenta Therapeutics Malvern, PA	NSCLC, SCLC (see also leukemia, lymphoma, prostate, stomach)	Phase II (610) 408-0301
AUY922	Novartis Pharmaceuticals East Hanover, NJ	NSCLC (see also breast, colorectal, multiple myeloma, stomach)	Phase II (888) 669-6682
AV-951 (tivozanib)	AVEO Pharmaceuticals Cambridge, MA	NSCLC (see also breast, kidney, stomach)	Phase I/II (617) 299-5000
<b>Avastin®</b> bevacizumab	Genentech South San Francisco, CA	NSCLC (adjuvant therapy) (see also brain, breast, colorectal, ovarian, other)	Phase III (650) 225-1000
axitinib	Pfizer New York, NY	NSCLC (see also kidney, other)	Phase II (860) 732-5156
bavituximab	Peregrine Pharmaceuticals Tustin, CA	NSCLC (see also liver, pancreatic)	Phase II (714) 508-6000
BAY 73-4506 (regorafenib)	Bayer HealthCare Pharmaceuticals Wayne, NJ	NSCLC (see also colorectal, kidney, stomach)	Phase I (888) 842-2937
belinostat	Spectrum Pharmaceuticals Irvine, CA TopoTarget USA Rockaway, NJ	NSCLC (see also lymphoma, other)	Phase I/II (949) 788-6700 (973) 895-6900
BI 2536	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT	SCLC (see also lymphoma)	Phase II completed (800) 243-0127
BIBF 1120 (intedanib)	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT	NSCLC	Phase III (800) 243-0127
BIBW 2992 (afatinib)	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT	NSCLC (Fast Track) (see also brain, breast, head/neck)	Phase III (800) 243-0127
BIIB 022	Biogen Idec Cambridge, MA	NSCLC (see also liver)	Phase I (617) 679-2000
BMS-690514 (HER/VEGFR2 inhibitor)	Bristol-Myers Squibb Princeton, NJ	NSCLC (see also breast)	Phase II (212) 546-4000
BMS-844203 (VEGF R-2 adnectin)	Bristol-Myers Squibb Princeton, NJ	NSCLC (see also brain, colorectal)	Phase II (212) 546-4000
cabozantinib (XL-184)	Exelixis South San Francisco, CA	NSCLC (see also other)	Phase I/II (650) 837-7000
CBP501	CanBas Shizuoka, Japan	mesothelioma, NSCLC	Phase II www.canbas.co.jp

## LUNG CANCER

Product Name	Sponsor	Indication	Development Status
conatumumab	Amgen <i>Thousand Oaks, CA</i>	NSCLC (see also colorectal, pancreatic, sarcoma)	Phase I/II (800) 772-6436
crizotinib	Pfizer <i>New York, NY</i>	NSCLC (Fast Track)	Phase III (860) 732-5156
CS-7017 (efatutazone)	Daiichi Sankyo <i>Parsippany, NJ</i>	NSCLC (see also colorectal, other)	Phase II (973) 944-2600
CST-101	ConKwest <i>Del Mar, CA</i>	NSCLC, SCLC (see also leukemia, lymphoma, skin)	Phase I (858) 380-1999
dalotuzumab	Merck <i>Whitehouse Station, NJ</i>	NSCLC (see also breast, colorectal, pancreatic, other)	Phase I/II (800) 672-6372
dinaciclib	Merck <i>Whitehouse Station, NJ</i>	NSCLC (see also breast, leukemia, lymphoma)	Phase II (800) 672-6372
EC-145	Endocyte <i>West Lafayette, IN</i>	late-stage NSCLC (see also ovarian, other)	Phase II (765) 463-7175
<b>Erbix<sup>®</sup></b> cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	NSCLC (see also bladder, breast, head/neck)	Phase III (212) 546-4000 (800) 545-5979 (212) 645-1405
eribulin (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	NSCLC (see also bladder, prostate, sarcoma)	Phase I/II (888) 422-4743
<b>Exelb<sup>™</sup></b> vinorelbine emulsion	ADVENTRX Pharmaceuticals <i>San Diego, CA</i>	NSCLC (see also breast, lymphoma)	application submitted (858) 552-0866
farletuzumab (MORAb-003)	Eisai <i>Woodcliff Lake, NJ</i>	NSCLC (see also ovarian)	Phase II (888) 422-4743
<b>Foloty<sup>®</sup></b> pralatrexate	Allos Therapeutics <i>Westminster, CO</i>	NSCLC (see also bladder, breast, lymphoma)	Phase II (303) 426-6262
ganetespib	Synta Pharmaceuticals <i>Lexington, MA</i>	NSCLC (see also breast, colorectal, stomach, other)	Phase II (781) 274-8200
GDC-0941 (PI3 kinase inhibitor)	Genentech <i>South San Francisco, CA</i>	metastatic NSCLC (see also breast, lymphoma, solid tumors)	Phase I (650) 224-1000
GI-4000	GlobelImmune <i>Louisville, CO</i>	NSCLC (see also colorectal, pancreatic)	Phase I (303) 625-2700
GRN-163L (imetelstat)	Geron <i>Menlo Park, CA</i>	NSCLC (see also breast, leukemia, multiple myeloma)	Phase II (650) 473-7700
GSK2302032A (PRAME immunotherapeutic recombinant vaccine)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	resectable NSCLC (see also skin)	Phase I (888) 825-5249



## LUNG CANCER

Product Name	Sponsor	Indication	Development Status
HS-L1	Heat Biologics <i>Miami Beach, FL</i>	NSCLC	Phase I (305) 432-4684
<b>HyperAcute® Lung</b> lung cancer vaccine	NewLink Genetics <i>Ames, IA</i>	NSCLC	Phase I/II (515) 296-5555
IMGN-901 <b>(Orphan Drug)</b>	ImmunoGen <i>Cambridge, MA</i>	SCLC (see also multiple myeloma)	Phase I/II (617) 995-2500
IMO-2055 (EMD-1201081)	EMD Serono <i>Rockland, MA</i> Idera Pharmaceuticals <i>Cambridge, MA</i>	NSCLC (see also colorectal, kidney)	Phase I (800) 283-8088 (617) 679-5500
<b>Imprime PGG®</b>	Biothera <i>Eagen, MN</i>	NSCLC (see also colorectal, leukemia, skin)	Phase II (651) 675-0300
iniparib (BSI-201)	BiPar Sciences <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i>	squamous lung cancer (see also breast, ovarian)	Phase III (650) 615-7000 (800) 633-1810
		----- non-squamous NSCLC	Phase II (650) 615-7000 (800) 633-1810
ipilimumab	Bristol-Myers Squibb <i>Princeton, NJ</i>	NSCLC (see also prostate, skin)	Phase II (212) 546-4000
<b>Ixempra®</b> ixabepilone	Bristol-Myers Squibb <i>Princeton, NJ</i>	NSCLC (see also breast, stomach, other)	Phase II (212) 546-4000
JNJ-26854165	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	NSCLC (see also prostate, solid tumors)	Phase I (800) 817-5286
<b>Lucanix®</b> belagenpumatucel-L	NovaRx <i>San Diego, CA</i>	NSCLC (Fast Track) (see also brain)	Phase III (858) 552-8600
MAGE-A3 recombinant vaccine (antigen-specific cancer immunotherapeutic)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	NSCLC (see also skin)	Phase III (888) 825-5249
mapatumumab	Human Genome Sciences <i>Rockville, MD</i>	NSCLC (see also liver, multiple myeloma)	Phase II (301) 309-8504
MetmAb (RG 3638)	Genentech <i>South San Francisco, CA</i>	NSCLC	Phase II (650) 225-1000
MGCD-265	MethylGene <i>Montreal, Canada</i>	NSCLC (see also solid tumors)	Phase II (514) 337-3333
MORAb-009	Eisai <i>Woodcliff Lake, NJ</i>	mesothelioma	Phase II (888) 422-4743
motesanib (AMG 706)	Amgen <i>Thousand Oaks, CA</i> Millennium Pharmaceuticals <i>Cambridge, MA</i>	NSCLC (see also breast)	Phase III (800) 772-6436 (800) 390-5663

## LUNG CANCER

Product Name	Sponsor	Indication	Development Status
naptumomab estafenatox	Active Biotech <i>Lund, Sweden</i>	NSCLC (Fast Track) (see also kidney, pancreatic)	Phase I completed <a href="http://www.activebiotech.com">www.activebiotech.com</a>
navitoclax (ABT-263/RG7433)	Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i>	SCLC (see also leukemia, lymphoma)	Phase II (847) 937-6100 (650) 225-1000
necitumumab (IMC-11F8)	Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	NSCLC	Phase III (212) 546-4000 (800) 545-5979 (212) 645-1405
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i>	NSCLC (see also breast, colorectal, kidney, liver, ovarian, other)	Phase III (888) 842-2837 (510) 597-6500
NK-012	Nippon Kayaku <i>Tokyo, Japan</i>	SCLC (see also breast)	Phase II
NTX-10	Neotropix <i>Malvern, PA</i>	SCLC (see also other)	Phase II (617) 460-1200
obatoclax	Gemin X Biotechnologies <i>Montreal, Canada</i>	SCLC (see also leukemia, lymphoma, multiple myeloma)	Phase I/II (514) 281-8989
OBP-301	Oncolys Biopharma <i>Tokyo, Japan</i>	mesothelioma (see also breast, head/neck)	Phase I <a href="http://www.oncolys.com">www.oncolys.com</a>
OGX-427	Oncogenex Pharmaceuticals <i>Bothell, WA</i>	NSCLC (see also bladder, breast, ovarian, prostate)	Phase I (425) 686-1500
<b>Onconase®</b> ranpirnase	Tamir Biotechnology <i>Monmouth Junction, NJ</i>	NSCLC	Phase II (732) 823-1003
<b>Opaxio™</b> paclitaxel poliglumex	Cell Therapeutics <i>Seattle, WA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>	NSCLC (see also ovarian, other)	Phase III (800) 215-2355 (888) 669-6682
OSI-906 (linsitinib)	OSI Pharmaceuticals <i>Melville, NY</i>	NSCLC (see also ovarian, other)	Phase II (631) 962-2000
P2045	Bryan Oncor <i>Somerville, MA</i>	NSCLC, SCLC	Phase I (617) 273-2466
palifosfamide (ZIO-201)	ZIOPHARM Oncology <i>New York, NY</i>	SCLC (see also sarcoma)	Phase I (212) 214-0700
PF-00299804	Pfizer <i>New York, NY</i>	NSCLC	Phase III (860) 732-5156
picoplatin intravenous <b>(Orphan Drug)</b>	Poniard Pharmaceuticals <i>San Francisco, CA</i>	SCLC (Fast Track) (see also colorectal, ovarian, prostate)	Phase II (650) 583-3774

## LUNG CANCER

Product Name	Sponsor	Indication	Development Status
plinabulin (NPI-2358)	Nereus Pharmaceuticals <i>San Diego, CA</i>	NSCLC	Phase II (858) 587-4090
PM-02734 (elisidepsin)	Pharmamar USA <i>New York, NY</i>	NSCLC	Phase II www.pharmamar.com
ramucirumab (IMC-1121B)	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	NSCLC (see also breast, colorectal, liver, stomach)	Phase III (800) 545-5979 (212) 645-1405
<b>Rencentin™</b> cediranib	AstraZeneca <i>Wilmington, DE</i>	NSCLC	Phase II (800) 236-9933
<b>Reolysin®</b> reovirus	Oncolytics Biotech <i>Calgary, Canada</i>	NSCLC (see also brain, colorectal, head/neck, pancreatic, sarcoma, skin)	Phase II (403) 670-7377
retaspimycin (IPI-504)	Infinity Pharmaceuticals <i>Cambridge, MA</i>	NSCLC (see also solid tumors)	Phase II (617) 453-1000
ridaforolimus	Merck <i>Whitehouse Station, NJ</i>	NSCLC (see also breast, sarcoma)	Phase II (800) 672-6372
rilotumumab	Amgen <i>Thousand Oaks, CA</i>	SCLC (see also brain, colorectal, prostate, stomach)	Phase II (800) 772-6436
salirasib	Concordia Pharmaceuticals <i>Ft. Lauderdale, FL</i>	NSCLC (see also pancreatic)	Phase II www.concordiapharma.com
sapacitabine	Cyclacel Pharmaceuticals <i>Short Hills, NJ</i>	NSCLC (see also leukemia)	Phase II (973) 847-5955
SNDX-275 (entinostat)	Syndax Pharmaceuticals <i>Waltham, MA</i>	NSCLC (see also breast, colorectal, leukemia, lymphoma)	Phase I/II (781) 419-1400
<b>Sprycel®</b> dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	NSCLC (see also brain, breast, colorectal, leukemia, lymphoma, multiple myeloma, prostate, skin)	Phase II (212) 546-4000
		mesothelioma	Phase I (212) 546-4000
<b>Stimuvax®</b> emepepimut-S (BLP25 liposomal cancer vaccine)	EMD Serono <i>Rockland, MA</i> Oncothyreon <i>Bellevue, WA</i>	NSCLC (Fast Track)	Phase III (800) 283-8088 (425) 450-0370
talactoferrin <b>(Orphan Drug)</b>	Agennix <i>Houston, TX</i>	NSCLC (Fast Track) (see also kidney)	Phase III (713) 552-1091
tamibarotene	CytRx <i>Los Angeles, CA</i>	NSCLC (see also leukemia)	Phase II (310) 826-5648
<b>Tarceva®</b> erlotinib	Roche <i>Nutley, NJ</i> OSI Pharmaceuticals <i>Melville, NY</i>	NSCLC (see also bladder, brain, breast, colorectal, head/neck, leukemia, liver, other)	Phase III (973) 235-5000 (800) 572-1932

## LUNG CANCER

Product Name	Sponsor	Indication	Development Status
<b>Tavocept™</b> dimesna	BioNumerik Pharmaceuticals <i>San Antonio, TX</i>	(see also cancer/chemotherapy)	Phase III (210) 614-1701
<b>Telcyta®</b> canfosfimide	Telik <i>Palo Alto, CA</i>	NSCLC (see also lymphoma, ovarian)	Phase III completed (650) 845-7700
<b>Temodar®</b> temozolomide	Merck <i>Whitehouse Station, NJ</i>	SCLC (see also leukemia, skin)	Phase II (800) 672-6372
topotecan liposomal	Talon Therapeutics <i>South San Francisco, CA</i>	SCLC (see also ovarian)	Phase I (650) 588-6404
TV-1011/OGX-011 (custiren)	Teva Pharmaceutical <i>Tikva, Israel</i> Oncogenex Pharmaceuticals <i>Bothell, WA</i>	NSCLC (see also prostate)	Phase I/II (425) 686-1500 www.tevapharm.com
veglin (VEGF antisense)	VasGene Therapeutics <i>Los Angeles, CA</i>	mesothelioma (see also kidney, skin)	Phase I (323) 221-7818
volociximab	Biogen Idec <i>Cambridge, MA</i> Facet Biotech <i>Redwood City, CA</i>	NSCLC (see also ovarian)	Phase II (617) 679-2000 (650) 454-1000
XL647	Symphony Evolution <i>Rockville, MD</i>	NSCLC	Phase II www.symphony evolution.com
<b>Zybrestat™</b> fosbretabulin	OXiGENE <i>South San Francisco, CA</i>	first-line NSCLC (see also ovarian, other)	Phase II (650) 635-7000

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
AEG-35156	Aegera Therapeutics <i>Montreal, Canada</i>	B-cell lymphoma (see also leukemia)	Phase I/II (514) 288-5532
AEZS-112	AEterna-Zentaris <i>Warren, NJ</i>	(see also solid tumors)	Phase I (908) 626-5428
<b>Afinitor®</b> everolimus	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	diffuse large B-cell lymphoma (see also breast, kidney, liver, stomach, other)	Phase III (888) 669-6682
		mantle-cell lymphoma	Phase II (888) 669-6682
AFM13	Affimed Therapeutics <i>Heidelberg, Germany</i>	Hodgkin's lymphoma	Phase I www.affimed.com
afutuzumab (GA101/RG7159)	Biogen Idec <i>Cambridge, MA</i> Roche <i>Nutley, NJ</i>	indolent non-Hodgkin's lymphoma (see also leukemia)	Phase III (617) 679-2000 (973) 235-5000
		aggressive non-Hodgkin's lymphoma	Phase II (617) 679-2000 (973) 235-5000

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
AME133 (anti-CD20mAb)	MENTRIK Biotech <i>Dallas, TX</i>	non-Hodgkin's lymphoma	Phase II completed (214) 594-0002
amuvatinib	SuperGen <i>Dublin, CA</i>	(see also solid tumors)	Phase I (925) 560-0100
anti-CD22 ADC	Genentech <i>South San Francisco, CA</i>	recurrent non-Hodgkin's lymphoma (see also leukemia)	Phase I (650) 225-1000
anti-CD22 mAb- toxin conjugate	Abiogen Pharma <i>Pisa, Italy</i> University of Texas Southwestern Medical Center <i>Dallas, TX</i>	B-cell lymphoma	Phase I www.abiogen.com
<b>Aplidin®</b> plitidepsin	PharmaMar USA <i>Cambridge, MA</i>	(see also multiple myeloma, solid tumors)	Phase I (617) 868-3797
AR-12	Arno Therapeutics <i>Parsippany, NJ</i>	(see also solid tumors)	Phase I (862) 703-7170
AR-42	Arno Therapeutics <i>Parsippany, NJ</i>	(see also leukemia, multiple myeloma)	Phase I/II (862) 703-7170
<b>Arzerra®</b> ofatumumab	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	follicular lymphoma, diffuse large B-cell lymphoma (see also leukemia)	Phase III (888) 825-5249
ASP-3026	Astellas Pharma US <i>Deerfield, IL</i>	late-stage non-Hodgkin's lymphoma	Phase I (800) 477-6472
AT-101	Ascenta Therapeutics <i>Malvern, PA</i>	non-Hodgkin's lymphoma (see also brain, leukemia, lung, prostate, stomach)	Phase II completed (610) 408-0301
AT-406	Ascenta Therapeutics <i>Malvern, PA</i>	lymphoma (see also solid tumors)	Phase I (610) 408-0313
AV-299 (ficlatuzumab)	AVEO Pharmaceuticals <i>Cambridge, MA</i>	(see also brain, multiple myeloma, solid tumors)	Phase I (617) 299-5000
belinostat	Spectrum Pharmaceuticals <i>Irvine, CA</i> TopoTarget USA <i>Rockaway, NJ</i>	peripheral T-cell lymphoma (see also lung, other)	Phase II (949) 788-6700 (973) 895-6900
<b>Bexxar®</b> tositumomab	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	mantle-cell lymphoma	Phase II (888) 825-5249
BI 2536	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	non-Hodgkin's lymphoma (see also lung)	Phase I (800) 243-0127
<b>BiovaxID®</b> B-cell lymphoma vaccine	Biovest International <i>Tampa, FL</i>	follicular lymphoma (Fast Track)	Phase III (813) 864-2554
		mantle-cell lymphoma	Phase II (813) 864-2554
blinatumomab	Micromet <i>Bethesda, MD</i>	non-Hodgkin's lymphoma (see also leukemia)	Phase I (240) 752-1420

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
CAL-101	Calistoga Pharmaceuticals <i>Seattle, WA</i>	non-Hodgkin's lymphoma (see also leukemia, multiple myeloma)	Phase I (206) 728-4700
cancer vaccine	Bayer Innovation <i>Dusseldorf, Germany</i> Stellar Biotechnologies <i>Port Hueneme, CA</i>	follicular lymphoma (prevention of relapse)	Phase I (805) 488-2147
CC-223	Celgene <i>Summit, NJ</i>	non-Hodgkin's lymphoma (see also leukemia, solid tumors)	Phase I/II (908) 673-9000
cilengitide	EMD Serono <i>Rockland, MA</i>	late-stage lymphoma (see also brain, prostate)	Phase I completed (800) 283-8088
CST-101	ConKwest <i>Del Mar, CA</i>	(see also leukemia, lung, skin)	Phase I (858) 380-1999
CT-011	CureTech <i>Yavne, Israel</i>	diffuse large B-cell lymphoma, follicular lymphoma (see also colorectal, leukemia)	Phase II www.curetechbio.com
dacetuzumab (anti-CD40)	Seattle Genetics <i>Bothell, WA</i>	non-Hodgkin's lymphoma (see also leukemia, multiple myeloma)	Phase I (425) 527-4000
darinaparsin (ZIO-101)	ZIOPHARM Oncology <i>New York, NY</i>	(see also liver, multiple myeloma, solid tumors)	Phase II (646) 214-0700
DI-Leu16-IL2 (antibody-cytokine fusion protein)	Provenance Biopharmaceuticals <i>Waltham, MA</i>	non-Hodgkin's lymphoma	Phase I (781) 497-9888
dinaciclib	Merck <i>Whitehouse Station, NJ</i>	mantle-cell lymphoma (see also breast, leukemia, lung)	Phase II (800) 672-6371
dulanermin (rhApo2L/TRAIL)	Amgen <i>Thousand Oaks, CA</i> Genentech <i>South San Francisco, CA</i>	non-Hodgkin's lymphoma (see also colorectal)	Phase I/II (800) 772-6436 (650) 225-1000
enzastaurin	Eli Lilly <i>Indianapolis, IN</i>	diffuse large B-cell lymphoma	Phase III (800) 545-5979
epratuzumab <b>(Orphan Drug)</b>	Immunomedics <i>Morris Plains, NJ</i>	diffuse large B-cell lymphoma, follicular lymphoma (see also leukemia)	Phase II (973) 605-8200
epratuzumab Y-90	Immunomedics <i>Morris Plains, NJ</i>	recurrent non-Hodgkin's lymphoma	Phase I/II (973) 605-8200
<b>Exelbine™</b> vinorelbine emulsion	ADVENTRX Pharmaceuticals <i>San Diego, CA</i>	non-Hodgkin's lymphoma (see also breast, lung)	application submitted (858) 552-0866
EZN-2968	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	(see also solid tumors)	Phase I (908) 541-8600
EZN-3042	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	(see also leukemia, solid tumors)	Phase I (908) 541-8600
<b>Fodosine™</b> forodesine	BioCryst Pharmaceuticals <i>Birmingham, AL</i>	cutaneous T-cell lymphoma (see also leukemia)	Phase II (205) 444-4600

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
<b>Folotyn®</b> pralatrexate (Orphan Drug)	Allos Therapeutics Westminster, CO	B-cell lymphoma (see also bladder, breast, lung)	Phase II (303) 426-6262
		Hodgkin's disease, non-Hodgkin's lymphoma	Phase I/II (303) 426-6262
		cutaneous T-cell lymphoma	Phase I (303) 426-6262
GDC-0917 (IAP antagonist)	Genentech South San Francisco, CA	(see also solid tumors)	Phase I (650) 224-1000
GDC-0941 (PI3 kinase inhibitor)	Genentech South San Francisco, CA	non-Hodgkin's lymphoma (see also breast, lung, solid tumors)	Phase I (650) 224-1000
GDC-0980 (PI3 kinase/mTOR dual inhibitor)	Genentech South San Francisco, CA	non-Hodgkin's lymphoma (see also breast, solid tumors)	Phase I (650) 224-1000
<b>Genasense®</b> oblimersen	Genta Berkeley Heights, NJ	non-Hodgkin's lymphoma (see also leukemia, skin)	Phase II (908) 286-9800
GSK2141795 (AKT protein kinase inhibitor)	GlaxoSmithKline Rsch. Triangle Park, NC	(see also solid tumors)	Phase I (888) 825-5249
HGS-1029	Human Genome Sciences Rockville, MD	(see also solid tumors)	Phase I (301) 309-8504
INK128 (TORC1/2 inhibitor)	Intellikine La Jolla, CA	Waldenström's macroglobulinemia (see also multiple myeloma, solid tumors)	Phase I (858) 768-6500
inotuzumab ozogamicin (CMC-544)	UCB Smyrna, GA Pfizer New York, NY	aggressive non-Hodgkin's lymphoma	Phase III (770) 970-7500 (860) 732-5156
		indolent non-Hodgkin's lymphoma	Phase II (770) 970-7500 (860) 732-5156
ISF35	Memgen Dallas, TX	diffuse large-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma	Phase II (214) 731-3141
<b>Istodax®</b> romidepsin (Orphan Drug)	Celgene Summit, NJ	peripheral T-cell lymphoma (Fast Track)	application submitted (908) 673-9000
LEE011	Novartis Pharmaceuticals East Hanover, NJ	(see also solid tumors)	Phase I (888) 669-6682
LG740	Lentigen Gaithersburg, MD University of Pennsylvania Philadelphia, PA	diffuse large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma (see also leukemia)	Phase I (301) 527-4200
lucatumumab (HCD122)	Novartis Pharmaceuticals East Hanover, NJ XOMA Berkeley, CA		Phase I/II (888) 669-6682 (510) 204-7200



## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
<b>MabThera® SC/</b> rHuPH20/ rituximab	Halozyne <i>San Diego, CA</i> Roche <i>Nutley, NJ</i>	follicular lymphoma	Phase III (858) 794-8889 (973) 235-5000
MDX-1203 (anti-CD70 ADC)	Bristol-Myers Squibb <i>Princeton, NJ</i>	non-Hodgkin's lymphoma (see also kidney)	Phase I (212) 546-4000
mechlorethamine gel <b>(Orphan Drug)</b>	Yaupon Therapeutics <i>Radnor, PA</i>	cutaneous T-cell lymphoma (Fast Track)	Phase III (610) 975-9290
MGCD-0103	MethylGene <i>Montreal, Canada</i>	diffuse large B-cell lymphoma, follicular lymphoma (see also leukemia, solid tumors)	Phase II (514) 337-3333
milatuzumab (IMMU-115)	Immunomedics <i>Morris Plains, NJ</i>	non-Hodgkin's lymphoma (see also leukemia, multiple myeloma)	Phase I/II (973) 605-8200
mogamulizumab	Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i>	T-cell lymphoma	Phase II (609) 919-1100
navitoclax (ABT-263/RG7433)	Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i>	relapsed or refractory lymphoid malignancies (see also leukemia, lung)	Phase I/II (847) 937-6100 (650) 225-1000
NPI-0052 (marizomib)	Nereus Pharmaceuticals <i>San Diego, CA</i>	(see also multiple myeloma, solid tumors)	Phase I (858) 587-4090
obatoclax	Gemin X Biotechnologies <i>Montreal, Canada</i>	follicular lymphoma (see also leukemia, lung, multiple myeloma)	Phase II (514) 281-8989
		----- mantle-cell lymphoma	Phase I/II (514) 281-8989
ON-01910	Onconova Therapeutics <i>Princeton, NJ</i>	(see also leukemia, ovarian, solid tumors)	Phase II (609) 844-7735
ON-013105	Onconova Therapeutics <i>Princeton, NJ</i>	(see also leukemia)	Phase I (609) 844-7735
OSI-027	OSI Pharmaceuticals <i>Melville, NY</i>	(see also kidney)	Phase I (800) 572-1932
P276	Piramal Life Sciences <i>Mumbai, India</i>	mantle-cell lymphoma	Phase II
panobinostat (LBH589)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	Hodgkin's lymphoma (see also multiple myeloma, other)	application submitted (888) 669-6682
PCI-24781 (HDAC inhibitor)	Pharmacyclics <i>Sunnyvale, CA</i>	(see also sarcoma)	Phase II (408) 774-0330
PCI-32765 (BTK inhibitor)	Pharmacyclics <i>Sunnyvale, CA</i>	mantle-cell lymphoma (see also leukemia)	Phase II (408) 774-0330

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
PD-0332991	Pfizer New York, NY	mantle-cell lymphoma (see also brain, breast, multiple myeloma, sarcoma)	Phase I (860) 732-5156
perifosine (KRX-0401)	AEterna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY	recurrent lymphoma, Waldenström's macroglobulinemia (see also brain, colorectal, kidney, leukemia, multiple myeloma, ovarian, sarcoma, stomach)	Phase II (212) 531-5965
<b>Pixuvri™</b> pixantrone	Cell Therapeutics Seattle, WA	non-Hodgkin's lymphoma (Fast Track) (see also breast)	application submitted (800) 215-2355
		diffuse large B-cell lymphoma	Phase II (800) 215-2355
PLX3397	Plexxikon Berkeley, CA	recurrent or refractory Hodgkin's disease (see also solid tumors)	Phase II (510) 647-4000
PX-478	Oncothyreon Seattle, WA	(see also solid tumors)	Phase I completed (206) 801-2100
<b>Rituxan®</b> rituxumab	Biogen Idec Cambridge, MA Roche Nutley, NJ	non-Hodgkin's lymphoma (subcutaneous)	Phase III (617) 679-2000 (973) 235-5000
		non-Hodgkin's lymphoma (fast fusion)	Phase III (617) 679-2000 (973) 235-5000
SAR3419	sanofi-aventis Bridgewater, NJ	non-Hodgkin's lymphoma	Phase I (800) 633-1610
SB1518	S*Bio Redwood City, CA	late-stage lymphoma (see also leukemia)	Phase II (650) 730-2860
SCH-900776	Merck Whitehouse Station, NJ	(see also leukemia)	Phase I (800) 672-6372
SGN-35 (brentuximab vedotin) <b>(Orphan Drug)</b>	Millennium Pharmaceuticals Cambridge, MA Seattle Genetics Bothell, WA	Hodgkin's disease (combination therapy), recurrent non-Hodgkin's lymphoma	application submitted (800) 390-5663 (425) 527-4000
		non-Hodgkin's lymphoma (monotherapy) (Fast Track)	Phase II (800) 390-5663 (425) 527-4000
SGN-75	Seattle Genetics Bothell, WA	non-Hodgkin's lymphoma (see also kidney)	Phase I (425) 527-4000
SNDX-275 (entinostat)	Syndax Pharmaceuticals Waltham, MA	Hodgkin's disease (see also breast, colorectal, leukemia, lung)	Phase II (781) 419-1400
<b>Sprycel®</b> dasatinib	Bristol-Myers Squibb Princeton, NJ	non-Hodgkin's lymphoma (see also brain, breast, colorectal, leukemia, lung, multiple myeloma, prostate, skin)	Phase I/II (212) 546-4000

## LYMPHOMA

Product Name	Sponsor	Indication	Development Status
stem cell therapy	Benitec <i>Melbourne, Australia</i> City of Hope Medical Center <i>Duarte, CA</i>	AIDS-related lymphoma	Phase I www.benitec.com
<b>Telcyta®</b> canfosfamide	Telik <i>Palo Alto, CA</i>	diffuse large B-cell lymphoma, mantle-cell lymphoma non-Hodgkin's lymphoma (see also lung, ovarian)	Phase II (650) 845-7700
thiarabine	Access Pharmaceuticals <i>Dallas, TX</i>	(see also leukemia)	Phase I/II (214) 905-5100
tigatuzumab	Daiichi Sankyo <i>Parsippany, NJ</i>	(see also colorectal, liver, ovarian, pancreatic)	Phase I completed (973) 359-2600
TKM-PLK1	Tekmira Pharmaceuticals <i>Vancouver, Canada</i>	(see also solid tumors)	Phase I (604) 419-3200
<b>Treanda®</b> bendamustine	Cephalon <i>Frazer, PA</i>	first-line non-Hodgkin's lymphoma	Phase III (610) 344-0200
		----- mantle-cell lymphoma	Phase II (610) 344-0200
TRU-016 (anti-CD37)	Emergent Biosolutions <i>Rockville, MD</i>	recurrent non-Hodgkin's lymphoma (see also leukemia)	Phase I (301) 795-1800
UNBS-5162	Drais Pharmaceuticals <i>Bridgewater, NJ</i>	(see also solid tumors)	Phase I (908) 895-1200
<b>Velcade®</b> bortezomib	Millennium Pharmaceuticals <i>Cambridge, MA</i>	relapsed or refractory follicular lymphoma, first-line mantle-cell lymphoma (see also multiple myeloma)	Phase III (800) 390-5663
		----- diffuse large B-cell lymphoma	Phase II (800) 390-5663
veltuzumab (IMMU-106)	Immunomedics <i>Morris Plains, NJ</i>	non-Hodgkin's lymphoma (see also leukemia)	Phase I/II (973) 605-8200
vinorelbine liposomal	Talon Therapeutics <i>South San Francisco, CA</i>	non-Hodgkin's lymphoma (see also solid tumors)	Phase I (650) 588-6404
XmAb 2513	Xencor <i>Monrovia, CA</i>	Hodgkin's disease, T-cell lymphoma	Phase I (626) 305-5900
YM-155	Astellas Pharma US <i>Deerfield, IL</i>	non-Hodgkin's lymphoma (see also breast)	Phase II (800) 727-7003
zanolimumab	TenX Biopharma <i>Philadelphia, PA</i>	cutaneous T-cell lymphoma (Fast Track)	Phase III (215) 774-1176
		----- peripheral T-cell lymphoma	Phase II completed (215) 774-1176

## MULTIPLE MYELOMA

Product Name	Sponsor	Indication	Development Status
ACE-041	Acceleron Pharma <i>Cambridge, MA</i>	(see also solid tumors)	Phase I (617) 649-9200
<b>Actimid™</b> pomalidomide	Celgene <i>Summit, NJ</i>	recurrent multiple myeloma	Phase II (908) 673-9000
ALXN-6000 (samalizumab)	Alexion Pharmaceuticals <i>Cheshire, CT</i>	(see also leukemia)	Phase I/II (203) 272-2596
anti-FGFR3 mAb (RG7444)	Genentech <i>South San Francisco, CA</i>	refractory, metastatic multiple myeloma	Phase I (650) 224-1000
<b>Aplidin®</b> plitidepsin <b>(Orphan Drug)</b>	PharmaMar USA <i>Cambridge, MA</i>	(see also lymphoma, solid tumors)	Phase III (617) 868-3797
AR-42	Arno Therapeutics <i>Parsippany, NJ</i>	(see also leukemia, lymphoma)	Phase I/II (862) 703-7170
ARRY-520	Array BioPharma <i>Boulder, CO</i>	(see also leukemia, solid tumors)	Phase II (303) 381-6600
AT7519	Astex Therapeutics <i>Cambridge, United Kingdom</i>	(see also solid tumors)	Phase I/II www.astex-therapeutics.com
ATN-224	Tactic Pharma <i>Evanston, IL</i>	(see also prostate, skin)	Phase I/II (847) 733-0940
AUY922	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also breast, colorectal, lung, stomach)	Phase I/II (888) 669-6682
AV-299 (ficlatuzumab)	AVEO Pharmaceuticals <i>Cambridge, MA</i>	(see also brain, lymphoma, solid tumors)	Phase I (617) 299-5000
BHQ880	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also solid tumors)	Phase II (888) 669-6682
BI-505	BioInvent International <i>Lund, Sweden</i>	late-stage multiple myeloma	Phase I www.bioinvent.com
BIW-8962	BioWa <i>Princeton, NJ</i>		Phase I/II (609) 580-7500
<b>BT-062</b> <b>(Orphan Drug)</b>	Biotest <i>Dreieich, Germany</i>		Phase I/II www.biotest.com
CAL-101	Calistoga Pharmaceuticals <i>Seattle, WA</i>	(see also leukemia, lymphoma)	Phase I (206) 728-4700
carfilzomib <b>(Orphan Drug)</b>	Onyx Pharmaceuticals <i>Emeryville, CA</i>	(Fast Track) (see also solid tumors)	application submitted (510) 597-6500
CB3304	Cougar Biotechnology <i>Los Angeles, CA</i>		Phase I/II (310) 943-8040
CC-223	Celgene <i>Summit, NJ</i>	(see also lymphoma, solid tumors)	Phase I/II (908) 673-9000
CEP-18770 (proteasome inhibitor)	Cephalon <i>Frazer, PA</i>		Phase II (610) 344-0200
CNTO 328 (siltuximab)	Centocor Ortho Biotech <i>Horsham, PA</i>	(see also prostate, other)	Phase II (800) 457-6399

## MULTIPLE MYELOMA

Product Name	Sponsor	Indication	Development Status
CX-4945	Cylene Pharmaceuticals <i>San Diego, CA</i>	(see also solid tumors, other)	Phase I (858) 875-5100
dacetuzumab (anti-CD40) <b>(Orphan Drug)</b>	Seattle Genetics <i>Bothell, WA</i>	(see also leukemia, lymphoma)	Phase I (425) 527-4000
darinaparsin (ZIO-101)	Ziopharm Oncology <i>New York, NY</i>	(see also liver, lymphoma, solid tumors)	Phase II completed (646) 214-0700
elotuzumab (BMS-901608)	Bristol-Myers Squibb <i>Princeton, NJ</i> Facet Biotech <i>Redwood City, CA</i>		Phase I/II (212) 546-4000 (650) 454-1000
ENMD-2076	EntreMed <i>Rockville, MD</i>	relapsed or refractory multiple myeloma (see also ovarian, other)	Phase I (240) 864-2600
GRN-163L (imetelstat)	Geron <i>Menlo Park, CA</i>	(see also breast, leukemia, lung)	Phase II (650) 473-7700
<b>GVAX® Multiple Myeloma</b>	BioSante Pharmaceuticals <i>Lincolnshire, IL</i>	(see also breast, colorectal, leukemia, pancreatic)	Phase II (847) 478-0500
IMGN-901	ImmunoGen <i>Cambridge, MA</i>	(see also lung)	Phase I (617) 995-2500
INK128 (TORC1/2 inhibitor)	Intellikine <i>La Jolla, CA</i>	(see also lymphoma, solid tumors)	Phase I (858) 768-6500
IPH-2101	Innate Pharma <i>Marseille, France</i>		Phase II <a href="http://www.innate-pharma.com">www.innate-pharma.com</a>
KW-2478	Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i>		Phase I/II (609) 919-1100
LY2127399 (BAFF antibody)	Applied Molecular Evolution <i>San Diego, CA</i> Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
mapatumumab	Human Genome Sciences <i>Rockville, MD</i>	(see also liver, lung)	Phase II (301) 309-8504
melfalan intravenous <b>(Orphan Drug)</b>	CyDex Pharmaceuticals <i>Lenexa, KS</i>		Phase II (888) 436-6910
milatuzumab (IMMU-115) <b>(Orphan Drug)</b>	Immunomedics <i>Morris Plains, NJ</i>	(see also leukemia, lymphoma)	Phase I/II (973) 605-8200
NPI-0052 (marizomib)	Nereus Pharmaceuticals <i>San Diego, CA</i>	(see also lymphoma, solid tumors)	Phase I (858) 587-4090
obatoclax	Gemin X Biotechnologies <i>Montreal, Canada</i>	(see also leukemia, lung, lymphoma)	Phase I (514) 281-8989
panobinostat (LBH589)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also lymphoma, other)	Phase III (888) 669-6682
PD-0332991	Pfizer <i>New York, NY</i>	(see also brain, breast, lymphoma, sarcoma)	Phase I/II (860) 732-5156

## MULTIPLE MYELOMA

Product Name	Sponsor	Indication	Development Status
perifosine (KRX-0401) <b>(Orphan Drug)</b>	AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i>	recurrent multiple myeloma (Fast Track) (see also brain, colorectal, kidney, leukemia, lymphoma, ovarian, sarcoma, stomach)	Phase III (212) 531-5965
<b>Quadramet®</b> samarium sm-153 lexidronam injection	EUSA Pharma <i>Langhorne, PA</i>	(see also prostate, sarcoma, other)	Phase I/II completed (800) 833-3533
SF1126	Semafore Pharmaceuticals <i>Indianapolis, IN</i>	(see also multiple myeloma, solid tumors)	Phase I (317) 876-3075
<b>Sprycel®</b> dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also brain, breast, colorectal, leukemia, lung, lymphoma, prostate, skin)	Phase I (212) 546-4000
<b>Treanda®</b> bendamustine	Cephalon <i>Frazer, PA</i>	(see also lymphoma)	Phase II (610) 344-0200
<b>Trisenox®</b> arsenic trioxide	Cephalon <i>Frazer, PA</i>	combination therapy (see also brain, leukemia)	Phase II (610) 344-0200
VEL-0230	Velcura Therapeutics <i>Ann Arbor, MI</i>		Phase I completed (734) 973-1000
<b>Velcade®</b> bortezomib (subcutaneous)	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also lymphoma)	Phase III (800) 390-5663
<b>Zolinza®</b> vorinostat <b>(Orphan Drug)</b>	Merck <i>Whitehouse Station, NJ</i>	(see also breast, other)	Phase III (800) 672-6372

## OVARIAN CANCER

Product Name	Sponsor	Indication	Development Status
Å6	Angstrom Pharmaceuticals <i>Solana Beach, CA</i>	(see also other)	Phase II (858) 314-2356
abagovomab (anti-idiotypic ovarian cancer vaccine) <b>(Orphan Drug)</b>	Menarini <i>Florence, Italy</i>		Phase II/III www.menarini.com
<b>Abraxane®</b> albumin-bound paclitaxel	Celgene <i>Summit, NJ</i>	(see also bladder, lung, pancreatic, skin)	Phase II (908) 673-9000
ABT-888 (veliparib)	Abbott Laboratories <i>Abbott Park, IL</i>	(see also brain, breast, colorectal, prostate, skin, other)	Phase II (847) 937-6100
AE-37	Antigen Express <i>Worcester, MA</i>	(see also breast)	Phase I (508) 852-8783
AMG 386	Amgen <i>Thousand Oaks, CA</i>	(see also breast, colorectal, kidney, liver, stomach, other)	Phase III (800) 772-6436

## OVARIAN CANCER

Product Name	Sponsor	Indication	Development Status
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	first-line metastatic ovarian cancer, recurrent platinum-sensitive ovarian cancer (see also brain, breast, colorectal, lung, other)	Phase III (650) 225-1000
BC-819	BioCancell Therapeutics <i>Jerusalem, Israel</i>	(see also bladder, pancreatic)	Phase I/II www.biocancell.com
catumaxomab	Fresenius Biotech North America <i>Waltham, MA</i>	(see also other)	Phase II www.fresenius-biotech.com
<b>CVax™</b> MUC-2 cancer vaccine	Prima BioMed <i>Armadale, Australia</i>		Phase II www.prima biomed.com.au
<b>DCVax®-L</b> ovarian cancer vaccine	Northwest Biotherapeutics <i>Bothell, WA</i>	(see also other)	Phase I/II (425) 608-3000
DPX-0907	Immunovaccine <i>Halifax, Canada</i>	(see also breast, prostate)	Phase I (902) 492-1819
EC-145	Endocyte <i>West Lafayette, IN</i>	(see also lung, other)	Phase II (765) 463-7175
EGEN 001 <b>(Orphan Drug)</b>	EGEN <i>Huntsville, AL</i>	recurrent ovarian cancer (see also other)	Phase II (256) 512-0077
		refractory metastatic ovarian cancer	Phase I (256) 512-0077
ENMD-2076	EntreMed <i>Rockville, MD</i>	platinum-resistant ovarian cancer (see also multiple myeloma, other)	Phase II (240) 864-2600
farletuzumab (MORAb-003)	Eisai <i>Woodcliff Lake, NJ</i>	(see also lung)	Phase III (888) 422-4743
iboctadekin	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>		Phase I (888) 825-5249
IMT-1012 (immunotherapeutic vaccine)	Immunotope <i>Doylestown, PA</i>	(see also breast)	Phase I (215) 253-4180
iniparib (BSI-201)	BiPar Sciences <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i>	(see also breast, lung)	Phase II (800) 633-1810
<b>Karenitecin®</b> cositecan	BioNumerik Pharmaceuticals <i>San Antonio, TX</i>	advanced epithelial ovarian cancer	Phase III (210) 614-1701
KHK-2866	Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i>	(see also solid tumors)	Phase I (609) 919-1100
lenvatinib (E7080)	Eisai <i>Woodcliff Lake, NJ</i>	(see also brain, kidney, liver, skin, other)	Phase I/II (888) 422-4743



## OVARIAN CANCER

Product Name	Sponsor	Indication	Development Status
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals Wayne, NJ Onyx Pharmaceuticals Emeryville, CA	(see also breast, colorectal, kidney, liver, lung, other)	Phase II (888) 842-2837 (510) 597-6500
NKTR-102	Nektar Therapeutics San Francisco, CA	metastatic ovarian cancer (see also breast, colorectal)	Phase II (415) 482-5300
NOV-002	Novelos Therapeutics Newton, MA	(see also breast)	Phase II completed (617) 244-1616
OGX-427	Oncogenex Pharmaceuticals Bothell, WA	(see also bladder, breast, lung, prostate)	Phase I (425) 686-1500
olaparib	AstraZeneca Wilmington, DE	serous ovarian cancer	Phase II (800) 236-9933
ON-01910	Onconova Therapeutics Princeton, NJ	(see also leukemia, lymphoma, solid tumors)	Phase II (609) 844-7735
<b>Opaxio™</b> paclitaxel poliglumex	Cell Therapeutics Seattle, WA Novartis Pharmaceuticals East Hanover, NJ	(see also lung, other)	Phase III (800) 215-2355 (888) 669-6682
oregovomab	Quest Pharmatech Edmonton, Canada		Phase I/II (780) 448-1400
OSI-906 (linsitinib)	OSI Pharmaceuticals Melville, NY	(see also lung, other)	Phase II (631) 962-2000
<b>OVax®</b> ovarian cancer vaccine <b>(Orphan Drug)</b>	AVAX Technologies Philadelphia, PA		Phase I/II (215) 241-9760
perifosine (KRX-0401)	AEterna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY	(see also brain, colorectal, kidney, leukemia, lymphoma, multiple myeloma, sarcoma, stomach)	Phase I (212) 531-5965
PF-01367338	Pfizer New York, NY	(see also breast, skin)	Phase II (860) 732-5156
phenoxodiol	Marshall Edwards San Diego, CA	late-stage ovarian cancer (Fast Track) (see also prostate, other)	Phase III (858) 792-6300
picoplatin intravenous	Poniard Pharmaceuticals San Francisco, CA	(see also colorectal, lung, prostate)	Phase II (650) 583-3774
<b>Quinamed®</b> amonafide	ChemGenex Pharmaceuticals Menlo Park, CA	(see also breast, prostate)	Phase II (650) 474-9800
sagopilone	Bayer HealthCare Pharmaceuticals Wayne, NJ	(see also brain, breast, prostate)	Phase II (888) 842-2937

## OVARIAN CANCER

Product Name	Sponsor	Indication	Development Status
SAR256212 (MM-121)	Merrimack Pharmaceuticals Cambridge, MA sanofi-aventis Bridgewater, NJ	(see also breast, solid tumors)	Phase I (617) 441-1000 (800) 633-1810
SG2000	Spirogen London, United Kingdom		Phase II www.spirogen.com
squalamine	OHR Pharmaceuticals New York, NY	resistant ovarian cancer	Phase II (212) 682-8452
<b>Telcyta®</b> canfosfamide	Telik Palo Alto, CA	(see also lung, lymphoma)	Phase III completed (650) 845-7700
tigatuzumab	Daiichi Sankyo Parsippany, NJ	(see also colorectal, liver, lymphoma, pancreatic)	Phase II (973) 359-2600
topotecan liposomal	Talon Therapeutics South San Francisco, CA	(see also lung)	Phase I (650) 588-6404
trabectedin (Orphan Drug)	Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ	(see also breast, prostate, sarcoma)	application submitted (800) 817-5286
volociximab	Biogen Idec Cambridge, MA Facet Biotech Redwood City, CA	(see also lung)	Phase II (617) 679-2000 (650) 454-1000
vosaroxin (SNS-595)	Sunesis Pharmaceuticals South San Francisco, CA	platinum-resistant ovarian cancer (see also leukemia)	Phase II (650) 266-3500
<b>Votrient®</b> pazopanib	GlaxoSmithKline Rsch. Triangle Park, NC	(see also breast, kidney, sarcoma)	Phase III (888) 825-5249
<b>Zybrexat™</b> fosbretabulin (Orphan Drug)	OXiGENE South San Francisco, CA	(see also lung, other)	Phase II (650) 635-7000

## PANCREATIC CANCER

Product Name	Sponsor	Indication	Development Status
<b>Abraxane®</b> albumin-bound paclitaxel (Orphan Drug)	Celgene Summit, NJ	(see also bladder, lung, ovarian, skin)	Phase III (908) 673-9000
AGS-1C4D4	Agensys Santa Monica, CA Astellas Pharma US Deerfield, IL		Phase II (310) 820-8029 (800) 477-6472
AMG 479 (ganitumab)	Amgen Thousand Oaks, CA	(see also breast, colorectal, lung, sarcoma, other)	Phase III (800) 772-6436
anti-MUC1 mAb	Quest PharmaTech Edmonton, Canada		Phase I/II (780) 448-1400

## PANCREATIC CANCER

Product Name	Sponsor	Indication	Development Status
apricoxib	Tragara Pharmaceuticals <i>San Diego, CA</i>	(see also lung)	Phase II (858) 350-6900
ARC-100	Archer Biosciences <i>New York, NY</i>	(see also brain, prostate, skin)	Phase II (646) 747-9090
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	(see also colorectal, kidney, liver, lung, sarcoma, solid tumors, other)	Phase I (781) 994-0300 (973) 944-2600
ASG-5ME	Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i>	metastatic pancreatic cancer (see also prostate)	Phase I (301) 820-8029 (800) 477-6472
bavituximab	Peregrine Pharmaceuticals <i>Tustin, CA</i>	(see also breast, liver)	Phase II (714) 508-6000
BC-819	BioCancell Therapeutics <i>Jerusalem, Israel</i>	inoperable/unresectable pancreatic cancer (see also bladder, ovarian)	Phase I/II www.biocancell.com
CO-101/CP-4126 (Orphan Drug)	Clovis Oncology <i>Boulder, CO</i>		Phase II (303) 625-5000
conatumumab	Amgen <i>Thousand Oaks, CA</i>	(see also colorectal, lung, sarcoma)	Phase I/II (800) 772-6436
CPI-613 (Orphan Drug)	Cornerstone Pharmaceuticals <i>Cranbury, NJ</i>	(see also other)	Phase I/II (609) 409-7050
dalotuzumab	Merck <i>Whitehouse Station, NJ</i>	(see also breast, colorectal, lung, other)	Phase I/II (888) 669-6682
encapsulated cell therapy (macrobeads)	Rogosin Institute <i>New York, NY</i>	refractory metastatic pancreatic cancer (see also colorectal, prostate)	Phase II (212) 746-1225
ensituximab	Neogenix Oncology <i>Great Neck, NY</i>	inoperable/unresectable, late-stage, metastatic pancreatic cancer (see also colorectal)	Phase I (516) 482-1200
FG-3019	Fibrogen <i>San Francisco, CA</i>		Phase II (415) 978-1200
GI-4000	GlobeImmune <i>Louisville, CO</i>	(see also colorectal, lung)	Phase II (303) 625-2700
glufosfamide (Orphan Drug)	Eleison Pharmaceuticals <i>Princeton, NJ</i>	(Fast Track)	Phase III completed (215) 416-7620
GSK1120212 (MEK inhibitor)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also skin, solid tumors)	Phase II (888) 825-5249
GVAX® Pancreatic (Orphan Drug)	BioSante Pharmaceuticals <i>Lincolnshire, IL</i>	(see also breast, colorectal, leukemia, multiple myeloma)	Phase II (847) 478-0500
HyperAcute® Pancreas algenpantucel-L (Orphan Drug)	NewLink Genetics <i>Ames, IA</i>	(Fast Track)	Phase III (515) 296-5555

## PANCREATIC CANCER

Product Name	Sponsor	Indication	Development Status
IPI-926	Infinity Pharmaceuticals <i>Cambridge, MA</i>	(see also sarcoma, solid tumors)	Phase I/II (617) 453-1000
JX-929	Jenerex Biotherapeutics <i>San Francisco, CA</i>		Phase I (415) 281-8886
LE-DT	NeoPharm <i>Lake Bluff, IL</i>	late-stage, metastatic pancreatic cancer (see also prostate)	Phase II (847) 887-0800
masitinib	AB Science USA <i>Short Hills, NJ</i>	(see also leukemia, stomach)	Phase III (973) 218-2437
MM-398	Merrimack Pharmaceuticals <i>Cambridge, MA</i>	metastatic pancreatic cancer	Phase II (617) 441-1000
naptumomab estafenatox	Active Biotech <i>Lund, Sweden</i>	(see also kidney, lung)	Phase I completed <a href="http://www.activebiotech.com">www.activebiotech.com</a>
<b>PancAtak™</b> gene therapy	Advantagene <i>Auburndale, MA</i>		Phase I (617) 916-5445
PCI-27483 (factor VIIa inhibitor)	Pharmacyclics <i>Sunnyvale, CA</i>		Phase II (408) 774-0330
polyclonal antibody stimulator <b>(Orphan Drug)</b>	Cancer Advances <i>Durham, NC</i>	(see also colorectal, stomach)	Phase III (919) 361-2162
<b>Reolysin®</b> reovirus	Oncolytics Biotech <i>Calgary, Canada</i>	(see also brain, colorectal, head/neck, lung, sarcoma, skin)	Phase II (403) 670-7377
<b>Rexin-G™</b> tumor-targeted gene therapy <b>(Orphan Drug)</b>	Epeius Biotechnologies <i>San Marino, CA</i>	recurrent, refractory metastatic pancreatic cancer (Fast Track) (see also breast, sarcoma)	Phase I/II (626) 441-6695
RX-0201 <b>(Orphan Drug)</b>	Rexahn Pharmaceuticals <i>Rockville, MD</i>		Phase II (240) 268-5300
salirasib <b>(Orphan Drug)</b>	Concordia Pharmaceuticals <i>Ft. Lauderdale, FL</i>	(see also lung)	Phase I/II <a href="http://www.concordiapharma.com">www.concordiapharma.com</a>
<b>Sutent®</b> sunitinib	Pfizer <i>New York, NY</i>	pancreatic islet cell tumors (see also kidney)	application submitted (860) 732-5156
TH-302	Threshold Pharmaceuticals <i>Redwood City, CA</i>	(see also leukemia, sarcoma, solid tumors)	Phase II (650) 474-8200
tigatuzumab	Daiichi Sankyo <i>Parsippany, NJ</i>	(see also colorectal, liver, lymphoma, ovarian)	Phase II completed (973) 359-2600
tremelimumab (CP-675206)	Pfizer <i>New York, NY</i>	(see also kidney, skin, stomach, other)	Phase II (860) 732-5156
virulizin	Zor Pharmaceuticals <i>Wilmington, NC</i>		Phase III (919) 946-4457
Y-90 hPAM4 (IMMU-107) <b>(Orphan Drug)</b>	Immunomedics <i>Morris Plains, NJ</i>		Phase I/II (973) 605-8200

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
ABI-008 (nab <sup>®</sup> -docetaxel)	Celgene <i>Summit, NJ</i>	hormone-refractory prostate cancer	Phase II (908) 673-9000
abiraterone acetate (CB7630)	Cougar Biotechnology <i>Raritan, NJ</i>	metastatic advanced prostate cancer (see also breast)	application submitted (800) 817-5286
ABR-215050 (tasquinimod)	Active Biotech <i>Lund, Sweden</i>		Phase III <a href="http://www.activebiotech.com">www.activebiotech.com</a>
ABT-888 (veliparib)	Abbott Laboratories <i>Abbott Park, IL</i>	(see also brain, breast, colorectal ovarian, skin, other)	Phase I (847) 937-6100
<b>Acapodene<sup>®</sup></b> toremifene	GTx <i>Memphis, TN</i>	prostatic intraepithelial neoplasia (prevention) (see also cancer/chemotherapy)	Phase III (901) 523-9700
AEZS-108	AEterna-Zentaris <i>Warren, NJ</i>	(see also bladder)	Phase I/II (908) 626-5428
aflibercept (VEGF-trap)	sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i>	first-line metastatic prostate cancer (see also colorectal, lung)	Phase III (800) 633-1610 (714) 345-7400
androgen receptor antagonist	Endo Pharmaceuticals <i>Chadds Ford, PA</i> Orion <i>Espoo, Finland</i>		Phase I (800) 462-3636
ARC-100	Archer Biosciences <i>New York, NY</i>	(see also brain, pancreatic, skin)	Phase II (646) 747-9090
ARN-509	Aragon Pharmaceuticals <i>San Diego, CA</i>		Phase I/II (858) 369-7600
ASG-5ME	Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i>	castration-resistant prostate cancer (see also pancreatic)	Phase I (301) 820-8029 (800) 477-6472
AT-101	Ascenta Therapeutics <i>Malvern, PA</i>	(see also brain, leukemia, lung, lymphoma, stomach)	Phase II (618) 408-0301
ATN-224	Tactic Pharma <i>Evanston, IL</i>	(see also multiple myeloma, skin)	Phase II (847) 733-0940
<b>Avodart<sup>®</sup></b> dutasteride	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	prostate cancer prevention, prostatic intraepithelial neoplasia	application submitted (888) 825-5249
AZD3514 (androgen receptor down regulator)	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
bafetinib	CytRx <i>Los Angeles, CA</i>	hormone-refractory prostate cancer (see also leukemia)	Phase II (310) 826-5648
BPX-101 (BP-GMAX-CD1)	Bellicum Pharmaceuticals <i>Houston, TX</i>		Phase I/II (713) 341-6472
carlumab	Centocor Ortho Biotech <i>Horsham, PA</i>	metastatic prostate cancer (see also solid tumors)	Phase II (800) 457-6399
cilengitide	EMD Serono <i>Rockland, MA</i>	(see also brain, lymphoma)	Phase II (800) 283-8088

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
CNTO 95	Centocor Ortho Biotech <i>Horsham, PA</i>	(see also skin, solid tumors)	Phase II completed (800) 457-6399
CNTO 328 (siltuximab)	Centocor Ortho Biotech <i>Horsham, PA</i>	hormone-refractory prostate cancer (see also multiple myeloma, other)	Phase I (800) 457-6399
CV9103	Curevac <i>Tübingen, Germany</i>		Phase I/II <a href="http://www.curevac.de">www.curevac.de</a>
<b>DCVax®-Prostate</b> prostate cancer vaccine	Northwest Biotherapeutics <i>Bothell, WA</i>		Phase III (425) 608-3000
DPX-0907	Immunovaccine <i>Halifax, Canada</i>	(see also breast, ovarian)	Phase I (902) 492-1819
encapsulated cell therapy (macrobeads)	Rogosin Institute <i>New York, NY</i>	refractory metastatic pancreatic cancer (see also colorectal, pancreatic)	Phase II (212) 746-1225
eribulin (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	(see also bladder, lung, sarcoma)	Phase II (888) 422-4743
<b>Gleevec®</b> imatinib	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase II/III (888) 669-6682
GRNVAC1	Geron <i>Menlo Park, CA</i>	(see also leukemia)	Phase I/II (650) 473-7700
GTx-758	GTx <i>Memphis, TN</i>		Phase II completed (901) 523-9700
HE-3235	Harbor Biosciences <i>San Diego, CA</i>	hormone-resistant prostate cancer	Phase II completed (858) 587-9333
<b>HyperAcute®</b> <b>Prostate</b> prostate cancer vaccine	NewLink Genetics <i>Ames, IA</i>	hormone-refractory prostate cancer	Phase I/II completed (515) 296-5555
INSM-18	Triact Therapeutics <i>Palo Alto, CA</i>		Phase I/II
ipilimumab	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also lung, skin)	Phase III (212) 546-4000
irofulven (E7850)	Eisai <i>Woodcliff Lake, NJ</i>		Phase II (888) 422-4743
irosustat	Ipsen <i>Paris, France</i>		Phase I <a href="http://www.ipsen.com">www.ipsen.com</a>
JNJ-26854165	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	(see also lung, solid tumors)	Phase I (800) 817-5286
KX2-391	Kinex Pharmaceuticals <i>Buffalo, NY</i>		Phase II (716) 881-8984
LE-DT	NeoPharm <i>Lake Bluff, IL</i>	castration-resistant metastatic prostate cancer (see also pancreatic)	Phase II (847) 887-0800

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
<b>Leupron Depot®</b> leuporelin depot (6-month formulation)	Abbott Pharmaceuticals <i>Abbott Park, IL</i>		application submitted (847) 937-6100
MDV-3100	Astellas Pharma US <i>Deerfield, IL</i> Medivation <i>San Francisco, CA</i>	hormone-refractory prostate cancer	Phase III (800) 727-7003 (415) 543-3470
mepacrine (CBLC102)	Incuron <i>Buffalo, NY</i>	hormone-refractory prostate cancer	Phase II completed (716) 849-6810
MER-104	Merrion Pharmaceuticals <i>Wilmington, NC</i>		Phase I (910) 799-1847
MIP1095	Molecular Insight Pharmaceuticals <i>Cambridge, MA</i>	diagnosis of prostate cancer	Phase I (617) 492-5554
MVA-5T4	Oxford BioMedica <i>Oxford, United Kingdom</i>		Phase II <a href="http://www.oxfordbiomedica.co.uk">www.oxfordbiomedica.co.uk</a>
<b>MVA-BN®-PRO</b>	BN ImmunoTherapeutics <i>Mountain View, CA</i>		Phase I/II (650) 681-4660
<b>NeuVax™</b> E75 cancer vaccine	Apthera <i>Scottsdale, AZ</i>	(see also breast)	Phase I/II <a href="http://www.apthera.com">www.apthera.com</a>
nimotuzumab	YM Biosciences USA <i>Lehigh Valley, PA</i>	(see also brain, breast)	Phase II (610) 560-0600
OGX-427	Oncogenex Pharmaceuticals <i>Bothell, WA</i>	hormone-refractory prostate cancer (see also bladder, breast, lung, ovarian)	Phase II (425) 686-1500
<b>Onyvax-P</b> anti-idiotypic cancer vaccine 105AD7	VaxOnco <i>Seoul, South Korea</i>		Phase II <a href="http://www.vaxonco.com">www.vaxonco.com</a>
ozarelix	Spectrum Pharmaceuticals <i>Irvine, CA</i>		Phase II (949) 788-6700
phenoxodiol	Marshall Edwards <i>San Diego, CA</i>	(Fast Track) (see also ovarian, other)	Phase II completed (858) 792-6300
picoplatin intravenous	Poniard Pharmaceuticals <i>San Francisco, CA</i>	(see also colorectal, lung, ovarian)	Phase II (650) 583-3774
polyphenon E	Polyphenon Pharma <i>New York, NY</i>	prostatic intraepithelial neoplasia (see also leukemia)	Phase II (212) 661-0578
<b>Proscar®</b> finasteride	Merck <i>Whitehouse Station, NJ</i>	prevention of prostate cancer	Phase III completed (800) 673-6372
<b>ProstAtak™</b> gene therapy	Advantagene <i>Auburndale, MA</i>		Phase II completed (617) 916-5445
<b>Prostvac®-VF</b> prostate cancer vaccine	BN ImmunoTherapeutics <i>Mountain View, CA</i>	metastatic prostate cancer (Fast Track)	Phase II (650) 681-4660



## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
<b>Provenge®</b> sipuleucel-T	Dendreon <i>Seattle, WA</i>	androgen-dependent recurrent prostate cancer	Phase III (877) 256-4545
		early-stage prostate cancer (neoadjuvant therapy)	Phase II (877) 256-4545
PRX302	Protox Therapeutics <i>Vancouver, Canada</i>		Phase II (604) 688-0199
PSMA ADC	Progenics Pharmaceuticals <i>Tarrytown, NY</i>		Phase I (914) 789-2800
PSMA subunit vaccine	Progenics <i>Tarrytown, NY</i>		Phase I (914) 789-2800
PSMA VRP	Progenics Pharmaceuticals <i>Tarrytown, NY</i>		Phase I (914) 789-2800
<b>Quadramet®</b> samarium SM-153 leixidronam injection	EUSA Pharma <i>Langhorne, PA</i>	(see also multiple myeloma, sarcoma, other)	Phase II (800) 833-3533
<b>Quinamed®</b> amonafile	ChemGenex Pharmaceuticals <i>Menlo Park, CA</i>	(see also breast, ovarian)	Phase II (650) 474-9800
REIC gene therapy	Momotaro-Gene <i>Okayama, Japan</i>		Phase I <a href="http://www.mt-gene.com">www.mt-gene.com</a>
<b>Revlimid®</b> lenalidomide	Celgene <i>Summit, NJ</i>		Phase III (908) 673-9000
rilotumumab	Amgen <i>Thousand Oaks, CA</i>	(see also brain, colorectal, lung, stomach)	Phase II (800) 772-6436
sagopilone	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	(see also brain, breast, ovarian)	Phase II (888) 842-2937
seocalcitol (CB1089)	Cougar Biotechnology <i>Los Angeles, CA</i>		Phase I (310) 943-8040
SL052	Quest PharmaTech <i>Edmonton, Canada</i>		Phase I/II (780) 448-1400
<b>Sprycel®</b> dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also brain, breast, colorectal, leukemia, lung, lymphoma, multiple myeloma, skin)	Phase II/III (212) 546-4000
TAK-448	Millennium Pharmaceuticals <i>Cambridge, MA</i>		Phase I/II (800) 390-5663
TAK-700 (orteronel)	Millennium Pharmaceuticals <i>Cambridge, MA</i>	metastatic hormone-refractory prostate cancer	Phase III (800) 390-5663
tesetaxel	Genta <i>Berkeley Heights, NJ</i>	advanced prostate cancer (see also bladder, breast, skin, stomach)	Phase II (908) 286-9800
tigapotide	Kotinos Pharmaceuticals <i>New York, NY</i>		Phase II

## PROSTATE CANCER

Product Name	Sponsor	Indication	Development Status
TOK-01	Tokai Pharmaceuticals <i>Cambridge, MA</i>		Phase I/II (617) 225-4305
trabectedin	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	(see also breast, ovarian, sarcoma)	Phase II (800) 817-5286
TRC105	TRACON Pharmaceuticals <i>San Diego, CA</i>	metastatic prostate cancer (see also solid tumors)	Phase I/II (858) 550-0780
<b>Trofex™</b> radiolabelled diagnostic	Molecular Insight Pharmaceuticals <i>Cambridge, MA</i>	diagnosis of prostate cancer	Phase I (617) 492-5554
TV-1001/OCX-011 (custiren)	OncoGenex Pharmaceuticals <i>Bothell, WA</i> Teva Pharmaceutical <i>Tikva, Israel</i>	metastatic prostate cancer (Fast Track) (see also lung)	Phase III (425) 686-1500 www.tevapharm.com
zibotentan	AstraZeneca <i>Wilmington, DE</i>	castration-resistant prostate cancer (Fast Track)	Phase III (800) 236-9933

## SARCOMA

Product Name	Sponsor	Indication	Development Status
8H9 mAb	United Therapeutics <i>Silver Spring, MD</i>	soft tissue sarcoma (see also brain, other)	Phase I (301) 608-9292
AMG 479 (ganitumab)	Amgen <i>Thousand Oaks, CA</i>	(see also breast, colorectal, lung, pancreatic, other)	Phase II (800) 772-6436
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	soft tissue sarcoma (see also colorectal, liver, lung, pancreatic, sarcoma, other)	Phase II (781) 994-0300 (973) 944-2600
cancer vaccine	MabVax Therapeutics <i>San Diego, CA</i>		Phase II (858) 259-9405
conatumumab	Amgen <i>Thousand Oaks, CA</i>	(see also colorectal, lung, pancreatic)	Phase I/II (800) 772-6436
eribulin (E7389)	Eisai <i>Woodcliff Lake, NJ</i>	(see also bladder, lung, prostate)	Phase II (888) 422-4743
IPI-926	Infinity Pharmaceuticals <i>Cambridge, MA</i>	inoperable/unresectable chondrosarcoma	Phase I (617) 453-1000
mifamurtide	Millennium Pharmaceuticals <i>Cambridge, MA</i>	osteosarcoma	Phase III (800) 390-5663
ombrabulin (AVE8062)	sanofi-aventis <i>Bridgewater, NJ</i>		Phase III (800) 633-1610

## SARCOMA

Product Name	Sponsor	Indication	Development Status
palifosfamide (ZIO-201) <b>(Orphan Drug)</b>	ZIOPHARM Oncology New York, NY	soft-tissue sarcoma (first-line therapy) (see also lung)	Phase III (212) 214-0700
		soft-tissue sarcoma (second-line therapy)	Phase I/II (212) 214-0700
PCI-24781 (HDAC inhibitor)	Pharmacyclics Sunnyvale, CA	(see also lymphoma)	Phase I (408) 774-0330
PD-0332991	Pfizer New York, NY	late-stage liposarcoma (see also brain, breast, lymphoma)	Phase II (860) 732-5156
perifosine (KRX-0401)	AEterna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY	(see also brain, colorectal, kidney, leukemia, lymphoma, multiple myeloma, ovarian, stomach)	Phase II (212) 531-5965
<b>Quadramet®</b> samarium sm-153 lexidronam injection	EUSA Pharma Langhorne, PA	osteosarcoma (see also multiple myeloma, prostate, other)	Phase I/II (800) 833-3533
<b>Reolysin®</b> reovirus	Oncolytics Biotech Calgary, Canada	(see also brain, colorectal, head/neck, lung, pancreatic, skin)	Phase II (403) 670-7377
<b>Rexin-G™</b> tumor-targeted gene therapy <b>(Orphan Drug)</b>	Epeius Biotechnologies San Marino, CA	osteosarcoma (see also breast, pancreatic)	Phase II (626) 441-6695
		soft tissue sarcoma	Phase I/II (626) 441-6695
ridaforolimus <b>(Orphan Drug)</b>	Merck Whitehouse Station, NJ	oral formulation (Fast Track) (see also breast, lung)	Phase III (800) 672-6372
		intravenous formulation	Phase II (800) 672-6372
robatumumab	Merck Whitehouse Station, NJ	osteosarcoma, sarcoma (see also solid tumors)	Phase II (800) 672-6372
TH-302	Threshold Pharmaceuticals Redwood City, CA	soft tissue sarcoma (see also leukemia, pancreatic, solid tumors)	Phase I/II (650) 474-8200
trabectedin <b>(Orphan Drug)</b>	Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ	soft tissue sarcoma (see also breast, ovarian, prostate, other)	Phase III (800) 817-5286
		soft tissue sarcoma in adolescents and children	Phase II (800) 817-5286
<b>Votrient®</b> pazopanib	GlaxoSmithKline Rsch. Triangle Park, NC	(see also breast, kidney, ovarian)	Phase III (888) 669-6682

## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
<b>Abraxane®</b> albumin-bound paclitaxel <b>(Orphan Drug)</b>	Celgene <i>Summit, NJ</i>	malignant melanoma (see also bladder, lung, ovarian, pancreatic)	Phase III (908) 673-9000
ABT-888 (veliparib)	Abbott Laboratories <i>Abbott Park, IL</i>	malignant melanoma (see also brain, breast, colorectal, ovarian, prostate, other)	Phase II (847) 937-6100
AD-1001	Intrexon <i>Germantown, MD</i> ZIOPHARM Oncology <i>New York, NY</i>	late-stage malignant melanoma	Phase I (646) 214-0700
ADI-PEG 20 <b>(Orphan Drug)</b>	Polaris Pharmaceuticals <i>San Diego, CA</i>	malignant melanoma (see also liver, lung)	Phase II (858) 452-6688
<b>Allovectin-7®</b> velimogene aliplasmid (immunotherapeutic vaccine) <b>(Orphan Drug)</b>	Vical <i>San Diego, CA</i>	malignant melanoma (Fast Track)	Phase III (858) 646-1100
ALS-357 (betulinic topical)	Advanced Life Sciences <i>Woodridge, IL</i>	malignant melanoma	Phase I (630) 739-6744
ALT-801	Altor BioScience <i>Miramar, FL</i>	malignant melanoma	Phase I/II (954) 443-8600
APN301 (hu14.18-IL2)	Apeiron Biologics <i>Vienna, Austria</i>	malignant melanoma (see also brain)	Phase II <a href="http://www.apeiron-biologics.com">www.apeiron-biologics.com</a>
ARC-100	Archer Biosciences <i>New York, NY</i>	malignant melanoma (see also brain, pancreatic, prostate)	Phase II (646) 747-9090
ATN-224	Tactic Pharma <i>Evanston, IL</i>	malignant melanoma (see also multiple myeloma, prostate)	Phase II (847) 733-0940
<b>Azixa™</b> (verubulin)	Myrexix <i>Salt Lake City, UT</i>	malignant melanoma (see also brain)	Phase II (801) 214-7800
BMS-908662 (RAF kinase inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i> Exelixis <i>South San Francisco, CA</i>	malignant melanoma (see also colorectal)	Phase I (212) 546-4000
BMS-936558 (anti-PD1)	Bristol-Myers Squibb <i>Princeton, NJ</i>	inoperable/unresectable malignant melanoma (see also solid tumors)	Phase I (212) 546-4000
CDX-011	Celldex Therapeutics <i>Needham, MA</i>	malignant melanoma (see also breast)	Phase II (781) 433-0771
CNTO 95	Centocor Ortho Biotech <i>Horsham, PA</i>	malignant melanoma (see also prostate, solid tumors)	Phase I/II (800) 457-6399
CST-101	ConKwest <i>Del Mar, CA</i>	stage IV malignant melanoma (see also leukemia, lung, lymphoma)	Phase I (858) 380-1999

## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
CYT-107	Cytheris <i>Rockville, MD</i>	malignant melanoma (see also kidney, leukemia, solid tumors)	Phase I (301) 231-0450
denenicokin (IL-21) <b>(Orphan Drug)</b>	Bristol-Myers Squibb <i>Princeton, NJ</i>	malignant melanoma	Phase II (212) 546-5000
E7272	Eisai <i>Woodcliff Lake, NJ</i>	melanoma	Phase II (888) 422-4743
ecromeximab	Life Sciences Pharmaceuticals <i>Darien, CT</i>	malignant melanoma	Phase II (203) 656-2500
GC-1008 (fresolimumab)	Genzyme <i>Cambridge, MA</i>	malignant melanoma (see also kidney)	Phase I (617) 252-7000
<b>Genasense®</b> oblimersen <b>(Orphan Drug)</b>	Genta <i>Berkeley Heights, NJ</i>	malignant melanoma (Fast Track) (see also leukemia, lymphoma)	Phase III (908) 286-9800
GMX-1777 (teglarinad)	Gemin X Biotechnologies <i>Montreal, Canada</i>	malignant melanoma	Phase I completed (514) 281-8989
GSK1120212 (MEK inhibitor)	GlaxoSmithKline <i>Rs. Triangle Park, NC</i>	malignant melanoma (see also pancreatic, solid tumors)	Phase III (888) 825-5249
		combination therapy	Phase II (888) 825-5249
GSK2118436 (Braf protein kinase inhibitor)	GlaxoSmithKline <i>Rs. Triangle Park, NC</i>	metastatic malignant melanoma (see also lung)	Phase III (888) 825-5249
GSK2302032A (PRAME immunotherapeutic recombinant vaccine)	GlaxoSmithKline <i>Rs. Triangle Park, NC</i>	metastatic melanoma	Phase I (888) 825-5249
GSK2401502	GlaxoSmithKline <i>Rs. Triangle Park, NC</i> Lipoteck <i>Acton, Australia</i>	malignant melanoma	Phase I (888) 825-5249
<b>HyperAcute®</b> <b>Melanoma</b> melanoma vaccine	NewLink Genetics <i>Ames, IA</i>	malignant melanoma	Phase II (515) 296-5555
IMC-20D7S	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	malignant melanoma	Phase I (800) 545-5979 (212) 645-1405
IMC-gp100	Immunocore <i>Oxon, United Kingdom</i>	malignant melanoma	Phase 0 www.immunocore.com
<b>Imprime PGG®</b>	Biothera <i>Eagen, MN</i>	malignant melanoma (see also colorectal, leukemia, lung)	Phase I/II (651) 675-0300

## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
ioflubenzamide I-131	Molecular Insight Pharmaceuticals Cambridge, MA	malignant melanoma	Phase I (617) 492-5554
ipilimumab (Orphan Drug)	Bristol-Myers Squibb Princeton, NJ	metastatic melanoma, combination therapy, first-line therapy (Fast Track) (see also lung, prostate)	Phase III (212) 546-4000
lenvatinib (E7080)	Eisai Woodcliff Lake, NJ	melanoma (see also brain, kidney, liver, other)	Phase I/II (888) 422-4743
<b>Levulan® Kerastick®</b> aminolevulinic acid	DUSA Pharmaceuticals Wilmington, MA	prevention of skin cancer in solid organ transplant patients	Phase II (978) 657-7500
<b>Lymphoseek™</b>	Neoprobe Dublin, OH	diagnosis of malignant melanoma (see also breast, head/neck)	Phase III (800) 793-0079
MAGE-A3 recombinant vaccine (antigen- specific cancer immunotherapeutic)	GlaxoSmithKline Rsch. Triangle Park, NC	malignant melanoma (see also lung)	Phase III (888) 825-5249
<b>Marqibo®</b> vincristine liposomal (Orphan Drug)	Talon Therapeutics South San Francisco, CA	malignant melanoma (see also leukemia)	Phase II (650) 588-6404
melanoma vaccine	Ichor Medical Systems San Diego, CA Memorial Sloan-Kettering Cancer Center New York, NY	malignant melanoma	Phase I (858) 550-2022
<b>Metvixia®</b> methyl aminolevulinate	PhotoCure Oslo, Norway	basal cell cancer	Phase III www.photocure.com
MKC1106-MT	MannKind Valencia, CA	malignant melanoma	Phase II (661) 775-5300
MORAb-028	Eisai Woodcliff Lake, NJ	malignant melanoma	Phase I (888) 422-4743
muparfostat (PI-88) (Orphan Drug)	Progen Pharmaceuticals Redwood City, CA	malignant melanoma (see also liver)	Phase II (650) 610-7080
OncoVEX <sup>GM-CSF</sup>	BioVex Woburn, MA	malignant melanoma (see also head/neck)	Phase III (781) 376-4900
<b>Ontak®</b> denileukin diftitox	Eisai Woodcliff Lake, NJ	melanoma	Phase II (888) 422-4743
PEP005	LEO Pharma Parsippany, NJ	non-melanoma skin cancer	Phase II (877) 494-4536
PF-1367338	Pfizer New York, NY	malignant melanoma (see also breast, ovarian)	Phase II (860) 732-5156

## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
prophage (vitespen) <b>(Orphan Drug)</b>	Agenus <i>Lexington, MA</i>	malignant melanoma (Fast Track) (see also brain, kidney)	Phase III (781) 674-4400
PTC299	PTC Therapeutics <i>South Plainfield, NJ</i>	Kaposi's sarcoma (see also breast, solid tumors, other)	Phase I/II (908) 222-7000
PTI-188	Pain Therapeutics <i>San Mateo, CA</i>	malignant melanoma	Phase I completed (650) 624-8200
PV-10	Provectus Pharmaceuticals <i>Knoxville, TN</i>	malignant melanoma (see also liver)	Phase II (866) 594-5999
RAF265	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	malignant melanoma	Phase I (888) 669-6682
<b>Reolysin®</b> reovirus	Oncolytics Biotech <i>Calgary, Canada</i>	malignant melanoma (see also brain, colorectal, head/neck, lung, pancreatic, sarcoma)	Phase II (403) 670-7377
RG3616 (systemic hedgehog antagonist)	Curis <i>Lexington, MA</i> Roche <i>Nutley, NJ</i>	basal cell carcinoma	Phase II (973) 235-5000
RG7204 (BRAF kinase inhibitor)	Plexxikon <i>Berkeley, CA</i> Roche <i>Nutley, NJ</i>	first-line malignant melanoma	Phase III (510) 647-4000 (973) 235-5000
		second- and third-line malignant melanoma	Phase II (510) 647-4000 (973) 235-5000
RG7256	Roche <i>Nutley, NJ</i>	BRAF-mutated malignant melanoma	Phase I (973) 235-5000
<b>Sprycel®</b> dasatinib	Bristol-Myers Squibb <i>Princeton, NJ</i>	malignant melanoma (see also brain, breast, colorectal, leukemia, lung, lymphoma, multiple myeloma, prostate)	Phase I/II (212) 546-4000
<b>Tasigna®</b> nilotinib	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	malignant melanoma (see also leukemia, stomach)	Phase III (888) 669-6682
<b>Temodar®</b> temozolomide	Merck <i>Whitehouse Station, NJ</i>	malignant melanoma (see also leukemia, lung)	Phase I (800) 672-6372
tesetaxel <b>(Orphan Drug)</b>	Genta <i>Berkeley Heights, NJ</i>	advanced melanoma (see also bladder, breast, prostate, stomach)	Phase II (908) 286-9800
<b>TNFerade™</b> golnerminogene pradenovec	GenVec <i>Gaithersburg, MD</i>	malignant melanoma (see also colorectal, head/neck, stomach)	Phase II completed (240) 632-0740
tremelimumab (CP-675206)	Pfizer <i>New York, NY</i>	malignant melanoma (see also kidney, pancreatic, stomach, other)	Phase II (860) 732-5156
TRX518	Tolerx <i>Cambridge, MA</i>	malignant melanoma	Phase I (617) 354-8100



## SKIN CANCER

Product Name	Sponsor	Indication	Development Status
veglin (VEGF antisense)	VasGene Therapeutics <i>Los Angeles, CA</i>	Kaposi's sarcoma (see also kidney, lung)	Phase I (323) 221-7818
<b>Zadaxin®</b> thymalfasin (Orphan Drug)	SciClone Pharmaceuticals <i>Foster City, CA</i>	malignant melanoma	Phase II completed (650) 358-3456

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
1MT	NewLink Genetics <i>Ames, IA</i>	metastatic disease	Phase I (515) 296-5555
ABI-009 (nab®-rapamycin)	Celgene <i>Summit, NJ</i>		Phase I (908) 673-9000
ABI-101 (nab®-17AAG)	Celgene <i>Summit, NJ</i>		Phase I (908) 673-9000
ABT-348	Abbott Laboratories <i>Abbott Park, IL</i>	late-stage disease (see also other)	Phase I (847) 937-6100
ABT-806	Abbott Laboratories <i>Abbott Park, IL</i>		Phase I (847) 937-6100
AC480	Ambit Biosciences <i>San Diego, CA</i>	(see also brain)	Phase II completed (858) 334-2100
		solid tumors (combination therapy)	Phase I (858) 334-2100
ACE-041	Acceleron Pharma <i>Cambridge, MA</i>	(see also multiple myeloma)	Phase I (617) 649-9200
AEW541	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also other)	Phase I (888) 669-6682
AEZS-112	AEterna-Zentaris <i>Warren, NJ</i>	(see also lymphoma)	Phase I (908) 626-5428
AFP-464	Tigris Pharmaceuticals <i>Bonita Springs, FL</i>		Phase I (239) 444-5400
AI-850	Acusphere <i>Watertown, MA</i> Cephalon <i>Frazer, PA</i>		Phase I (617) 648-8800 (610) 344-0200
ALB 109564(a)	AMRI <i>Albany, NY</i>		Phase I (518) 512-2000
AMG 208	Amgen <i>Thousand Oaks, CA</i>		Phase I (800) 772-6436
AMG 780	Amgen <i>Thousand Oaks, CA</i>		Phase I (800) 772-6436
AMG 820	Amgen <i>Thousand Oaks, CA</i>		Phase I (800) 772-6436

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
AMG 888 (U3-1287)	Amgen <i>Thousand Oaks, CA</i>		Phase I (800) 772-6436
AMG 900	Amgen <i>Thousand Oaks, CA</i>		Phase I (800) 772-6436
<b>Amplimexon®</b> imexon	AmpliMed <i>Tucson, AZ</i>		Phase I/II completed (520) 529-1000
amuvatinib	SuperGen <i>Dublin, CA</i>	(see also lymphoma)	Phase I (925) 560-0100
anti-EGFL7 mAb (RG7414)	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
anti-HER3/EGFR DAF (RG7597)	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
<b>Aplidin®</b> plitidepsin	PharmaMar USA <i>Cambridge, MA</i>	(see also lymphoma, multiple myeloma)	Phase I (617) 868-3797
AR-12	Arno Therapeutics <i>Parsippany, NJ</i>	(see also lymphoma)	Phase I (862) 703-7170
ARQ-621	ArQule <i>Woburn, MA</i>	late-stage solid tumors	Phase I (781) 994-0300
ARQ-736	ArQule <i>Woburn, MA</i>	late-stage solid tumors	Phase I (781) 994-0300
ARRY-520	Array BioPharma <i>Boulder, CO</i>	(see also leukemia, multiple myeloma)	Phase I (303) 381-6600
ARRY-543 (varlitinib)	Array BioPharma <i>Boulder, CO</i>		Phase II (303) 381-6600
AT-406	Ascenta Therapeutics <i>Malvern, PA</i>	(see also lymphoma)	Phase I (610) 408-0313
AT7519	Astex Therapeutics <i>Cambridge, United Kingdom</i>	(see also multiple myeloma)	Phase I <a href="http://www.astex-therapeutics.com">www.astex-therapeutics.com</a>
AT9283	Astex Therapeutics <i>Cambridge, United Kingdom</i>	(see also leukemia)	Phase I <a href="http://www.astex-therapeutics.com">www.astex-therapeutics.com</a>
ATI-1123	Azaya Therapeutics <i>San Antonio, TX</i>		Phase I (210) 341-6600
AT13387	Astex Therapeutics <i>Cambridge, United Kingdom</i>		Phase I <a href="http://www.astex-therapeutics.com">www.astex-therapeutics.com</a>
ATN-161	Tactic Pharma <i>Evanston, IL</i>		Phase II (847) 733-0940
AV-299 (ficlatuzumab)	AVEO Pharmaceuticals <i>Cambridge, MA</i>	(see also glioblastoma, lymphoma, multiple myeloma)	Phase I (617) 299-5000
AZD1480 (JAK2 inhibitor)	AstraZeneca <i>Wilmington, DE</i>	(see also other)	Phase I (800) 236-9933
AZD2014 (TOR kinase inhibitor)	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
AZD2461 (PARP inhibitor)	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZD4547 (FGFR tyrosine kinase inhibitor)	AstraZeneca <i>Wilmington, DE</i>		Phase I/II (800) 236-9933
AZD5363 (AKT inhibitor)	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZD7762 (CHK1 kinase inhibitor)	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZD8055 (TOR kinase inhibitor)	AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZD8330 (ARRY-704)	Array Bio Pharma <i>Boulder, CO</i> AstraZeneca <i>Wilmington, DE</i>		Phase I (800) 236-9933
AZD8931 (erbB kinase inhibitor)	AstraZeneca <i>Wilmington, DE</i>	(see also breast)	Phase II (800) 236-9933
BAY 79-4620	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>		Phase I (888) 842-2937
BAY 80-6946	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>		Phase I (888) 842-2937
BAY 10-00394	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>		Phase I (888) 842-2937
BBI608	Boston Biomedical <i>Norwood, MA</i>		Phase I (781) 278-0900
BEZ235	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	late-stage solid tumors	Phase I/II (888) 669-6682
BGJ398	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (888) 669-6682
BGT226	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I/II (888) 669-6682
BHQ880	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also multiple myeloma)	Phase I (888) 669-6682
BI 811283	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	(see also leukemia)	Phase I (800) 243-0127
BI 831266	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>		Phase I (800) 243-0127

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
BIIB 015	Biogen Idec <i>Cambridge, MA</i>		Phase I (617) 679-2000
BKM120	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also breast)	Phase I (888) 669-6682
BMN-673	BioMarin Pharmaceuticals <i>Novato, CA</i>		Phase I/II (415) 506-6700
BMS-247615 (DNA topoisomerase I and II inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>		Phase I (212) 546-4000
BMS-754807 (IGF-1R antagonist)	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also breast)	Phase I/II (212) 546-4000
BMS-777607 (receptor protein- tyrosine kinase antagonists)	Bristol-Myers Squibb <i>Princeton, NJ</i>	advanced solid tumors	Phase I/II completed (212) 546-4000
BMS-833923 (SMO inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>		Phase I (212) 546-4000
BMS-936558 (anti-PD1)	Bristol-Myers Squibb <i>Princeton, NJ</i>	(see also skin)	Phase I (212) 546-4000
BMS-936559 (anti-PDL-L1)	Bristol-Myers Squibb <i>Princeton, NJ</i>		Phase I (212) 546-4000
BQS481	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (888) 669-6682
BYL719	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	late-stage solid tumors	Phase I (888) 669-6682
c31510 for injection	Cytotech Labs <i>Natick, MA</i>		Phase I
CALAA 01	Calando Pharmaceuticals <i>Pasadena, CA</i>		Phase I (626) 683-7200
carfilzomib	Onyx Pharmaceuticals <i>Emeryville, CA</i>	(see also multiple myeloma)	Phase II (510) 597-6500
carlumab	Centocor Ortho Biotech <i>Horsham, PA</i>	(see also prostate)	Phase I (800) 457-6399
CC-223	Celgene <i>Summit, NJ</i>	late-stage solid tumors (see also leukemia, lymphoma)	Phase I/II (908) 673-9000
CDX-1401	CellDex Therapeutics <i>Needham, MA</i>		Phase I/II (781) 433-0771
CEP-9722 (PARP inhibitor)	Cephalon <i>Frazer, PA</i>		Phase I (610) 344-0200
CEP-11981 (VEGF-R/TIE2 kinase inhibitor)	Cephalon <i>Frazer, PA</i>		Phase I (610) 344-0200
CG201	CG Therapeutics <i>Seattle, WA</i>		Phase II (206) 336-5604

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
CLR1404	Cellectar <i>Madison, WI</i>		Phase I (608) 441-8120
CNTO 95	Centocor Ortho Biotech <i>Horsham, PA</i>	(see also prostate, skin)	Phase I completed (800) 457-6399
CRLX101	Cerulean Pharma <i>Cambridge, MA</i>	late-stage solid tumors	Phase I/II (617) 551-9600
crolibulin	EpiCept <i>Tarrytown, NY</i>		Phase I/II (914) 606-3500
CRS-207	Aduro BioTech <i>Berkeley, CA</i>		Phase I (510) 848-4400
CUDC-101	Curis <i>Cambridge, MA</i>		Phase I (617) 503-6500
CX-4945	Cylene Pharmaceuticals <i>San Diego, CA</i>	(see also multiple myeloma, other)	Phase I (858) 875-5100
CYC-116	Cyclacel Pharmaceuticals <i>Berkeley Heights, NJ</i>		Phase I (908) 517-7330
CYT-107	Cytheris <i>Rockville, MD</i>	vaccine enhancer (see also kidney, leukemia, skin)	Phase I (301) 231-0450
CYT 6091	CytImmune Sciences <i>Rockville, MD</i>		Phase I (301) 825-3041
darinaparsin oral (ZIO-101)	ZIOPHARM Oncology <i>New York, NY</i>	(see also liver, lymphoma, multiple myeloma)	Phase I (646) 214-0700
denibulin (MN-029)	MediciNova <i>San Diego, CA</i>		Phase I (858) 373-1500
dovitinib (TKI258)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase II (888) 669-6682
EC-0489	Endocyte <i>West Lafayette, IN</i>		Phase I (765) 463-7175
elsamitrucin	Spectrum Pharmaceuticals <i>Irvine, CA</i>	advanced solid tumors	Phase I (949) 788-6700
EMD-1204831 (c-Met kinase inhibitor)	EMD Serono <i>Rockland, MA</i>	late-stage solid tumors	Phase I (800) 283-8088
EMD-1214063 (c-Met kinase inhibitor)	EMD Serono <i>Rockland, MA</i>		Phase I (800) 283-8088
EP-100	Esperance Pharmaceuticals <i>Baton Rouge, LA</i>		Phase I (225) 615-8944
ETBX-011	Etubics <i>Seattle, WA</i>	late-stage solid tumors	Phase I (206) 838-5110
EZN-2208	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	refractory metastatic solid tumors (see also breast, colorectal)	Phase I (908) 541-8600

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
EZN-2968	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	(see also lymphoma)	Phase I (908) 541-8600
EZN-3042	Enzon Pharmaceuticals <i>Bridgewater, NJ</i>	(see also leukemia, lymphoma)	Phase I (908) 541-8600
fluciclatide F-18	GE Healthcare <i>Waukesha, WI</i>	diagnosis of solid tumors	Phase II
FP-1039	Five Prime Therapeutics <i>San Francisco, CA</i>	(see also other)	Phase I (415) 365-5600
G-202	GenSpera <i>San Antonio, TX</i>		Phase I (210) 479-8112
GDC-0068 (Akt inhibitor)	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
GDC-0623 (MEK inhibitor)	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
GDC-0917 (IAP antagonist)	Genentech <i>South San Francisco, CA</i>	(see also lymphoma)	Phase I (650) 224-1000
GDC-0941 (PI3 kinase inhibitor)	Genentech <i>South San Francisco, CA</i>	(see also breast, lung, lymphoma)	Phase I (650) 224-1000
GDC-0973 (MEK inhibitor)	Exelixis <i>South San Francisco, CA</i> Genentech <i>South San Francisco, CA</i>		Phase I (650) 837-7000
GDC-0980 (PI3 kinase/mTOR dual inhibitor)	Genentech <i>South San Francisco, CA</i>	(see also breast, lymphoma)	Phase I (650) 224-1000
<b>Genasense®</b> oblimersen	Genta <i>Berkeley Heights, NJ</i>	brief, high-dose IV-infusion (see also breast, leukemia, lung, lymphoma, skin)	Phase I/II (908) 286-9800
		intermittent therapy	Phase I (908) 286-9800
Genz-644282	Genzyme <i>Cambridge, MA</i>		Phase I (617) 252-7500
GGTI-2418	Tigris Pharmaceuticals <i>Bonita Springs, FL</i>		Phase I (239) 444-5400
GL-ONC1	Genelux <i>San Diego, CA</i>		Phase I (858) 483-0024
GO-203-2c	Genus Oncology <i>Vernon Hills, IL</i>	advanced solid tumors	Phase I (847) 549-6500
GS 6624	Gilead Sciences <i>Foster City, CA</i>		Phase I (800) 445-3235
GSK1070916A	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>		Phase I (888) 825-5249
GSK1120212 (MEK inhibitor)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also pancreatic, skin)	Phase I (888) 825-5249

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
GSK2141795 (AKT protein kinase inhibitor)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	(see also lymphoma)	Phase I (888) 825-5249
GSK2256098 (FAK inhibitor)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>		Phase I (888) 825-5249
HER2/neu receptor (active cellular immunotherapy)	Dendreon <i>Seattle, WA</i>		Phase I (877) 256-4545
HGS-1029	Human Genome Sciences <i>Rockville, MD</i>	(see also lymphoma)	Phase I (301) 309-8504
HSP990	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (888) 669-6682
IMC-RON8	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>		Phase I (800) 545-5979 (212) 645-1405
IMGN-388	ImmunoGen <i>Waltham, MA</i>		Phase I (781) 895-0600
INCB-18424 (ruxolitinib)	Incyte <i>Wilmington, DE</i>		Phase I (302) 498-6700
INCB-24360 (IDO inhibitor)	Incyte <i>Wilmington, DE</i>		Phase I/II (302) 498-6700
INCB-28060 (c-MET inhibitor)	Incyte <i>Wilmington, DE</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I/II (302) 498-6700 (888) 669-6682
INK128 (TORC1/2 inhibitor)	Intellikine <i>La Jolla, CA</i>	(see also lymphoma, multiple myeloma)	Phase I (858) 768-6500
INNO-206	CytRx <i>Los Angeles, CA</i>		Phase I completed (310) 826-5648
IPI-493	Infinity Pharmaceuticals <i>Cambridge, MA</i>	advanced solid tumors (see also other)	Phase I (617) 453-1000
IPI-926	Infinity Pharmaceuticals <i>Cambridge, MA</i>	(see also pancreatic, sarcoma)	Phase I (617) 453-1000
JI-101	Jubilant Innovation <i>Bedminster, NJ</i>		Phase I/II (215) 369-0965
JNJ-26854165	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>	late-stage solid tumors (see also lung, prostate)	Phase I (800) 817-5286
JNJ-38877605	Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i>		Phase I/II (800) 817-5286
KHK-2866	Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i>	(see also ovarian)	Phase I (609) 919-1100



## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
LCL161	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (888) 669-6682
LDE225	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase II (888) 669-6682
LDK378	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase II (888) 669-6682
LEE011	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	(see also lymphoma)	Phase I (888) 669-6682
LEQ506	Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (888) 669-6682
L-MDAM	BioNumerik Pharmaceuticals <i>San Antonio, TX</i>		Phase I (210) 614-1701
LOR-253	Lorus Therapeutics <i>Toronto, Canada</i>		Phase I (416) 798-1200
LP-261	Ansaris <i>Blue Bell, PA</i>		Phase I (215) 358-2000
MEDI-565 (anti-CEA BiTE)	AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i>		Phase I (800) 236-9933 (301) 398-0000
MEDI-573 (anti-IGF mAb)	AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i>		Phase I (800) 236-9933 (301) 398-0000
MEDI-575	AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i>		Phase II (800) 236-9933 (301) 398-0000
MEDI-3617 (anti-ANG-2 mAb)	AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i>		Phase I (800) 236-9933 (301) 398-0000
MEK162/ ARRY-162	Array BioPharma <i>Boulder, CO</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (303) 381-6600 (888) 669-6682
MGAH22 (anti-HER2)	MacroGenics <i>Rockville, MD</i>		Phase I (301) 251-5172
MGCD-265	MethylGene <i>Montreal, Canada</i>	late-stage solid tumors (see also lung)	Phase I (514) 337-3333
MGCD-0103	MethylGene <i>Montreal, Canada</i>	(see also leukemia, lymphoma)	Phase I/II (514) 337-3333
MINT-1526A (anti-angiogenic)	Genentech <i>South San Francisco, CA</i>	advanced solid tumors	Phase I (650) 224-1000

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
MK-0752	Merck <i>Whitehouse Station, NJ</i>	(see also breast)	Phase I (800) 672-6372
MK-1496	Merck <i>Whitehouse Station, NJ</i>		Phase I completed (800) 672-6372
MK-1775	Merck <i>Whitehouse Station, NJ</i>		Phase I (800) 672-6372
MK-4827	Merck <i>Whitehouse Station, NJ</i>	late-stage solid tumors	Phase I (800) 672-6372
MK-5108 (VX-689)	Merck <i>Whitehouse Station, NJ</i> Vertex Pharmaceuticals <i>Cambridge, MA</i>	late-stage or refractory solid tumors	Phase I (800) 672-6372
MKC1106-PP	MannKind <i>Valencia, CA</i>		Phase I completed (661) 775-5300
MLN4924	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also other)	Phase I (800) 390-5663
MLN8237	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also other)	Phase I/II (800) 390-5663
MLN9708	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also other)	Phase I/II (800) 390-5663
MM-111	Merrimack Pharmaceuticals <i>Cambridge, MA</i>	(see also breast)	Phase I/II (617) 441-1000
MN-201	Marillion Pharmaceuticals <i>Exton, PA</i>	advanced solid tumors	Phase I (484) 875-3018
MORAb-004	Eisai <i>Woodcliff Lake, NJ</i>		Phase I (888) 422-4743
MT-110	Micromet <i>Bethesda, MD</i>		Phase I (240) 752-1420
NB-1011	Kiadis Pharma <i>Amsterdam, The Netherlands</i>		Phase I/II <a href="http://www.kiadis.com">www.kiadis.com</a>
NKTR-105 (pegylated docetaxel)	Nektar Therapeutics <i>San Francisco, CA</i>		Phase I (415) 482-5300
NMS-1116354	Nerviano Medical Sciences <i>Milan, Italy</i>	metastatic solid tumors	Phase I <a href="http://www.nervianoms.com">www.nervianoms.com</a>
NMS-1286937	Nerviano Medical Sciences <i>Milan, Italy</i>		Phase I <a href="http://www.nervianoms.com">www.nervianoms.com</a>
NPI-0052 (marizomib)	Nereus Pharmaceuticals <i>San Diego, CA</i>	(see also lymphoma, multiple myeloma)	Phase I (858) 587-4090
OMP-21M18	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> OncoMed Pharmaceuticals <i>Redwood City, CA</i>		Phase I (888) 825-5249 (650) 995-8200

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
OMP-59R5	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> OncoMed Pharmaceuticals <i>Redwood City, CA</i>	late-stage solid tumors	Phase I (888) 825-5249 (650) 995-8200
omtriptolide	Pharmagenesis <i>Redwood City, CA</i> Pierre Fabre Pharmaceuticals <i>Parsippany, NJ</i>		Phase I (650) 842-7060 (973) 898-1042
ON-01910	Onconova Therapeutics <i>Princeton, NJ</i>	(see also leukemia, lymphoma, ovarian)	Phase I (609) 844-7735
ONX-0801	Onyx Pharmaceuticals <i>Emeryville, CA</i>		Phase I (510) 597-6500
ONX-0912	Onyx Pharmaceuticals <i>Emeryville, CA</i>	late-stage solid tumors	Phase I (510) 597-6500
ortatexal	Spectrum Pharmaceuticals <i>Irvine, CA</i>	taxane-refractory solid tumors	Phase II (949) 788-6700
OSI-930	OSI Pharmaceuticals <i>Melville, NY</i>	late-stage solid tumors	Phase I (631) 962-2000
OXi4503	OXIGENE <i>South San Francisco, CA</i>	(see also leukemia)	Phase I/II (650) 635-7000
PA799	Chugai Pharma USA <i>Berkeley Heights, NJ</i>		Phase I (908) 516-1350
PDL-192 (enavatuzumab)	Facet Biotech <i>Redwood City, CA</i>		Phase I (650) 454-1000
PEGPH20 (pegylated recombinant human hyaluronidase)	Halozyme <i>San Diego, CA</i>		Phase I (858) 794-8889
PF-03446962	Pfizer <i>New York, NY</i>	late-stage solid tumors	Phase I (860) 732-5156
PF-03758309	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-04605412	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-04691502	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-04856884 (CVX060)	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-05057459 (CVX 241)	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PG11047	Progen Pharmaceuticals <i>Redwood City, CA</i>		Phase I (650) 610-7800
picoplatin oral	Poniard Pharmaceuticals <i>San Francisco, CA</i>		Phase I (650) 583-3774

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
PLX3397	Plexxikon <i>Berkeley, CA</i>	(see also lymphoma)	Phase I (510) 647-4000
PM-01183	PharmaMar USA <i>Cambridge, MA</i>		Phase I completed (617) 868-3797
PM-060184	PharmaMar USA <i>Cambridge, MA</i>		Phase I (617) 868-3797
PNT2258	ProNAi Therapeutics <i>Kalamazoo, MI</i>		Phase I (269) 815-8098
PRLX-93936	Prolexys Pharmaceuticals <i>Salt Lake City, UT</i>		Phase I (801) 303-1700
PTC299	PTC Therapeutics <i>South Plainfield, NJ</i>	(see also breast, skin, other)	Phase I (908) 222-7000
purine nucleoside phosphorylase gene therapy	PNP Therapeutics <i>Birmingham, AL</i>		Phase I <a href="http://www.pnptherapeutics.com">www.pnptherapeutics.com</a>
PX-478	Oncothyreon <i>Seattle, WA</i>	(see also lymphoma)	Phase I completed (206) 801-2100
PX-866	Oncothyreon <i>Seattle, WA</i>		Phase I/II (206) 801-2100
quizartinib	Ambit Biosciences <i>San Diego, CA</i> Astellas Pharma US <i>Deerfield, IL</i>	late-stage solid tumors (see also leukemia)	Phase I (858) 334-2100 (800) 727-7003
retaspimycin (IPI 504)	Infinity Pharmaceuticals <i>Cambridge, MA</i>	(see also lung)	Phase I (617) 453-1000
RG7112	Roche <i>Nutley, NJ</i>	(see also other)	Phase I (973) 235-5000
RG7160 (HumAb EGFR)	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
RG7167	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
RG7304 (Raf/MEK dual inhibitor)	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
RG7334 (anti-PLGF mAb)	Roche <i>Nutley, NJ</i>		Phase I (973) 235-5000
RG7347	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
RG7422 (PI3 kinase inhibitor)	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
RG7593	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
RG7594	Genentech <i>South San Francisco, CA</i>		Phase I (650) 224-1000
rindopepimut	Celldex Therapeutics <i>Needham, MA</i>	(see also brain)	Phase I (860) 732-5156

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
robatumumab	Merck <i>Whitehouse Station, NJ</i>	solid tumors (see also sarcoma)	Phase II (800) 672-6372
		solid tumors in children	Phase I (800) 672-6372
SAR256212 (MM-121)	Merrimack Pharmaceuticals <i>Cambridge, MA</i> sanofi-aventis <i>Bridgewater, NJ</i>	(see also ovarian)	Phase I (617) 441-1000 (800) 633-1810
SAR566658 (maytansin-loaded anti-DS6)	sanofi-aventis <i>Bridgewater, NJ</i>		Phase I (800) 633-1810
SB939	S*Bio <i>Redwood City, CA</i>	late-stage solid tumors (see also leukemia)	Phase I (650) 730-2860
selumetinib (AZD6244/ ARRY-886)	Array BioPharma <i>Boulder, CO</i> AstraZeneca <i>Wilmington, DE</i>		Phase II (800) 236-9933
selumetinib (AZD6244/ ARRY-886) MK-2206 combination	Array Bio Pharma <i>Boulder, CO</i> AstraZeneca <i>Wilmington, DE</i> Merck <i>Whitehouse Station, NJ</i>		Phase I (800) 236-9933 (800) 672-6372
SF1126	Semafore Pharmaceuticals <i>Indianapolis, IN</i>	(see also leukemia, multiple myeloma)	Phase I (317) 876-3075
simotaxel	Taxolog <i>Fairfield, NJ</i>		Phase I (877) 829-6564
SN2310	OncoGenex Pharmaceuticals <i>Bothell, WA</i>		Phase I completed (425) 686-1500
sonepcizumab	Lpath <i>San Diego, CA</i>		Phase II (858) 678-0800
Sym004	Symphogen <i>Lyngby, Denmark</i>		Phase I <a href="http://www.symphogen.com">www.symphogen.com</a>
TAK-441	Millennium Pharmaceuticals <i>Cambridge, MA</i>	late-stage solid tumors	Phase I (800) 390-5663
TAK-701	Millennium Pharmaceuticals <i>Cambridge, MA</i>		Phase I (800) 390-5663
TAK-733	Millennium Pharmaceuticals <i>Cambridge, MA</i>		Phase I (800) 390-5663
TAK-901	Millennium Pharmaceuticals <i>Cambridge, MA</i>	(see also other)	Phase I (800) 390-5663
TAK-960	Millennium Pharmaceuticals <i>Cambridge, MA</i>		Phase I (800) 390-5663
terameprocol (intravenous)	Erimos Pharmaceuticals <i>Houston, TX</i>	(see also brain, cervical, head/neck, other)	Phase I (713) 541-2000

## SOLID TUMORS

Product Name	Sponsor	Indication	Development Status
TH-302	Threshold Pharmaceuticals <i>Redwood City, CA</i>	late-stage solid tumors (see also leukemia, sarcoma)	Phase I/II (650) 474-8200
TKM-PLK1	Tekmira Pharmaceuticals <i>Vancouver, Canada</i>	(see also lymphoma)	Phase I (604) 419-3200
TLC388	Taiwan Liposome <i>Taipei, Taiwan</i>		Phase I
TRC093	TRACON Pharmaceuticals <i>San Diego, CA</i>		Phase I completed (858) 550-0780
TRC102	TRACON Pharmaceuticals <i>San Diego, CA</i>		Phase I (858) 550-0780
TRC105	TRACON Pharmaceuticals <i>San Diego, CA</i>	locally advanced or metastatic solid tumors (see also prostate)	Phase I (858) 550-0780
TRPM8 (D-3263)	Dendreon <i>Seattle, WA</i>		Phase I (877) 256-4545
TST10088	Cangene <i>Winnipeg, Canada</i>		Phase I (204) 275-4200
U3-1565	Amgen <i>Thousand Oaks, CA</i> U3 Pharma <i>Martinsried, Germany</i>		Phase I (800) 772-6436 (973) 359-2600
UNBS-5162	Drais Pharmaceuticals <i>Bridgewater, NJ</i>	(see also lymphoma)	Phase I (908) 895-1200
V935	Merck <i>Whitehouse Station, NJ</i>		Phase I (800) 672-6372
vinorelbine liposomal	Talon Therapeutics <i>South San Francisco, CA</i>	(see also lymphoma)	Phase I (650) 588-6404
VX15	Vaccinex <i>Rochester, NY</i>		Phase I (585) 271-2700
WX-UK1	Wilex <i>Munich, Germany</i>		Phase I www.wilex.com
X-82	Tyrogenex <i>West Palm Beach, FL</i>		Phase I (561) 835-9356
XMT-1001	Mersana Therapeutics <i>Cambridge, MA</i>	refractory metastatic disease	Phase I (617) 498-0020
XMT-1107	Mersana Therapeutics <i>Cambridge, MA</i>		Phase I (617) 498-0020

## STOMACH CANCER

Product Name	Sponsor	Indication	Development Status
<b>Afinitor®</b> everolimus	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	GIST (see also breast, kidney, liver, lymphoma, other)	Phase III (888) 669-6682

## STOMACH CANCER

Product Name	Sponsor	Indication	Development Status
AMG 386	Amgen <i>Thousand Oaks, CA</i>	gastric and gastroesophageal junction adenocarcinoma (see also breast, colorectal, kidney, liver, ovarian, other)	Phase II (800) 772-6436
		distal esophageal adenocarcinoma	Phase II (800) 772-6436
AT-101	Ascenta Therapeutics <i>Malvern, PA</i>	esophageal cancer (see also brain, leukemia, lung, lymphoma, prostate)	Phase II (610) 408-0313
AUY922	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	gastric cancer (see also breast, colorectal, lung, multiple myeloma)	Phase II (888) 669-6682
AV-951 (tivozanib)	AVEO Pharmaceuticals <i>Cambridge, MA</i>	gastrointestinal cancer (see also breast, kidney, lung)	Phase I/II (617) 299-5000
BAY 73-4506 (regorafenib) <b>(Orphan Drug)</b>	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	late-stage GIST (see also colorectal, kidney, lung)	Phase III (888) 842-2937
brivanib (VEGFR/FGFR kinase inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i>	gastrointestinal cancer (see also liver)	Phase I (212) 546-4000
CNF-2024	Biogen Idec <i>Weston MA</i>	GIST (see also breast)	Phase II (781) 464-2000
E7050	Eisai <i>Woodcliff Lake, NJ</i>	gastric cancer (see also liver, other)	Phase I/II (888) 422-4743
ganetespib	Synta Pharmaceuticals <i>Lexington, MA</i>	esophageal cancer, GIST (see also breast, colorectal, lung, other)	Phase II (781) 274-8200
<b>Ixempra®</b> ixabepilone	Bristol-Myers Squibb <i>Princeton, NJ</i>	gastric cancer, esophageal cancer (see also breast, lung, other)	Phase II (212) 546-4000
masitinib	AB Science USA <i>Short Hills, NJ</i>	GIST (see also leukemia, pancreatic)	Phase III (973) 218-2437
<b>OncoGel™</b> paclitaxel controlled-release <b>(Orphan Drug)</b>	Protherics <i>Brentwood, TN</i>	esophageal cancer	Phase II (615) 327-1027
perifosine (KRX-1401)	Aeterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i>	late-stage GIST (see also brain, colorectal, kidney, leukemia, lymphoma, multiple myeloma, sarcoma, ovarian)	Phase II (212) 531-5965
polyclonal antibody stimulator <b>(Orphan Drug)</b>	Cancer Advances <i>Durham, NC</i>	gastric cancer (see also colorectal, pancreatic)	Phase III (919) 361-2162
ramucirumab (IMC-1121B)	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	gastric cancer (see also breast, colorectal, liver, lung)	Phase III (800) 545-5979 (212) 645-1405

## STOMACH CANCER

Product Name	Sponsor	Indication	Development Status
rilotumumab	Amgen <i>Thousand Oaks, CA</i>	gastric cancer (see also brain, colorectal, lung, prostate)	Phase II (800) 772-6436
S-1	Taiho Pharma USA <i>Princeton, NJ</i>	gastric cancer	Phase III (609) 750-5300
<b>Tasigna®</b> nilotinib (Orphan Drug)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	GIST (see also leukemia, skin)	Phase III (888) 669-6682
telatinib (Orphan Drug)	ACT Biotech <i>San Francisco, CA</i>	late-stage gastric cancer (see also colorectal)	Phase II (415) 230-3900
tesetaxel (Orphan Drug)	Genta <i>Berkeley Heights, NJ</i>	advanced gastric cancer (Fast Track) (see also bladder, breast, prostate, skin)	Phase II (908) 286-9800
<b>TNFrade™</b> golnerminogene pradenovec	GenVec <i>Gaithersburg, MD</i>	esophageal cancer (see also colorectal, head/neck, pancreatic, skin)	Phase II completed (240) 632-0740
tremelimumab (CP-675206)	Pfizer <i>New York, NY</i>	gastrointestinal cancer (see also kidney, pancreatic, skin, other)	Phase II (860) 732-5156
<b>Tykerb®</b> lapatinib	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	gastric cancer (see also breast, head/neck)	Phase III (888) 825-5249

## CANCER/CHEMOTHERAPY-RELATED CONDITIONS

Product Name	Sponsor	Indication	Development Status
<b>Acapodene®</b> toremifene	GTx <i>Memphis, TN</i>	complications from androgen deprivation therapy (see also prostate)	application submitted (901) 523-9700
ACE-011 (sotatercept)	Acceleron Pharma <i>Cambridge, MA</i> Celgene <i>Summit, NJ</i>	chemotherapy-induced anemia (see also other)	Phase II/III (617) 649-9200 (908) 673-9000
AG013	ActoGeniX <i>Zwijnaarde, Belgium</i>	mucositis	Phase I <a href="http://www.actogenix.com">www.actogenix.com</a>
ARX-02 (sufentanil sublingual)	AcelRx Pharmaceuticals <i>Redwood City, CA</i>	cancer breakthrough pain	Phase II (650) 216-3500
<b>Campath®</b> alemtuzumab (intravenous)	Genzyme <i>Cambridge, MA</i>	chronic graft-versus-host disease	Phase I (617) 252-7500
CB1400	Canopus BioPharma <i>Studio City, CA</i>	mucositis (prevention)	Phase II (818) 980-5008
<b>Emend® for Injection</b> fosaprepitant	Merck <i>Whitehouse Station, NJ</i> Fate Therapeutics <i>San Diego, CA</i>	chemotherapy-induced nausea and vomiting (CINV) in adolescents, children and infants	Phase I (800) 672-6372



## CANCER/CHEMOTHERAPY-RELATED CONDITIONS

Product Name	Sponsor	Indication	Development Status
<b>Ereska™</b> ketamine intranasal	Javelin Pharmaceuticals <i>Cambridge, MA</i>	cancer pain	Phase III (617) 349-4500
fentanyl sublingual spray	INSYS Therapeutics <i>Phoenix, AZ</i>	cancer pain	Phase III (602) 910-2617
FT1050 <b>(Orphan Drug)</b>	Fate Therapeutics <i>San Diego, CA</i>	hematopoietic stem cell support in patients with hematological malignancies	Phase I (858) 875-1800
golotimod	SciClone Pharmaceuticals <i>Foster City, CA</i>	chemotherapy-induced stomatitis (prevention)	Phase II (650) 358-3456
morphine intranasal	Marina Biotech <i>Bothell, WA</i>	cancer pain	Phase II (425) 908-3600
MRX-1024	Molecular Therapeutics <i>Ann Arbor, MI</i>	mucositis	Phase I (734) 259-4574
nabiximols	Otsuka America Pharmaceutical <i>Rockville, MD</i>	advanced cancer pain	Phase II (800) 438-6124
<b>Nasalfent®</b> fentanyl intranasal	Archimedes Pharma <i>Reading, United Kingdom</i>	cancer pain	application submitted
norepinephrine topical	ProCetus BioPharm <i>Madison, WI</i>	prevention of radiodermatitis in patients undergoing radiation therapy	Phase I/II (608) 273-8862
		prevention of oral mucositis in patients undergoing radiation therapy	Phase I/II (608) 273-8862
		prevention of chemo- and radio- therapy-induced alopecia	Phase I/II (608) 273-8862
NP-2 gene therapy (intradermal)	Diamyd Medical <i>Pittsburgh, PA</i>	cancer pain	Phase II (412) 770-1310
<b>Nplate™</b> romiplostim	Amgen <i>Thousand Oaks, CA</i>	chemotherapy-induced thrombocytopenia (see also leukemia)	Phase II (800) 772-6436
<b>orBec®</b> beclometasone <b>(Orphan Drug)</b>	Soligenix <i>Princeton, NJ</i> Sigma-Tau Pharmaceuticals <i>Gaithersburg, MD</i>	graft-versus-host disease (Fast Track)	Phase III (609) 538-8200 (800) 447-0169
		graft-versus-host disease (prevention)	Phase II (609) 538-8200 (800) 447-0169
		acute radiation enteritis (Fast Track)	Phase I/II (609) 538-8200 (800) 447-0169
PF-4383119 (tanezumab)	Pfizer <i>New York, NY</i>	cancer pain	Phase II (860) 732-5156

## CANCER/CHEMOTHERAPY-RELATED CONDITIONS

Product Name	Sponsor	Indication	Development Status
PHY-906	PhytoCeutica New Haven, CT	chemoprotection	Phase I/II (203) 777-3462
<b>Prochymal®</b> remestemcel-L (Orphan Drug)	Osiris Therapeutics Columbia, MD	graft-versus-host disease (Fast Track)	Phase III (443) 545-1800
<b>Promacta®</b> eltrombopag	GlaxoSmithKline Rsch. Triangle Park, NC	chemotherapy-induced thrombocytopenia	Phase II (888) 825-5249
<b>Reviroc™</b> (Orphan Drug)	Kiadai's Pharma St. Laurent, Canada	bone marrow transplant rejection	Phase II/III (514) 336-4886
		graft-versus-host disease	Phase I/II (514) 336-4886
rolapitant	TESARO Waltham, MA	chemotherapy-induced nausea and vomiting	Phase II completed (339) 970-0900
SAR411298 (FAAH inhibitor)	sanofi-aventis Bridgewater, NJ	cancer pain	Phase I (800) 633-1810
tapentadol controlled-release	Grunenthal Aachen, Germany Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ	cancer pain	Phase II (800) 817-5286
<b>Tavocept™</b> dimesna	BioNumerik Pharmaceuticals San Antonio, TX	chemoprotection (Fast Track) (see also lung)	Phase III (210) 614-1701
TH-9402	Kiadis Pharma Amsterdam, The Netherlands	graft-versus-host disease	Phase I/II www.kiadis.com
TXA127	Tarix Pharmaceuticals Brookline, MA	chemotherapy-induced thrombocytopenia	Phase II (617) 827-6824
<b>Voraxaze®</b> glucarpidase (Orphan Drug)	Protherics Brentwood, TN	chemoprotection	application submitted (615) 327-1027
Xen2174	Xenome Queensland, Australia	cancer pain	Phase II www.xenome.com

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
8H9 mAb	United Therapeutics Silver Spring, MD	peritoneal cancer (see also brain, sarcoma)	Phase I (301) 608-9292
Å6	Angstrom Pharmaceuticals Solana Beach, CA	advanced gynecological cancer (see also ovarian)	Phase I (858) 314-2356
ABT-348	Abbott Laboratories Abbott Park, IL	hematological malignancies (see also solid tumors)	Phase I (847) 937-6100

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
ABT-888 (veliparib)	Abbott Laboratories <i>Abbott Park, IL</i>	fallopian tube cancer, peritoneal cancer (see also brain, breast, colorectal, ovarian, prostate, skin)	Phase II (847) 937-6100
ACE-011 (sotatercept)	Acceleron Pharma <i>Cambridge, MA</i> Celgene <i>Summit, NJ</i>	cancer metastases (see also cancer/chemotherapy)	Phase II (617) 649-9200 (908) 673-9000
AEG-41174	Aegera Therapeutics <i>Montreal, Canada</i>	hematological malignancies	Phase I (514) 288-5532
AEW541	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	hematological malignancies (see also solid tumors)	Phase I (888) 669-6682
<b>Afinitor®</b> everolimus	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	neuroendocrine tumors (see also breast, kidney, liver, lymphoma, pancreatic, stomach)	application submitted (888) 669-6682
		urogenital cancer	Phase I (888) 669-6682
<b>AlloStim™</b>	Immunovative Therapies <i>Shoham, Israel</i>	hematological malignancies	Phase I/II <a href="http://www.immunovative.co.il">www.immunovative.co.il</a>
AMG 319	Amgen <i>Thousand Oaks, CA</i>	hematological malignancies	Phase I (800) 772-6436
AMG 386	Amgen <i>Thousand Oaks, CA</i>	fallopian tube cancer, peritoneal cancer (see also breast, colorectal, kidney, liver, ovarian, stomach)	Phase III (800) 772-6436
AMG 479 (ganitumab)	Amgen <i>Thousand Oaks, CA</i>	neuroendocrine tumors (see also breast, colorectal, lung, pancreatic, sarcoma)	Phase II (800) 772-6436
antineoplaston- AS2-1 oral	Burzynski Research Institute <i>Houston, TX</i>	cancer metastases	Phase II (713) 335-5697
AR-67	Arno Therapeutics <i>Parsippany, NJ</i>	myelodysplastic syndromes (see also brain)	Phase II (862) 703-7170
ARQ-197	ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i>	germ cell and embryonal neoplasms (see also colorectal, kidney, liver, lung, pancreatic, sarcoma, solid tumors)	Phase II (781) 994-0300 (973) 944-2600
AS703026	EMD Serono <i>Rockland, MA</i>	hematological malignancies	Phase I/II (800) 283-8088
ATI-BC-1	Algeta <i>Oslo, Norway</i> Bayer Healthcare Pharmaceuticals <i>Wayne, NJ</i>	bone metastases	Phase III (888) 842-2937
<b>Avastin®</b> bevacizumab	Genentech <i>South San Francisco, CA</i>	high-risk carcinoid tumors (see also brain, breast, colorectal, lung, ovarian)	Phase III (650) 225-1000

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
axitinib	Pfizer New York, NY	thyroid cancer (see also kidney, lung)	Phase II (860) 732-5156
AZD1152 (aurora kinase inhibitor)	AstraZeneca Wilmington, DE	hematological malignancies	Phase II (800) 236-9933
AZD1480	AstraZeneca Wilmington, DE	myeloproliferative diseases (see also solid tumors)	Phase I (800) 236-9933
<b>Azedra™</b> iodine-labeled metaiodobenzyl- guanidine (Orphan Drug)	Molecular Insight Pharmaceuticals Cambridge, MA	paraganglioma, pheochromocytoma (Fast Track) (see also brain)	Phase II (617) 492-5554
BAY 94-9392	Bayer HealthCare Pharmaceuticals Wayne, NJ	diagnosis of cancer	Phase I (888) 842-2937
belinostat	Spectrum Pharmaceuticals Irvine, CA TopoTarget USA Rockaway, NJ	cancer of unknown primary site	Phase II (949) 788-6700 (973) 895-6900
<b>Bonefos®</b> clodronic acid	Bayer HealthCare Pharmaceuticals Wayne, NJ	cancer metastases	application submitted (888) 842-2937
BP-100-1.01	Bio-Path Ogden, UT	hematological malignancies	Phase I (801) 580-2326
cabozantinib (XL-184) (Orphan Drug)	Exelixis South San Francisco, CA	medullary thyroid cancer (see also lung)	Phase III (650) 837-7000
CAT-8015 (anti-CD22 recombinant immunotoxin)	AstraZeneca Wilmington, DE MedImmune Gaithersburg, MD	hematological malignancies	Phase I (800) 236-9933 (301) 398-0000
catumaxomab	Fresenius Biotech North America Waltham, MA	malignant ascites (see also ovarian)	Phase II www.fresenius-biotech.com
CDB-4124	Repros Therapeutics The Woodlands, TX	uterine leiomyoma	Phase I/II (281) 719-3400
cell therapy	Cell Medica London, United Kingdom Center for Cell and Gene Therapy Houston, TX	cancer-associated with Epstein-Barr virus infections	Phase II www.cellmedica.co.uk (713) 798-1246
CLT-008	Cellerant Therapies San Carlos, CA	hematological malignancies	Phase I (650) 232-2122
CNTO 328 (siltuximab)	Centocor Ortho Biotech Horsham, PA	giant lymph node hyperplasia (see also multiple myeloma, prostate)	Phase II (800) 457-6399
CPI-613	Cornerstone Pharmaceuticals Cranbury, NJ	hematological malignancies (see also pancreatic)	Phase I (609) 409-7050

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
CS-7017 (efatutazone)	Daiichi Sankyo <i>Parsippany, NJ</i>	thyroid cancer (see also colorectal, lung)	Phase I/II (973) 944-2600
CX-4945	Cylene Pharmaceuticals <i>San Diego, CA</i>	giant lymph node hyperplasia (see also multiple myeloma, solid tumors)	Phase I (858) 875-5100
dalotuzumab	Merck <i>Whitehouse Station, NJ</i>	neuroendocrine tumors (see also breast, lung, pancreatic)	Phase II completed (800) 672-6372
<b>DCVax®-L</b> ovarian cancer vaccine	Northwest Biotherapeutics <i>Bothell, WA</i>	peritoneal cancer (see also ovarian)	Phase I/II (425) 608-3000
DM-CHOC-PEN	Dekk-Tec <i>New Orleans, LA</i>	central nervous system cancer	Phase I (504) 583-6135
E7050	Eisai <i>Woodcliff Lake, NJ</i>	squamous cell carcinoma (see also liver, stomach)	Phase I/II (888) 422-4743
EC-20	Endocyte <i>West Lafayette, IN</i>	diagnosis of folate receptor- positive cancers	Phase II (765) 463-7175
EC-145	Endocyte <i>West Lafayette, IN</i>	endometrial cancer (see also lung, ovarian)	Phase II (765) 463-7175
EGEN 001	EGEN <i>Huntsville, AL</i>	recurrent fallopian tube cancer, recurrent peritoneal cancer (see also ovarian)	Phase II (356) 512-0077
ELND002	Elan <i>Dublin, Ireland</i>	hematological malignancies	Phase I www.elan.com
ENMD-2076	EntreMed <i>Rockville, MD</i>	refractory metastatic late-stage cancer (see also multiple myeloma, ovarian)	Phase I (240) 864-2600
<b>Femara®</b> letrozole	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	endometrial cancer	Phase II (888) 669-6682
FP-1039	Five Prime Therapeutics <i>San Francisco, CA</i>	endometrial cancer (see also solid tumors)	Phase II (415) 365-5600
ganetespib	Synta Pharmaceuticals <i>Lexington, MA</i>	hematological malignancies (see also breast, colorectal, lung, stomach)	Phase I/II (781) 274-8200
GSK2110183 (AKT protein kinase inhibitor)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>	hematological malignancies	Phase I (888) 825-5249
HQK-1004	HemaQuest <i>Seattle, WA</i>	Epstein-Barr virus-related lymphoid malignancies	Phase II (206) 682-1233
IPI-493	Infinity Pharmaceuticals <i>Cambridge, MA</i>	hematological malignancies (see also solid tumors)	Phase I (617) 453-1000
<b>Ixempra®</b> ixabepilone	Bristol-Myers Squibb <i>Princeton, NJ</i>	endometrial cancer (see also breast, lung, stomach)	Phase II (212) 546-4000
KB004	KaloBios Pharmaceuticals <i>South San Francisco, CA</i>	hematological malignancies	Phase I (650) 243-3100

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
lenvatinib (E7080)	Eisai <i>Woodcliff Lake, NJ</i>	thyroid cancer (see also brain, kidney, liver, skin)	Phase III (888) 422-4743
		endometrial cancer	Phase II (888) 422-4743
MEDI-551 (anti-CD19 mAb)	AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i>	hematological malignancies	Phase I (800) 236-9933 (301) 398-0000
MER-101 (oral zoledronic acid)	Merrion Pharmaceuticals <i>Wilmington, NC</i>	bone metastases	Phase II (910) 799-1847
mesenchymal stem cell therapy (implant)	Cephalon <i>Frazer, PA</i> Mesoblast <i>New York, NY</i>	for bone marrow regeneration in patients undergoing bone marrow transplantation in hematological malignancies	Phase II (610) 344-0200 (212) 880-2060
<b>Mirena®</b> levonorgestrel-releasing intrauterine system	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	endometrial cancer	Phase II (888) 842-2937
MK-2206	Merck <i>Whitehouse Station, NJ</i>	neuroendocrine tumors (see also breast, colorectal)	Phase II (800) 672-6372
MLN4924	Millennium Pharmaceuticals <i>Cambridge, MA</i>	hematological malignancies (see also solid tumors)	Phase I (800) 390-5663
MLN8237	Millennium Pharmaceuticals <i>Cambridge, MA</i>	hematological malignancies (see also solid tumors)	Phase II (800) 390-5663
MLN9708	Millennium Pharmaceuticals <i>Cambridge, MA</i>	hematological malignancies (see also solid tumors)	Phase I (800) 390-5663
NBI-56418 (elagolix)	Abbott <i>Abbott Park, IL</i> Neurocrine Biosciences <i>San Diego, CA</i>	uterine leiomyoma	Phase I (847) 937-6100 (858) 617-7600
<b>Nexavar®</b> sorafenib	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i>	thyroid cancer (see also breast, colorectal, kidney, liver, lung, ovarian)	Phase III (888) 842-2837 (510) 597-6500
NTX-10	Neotropix <i>Malvern, PA</i>	neuroendocrine tumors (see also lung)	Phase I (617) 460-1200
octreotide implant	Endo Pharmaceuticals <i>Chadds Ford, PA</i>	malignant carcinoid syndrome	Phase II (610) 558-9800
<b>Opaxio™</b> paclitaxel poliglumex	Cell Therapeutics <i>Seattle, WA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>	peritoneal cancer (see also lung, ovarian)	Phase III (800) 215-2355 (888) 669-6682
OSI-906 (linsitinib)	OSI Pharmaceuticals <i>Melville, NY</i>	adrenocortical carcinoma (see also lung, ovarian)	Phase III (631) 962-2000

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
panobinostat (LBH589)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	hematological malignancies (see also lymphoma, multiple myeloma)	Phase II (888) 669-6682
pasireotide (SDM230)	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	neuroendocrine tumors	Phase III (888) 669-6682
		meningioma	Phase II (888) 669-6682
PF-04449913	Pfizer <i>New York, NY</i>	hematological malignancies	Phase I (860) 732-5156
PHA-848125	Nerviano Medical Sciences <i>Nerviano, Italy</i>	inoperable/unresectable thymoma	Phase II <a href="http://www.nervianoms.com">www.nervianoms.com</a>
phenoxodiol	Marshall Edwards <i>San Diego, CA</i>	fallopian tube cancer (see also ovarian, prostate)	Phase I/II (858) 792-6300
PM-00104	PharmaMar USA <i>Cambridge, MA</i>	endometrial cancer (see also cervical)	Phase II (617) 868-3797
PTC299	PTC Therapeutics <i>South Plainfield, NJ</i>	central nervous system cancer in children (see also breast, skin, solid tumors)	Phase I (908) 222-7000
<b>Quadramet®</b> samarium sm-153 lexidronam injection	EUSA Pharma <i>Langhorne, PA</i>	bone metastases (see also multiple myeloma, prostate, sarcoma)	Phase III (800) 833-3533
quarfloxin	Cylene Pharmaceuticals <i>San Diego, CA</i>	neuroendocrine tumors	Phase II (858) 875-5100
R763	Rigel Pharmaceuticals <i>South San Francisco, CA</i>	hematological malignancies	Phase I (650) 624-1100
RG7112	Roche <i>Nutley, NJ</i>	hematological malignancies (see also solid tumors)	Phase I (973) 235-5000
SAR245408 (XL-147)	Exelixis <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i>	endometrial cancer	Phase II (650) 837-7000 (800) 633-1810
SAR650984 (anti-CD38 naked mAb)	sanofi-aventis <i>Bridgewater, NJ</i>	hematological malignancies	Phase I (800) 633-1810
seliciclib	Cyclacel Pharmaceuticals <i>Short Hills, NJ</i>	nasopharyngeal cancer	Phase II (973) 847-5955
<b>Somatuline Autogel®</b> lanreotide	Tercica <i>Brisbane, CA</i>	neuroendocrine tumors	Phase III (650) 624-4900
S-PRAnt	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i>	uterine leiomyoma	Phase I (888) 842-2937

## OTHER CANCERS

Product Name	Sponsor	Indication	Development Status
<b>StemEx®</b> carlecortemcel-L (Orphan Drug)	Gamida Cell <i>Jerusalem, Israel</i> Teva Pharmaceuticals USA <i>North Wales, PA</i>	hematological malignancies (Fast Track)	Phase II/III (215) 591-3000
TAK-901	Millennium Pharmaceuticals <i>Cambridge, MA</i>	hematological malignancies (see also solid tumors)	Phase I (800) 390-5663
<b>Tarceva®</b> erlotinib	Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i>	gynecological cancer, squamous cell cancer (see also bladder, brain, breast, colorectal, head/neck, leukemia, liver, lung)	Phase II (650) 224-1000 (800) 572-1932
terameprocol (intravenous)	Erimos Pharmaceuticals <i>Houston, TX</i>	hematological malignancies (see also brain, cervical, head/neck, solid tumors)	Phase I (713) 541-2000
testosterone vaginal	Columbia Laboratories <i>Livingston, NJ</i>	uterine leiomyoma	Phase I (866) 566-5636
TG-02	S*Bio <i>Redwood City, CA</i>	hematological malignancies	Phase I (650) 730-2860
tremelimumab (CP-675206)	Pfizer <i>New York, NY</i>	genitourinary cancer (see also kidney, pancreatic, skin, stomach)	Phase II (860) 732-5156
V503	Merck <i>Whitehouse Station, NJ</i>	vulvovaginal cancer prevention (see also cervical)	Phase III (800) 672-6372
vandetanib	AstraZeneca <i>Wilmington, DE</i>	medullary thyroid cancer (Fast Track)	application submitted (800) 236-9933
VB-111	VBL Therapeutics <i>Or Yehuda, Israel</i>	thyroid cancer (see also brain)	Phase II www.vblrx.com
volasertib	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	urogenital cancer	Phase II (800) 243-0127
<b>Xgeva™</b> denosumab	Amgen <i>Thousand Oaks, CA</i>	prevention of bone metastases in breast cancer	Phase III (800) 772-6436
		prevention of bone metastases in prostate cancer	Phase III (800) 772-6436
<b>Zolinza®</b> vorinostat	Merck <i>Whitehouse Station, NJ</i>	gynecological cancer, peritoneal cancer (see also breast, multiple myeloma)	Phase I/II (800) 672-6372
<b>Zybrestat™</b> fosbretabulin (Orphan Drug)	OXiGENE <i>South San Francisco, CA</i>	thyroid cancer (combination therapy) (Fast Track) (see also lung, ovarian)	Phase II/III (650) 635-7000



## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
AFX-9901	Afecta Pharmaceuticals <i>Irvine, CA</i>		in clinical trials (949) 253-4688
AGS-6MF	Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i>		Phase I (800) 695-4321
AMG 337	Amgen <i>Thousand Oaks, CA</i>		Phase I (800) 772-6436
antineoplaston-A10 IV	Burzynski Research Institute <i>Houston, TX</i>		Phase II (713) 335-5697
antineoplaston-A10 oral	Burzynski Research Institute <i>Houston, TX</i>		Phase II (713) 335-5697
ANX-514 (docetaxel emulsion)	ADVENTRX Pharmaceuticals <i>San Diego, CA</i>		Phase I (858) 552-0866
ARRY-300	Array BioPharma <i>Boulder, CO</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i>		Phase I (303) 381-6600 (888) 669-6682
AVL-292	Avila Therapeutics <i>Waltham, MA</i>		Phase I (781) 891-0086
B7-2/GM-CSF cancer gene therapy	NuVax Therapeutics <i>Tustin, CA</i>		Phase I (714) 505-4461
BMS-663513 (anti-CD137)	Bristol-Myers Squibb <i>Princeton, NJ</i>		Phase I (212) 235-5000
CA-18C3	Xbiotech <i>Austin, TX</i>		Phase I (512) 386-2900
cancer compound	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
cancer compound	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
cancer compound	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
cancer compound	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
cancer vaccine (oral)	Immunitor USA <i>College Park, MD</i>		Phase I/II (301) 476-0930
carboxy- amidotriazole orotate (CTO)	Tactical Therapeutics <i>New York, NY</i>		Phase I (212) 651-9653

## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
chidamide	HUYA Bioscience International <i>San Diego, CA</i> Quintiles <i>Rsch. Triangle Park, NC</i>		Phase I (858) 798-8800 (919) 998-2003
cixutumumab	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>		Phase II (800) 545-5979 (212) 645-1405
CNDO-101	Coronado Biosciences <i>New York, NY</i>		Phase I (212) 332-1665
crenolanib (CP-868-596)	AROG Pharmaceuticals <i>Dallas, TX</i>		Phase I (214) 593-0500
docetaxel nanopharmaceutical	BIND Biosciences <i>Cambridge, MA</i>		Phase I (617) 419-3400
E7016	Eisai <i>Woodcliff Lake, NJ</i>		Phase I (888) 422-4743
E6201	Eisai <i>Woodcliff Lake, NJ</i>		Phase I (888) 422-4743
EC-0225	Endocyte <i>West Lafayette, IN</i>		Phase I completed (765) 463-7175
EVO 011	Evolve Oncology <i>New York, NY</i>		in clinical trials (646) 723-8941
EVO 044	Evolve Oncology <i>New York, NY</i>		in clinical trials (646) 723-8941
<b>FANG™</b> vaccine (autologous tumour cell vaccine)	Gradalis <i>Carrollton, TX</i>		Phase II (214) 442-8100
fenretinide intravenous (4-HPR)	CerRx <i>Lubbock, TX</i>		Phase I www.cerrx.com
GI-6207	GlobeImmune <i>Louisville, CO</i>		Phase I (303) 625-2700
GSK2126458 (PI3 kinase inhibitor)	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>		Phase I (888) 825-5249
GSK2586881	GlaxoSmithKline <i>Rsch. Triangle Park, NC</i>		Phase I (888) 825-5249
hTERT cancer vaccine (human telomerase reverse transcriptase)	Merck <i>Whitehouse Station, NJ</i> Vical <i>San Diego, CA</i>		Phase I (800) 672-6372 (858) 646-1100
HuCAL-derived antibody	Centocor Ortho Biotech <i>Horsham, PA</i> MorphoSys <i>Munich, Germany</i>		Phase I (800) 457-6399

## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
IMC-3G3 (olaratumab)	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>		Phase II (800) 545-5979 (212) 645-1405
IMC-18F1 (icrucumab)	Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>		Phase II (800) 545-5979
ISIS-EIF4ERx (eIF-4E ASO)	Eli Lilly <i>Indianapolis, IN</i> Isis Pharmaceuticals <i>Carlsbad, CA</i>		Phase II (800) 545-5979 (760) 931-9200
ixabepilone (oral formulation)	Bristol-Myers Squibb <i>Princeton, NJ</i>		Phase I/II (212) 546-4000
LY2090314	Eli Lilly <i>Indianapolis, IN</i>		Phase II (800) 545-5979
LY2157299 (TGF $\beta$ inhibitor)	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2181308 (survivin ASO)	Eli Lilly <i>Indianapolis, IN</i> Isis Pharmaceuticals <i>Carlsbad, CA</i>		Phase II (800) 545-5979 (760) 931-9200
LY2334737 (Gem prodrug)	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2523355 (Eg5 inhibitor)	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2584702	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2603618 (ChK-1 inhibitor)	Eli Lilly <i>Indianapolis, IN</i>		Phase II (800) 545-5979
LY2606368	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2624587	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2780301	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2801653	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2874455	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2875358	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
LY2940680	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979

## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
MK-4101	Merck <i>Whitehouse Station, NJ</i>		Phase I (800) 672-6372
MK-8033	Merck <i>Whitehouse Station, NJ</i>		Phase I (800) 672-6372
MPC-3100	Myrexix <i>Salt Lake City, UT</i>		Phase I (801) 214-7800
notch signalling pathway inhibitor	Eli Lilly <i>Indianapolis, IN</i>		Phase I (800) 545-5979
NRX-4204	NuRx Pharmaceuticals <i>Irvine, CA</i>		Phase I (949) 336-7111
OPB-31121	Otsuka America Pharmaceutical <i>Rockville, MD</i>		Phase I (800) 562-3974
OPB-51602	Otsuka America Pharmaceutical <i>Rockville, MD</i>		Phase I (800) 562-3974
OVI-237	OncoVista <i>San Antonio, TX</i>		Phase II (210) 677-6000
oxaliplatin liposomal	Mebiopharm <i>Tokyo, Japan</i>		Phase I/II <a href="http://www.mebiopharm.com">www.mebiopharm.com</a>
PBI-05204	Phoenix Biotechnology <i>San Antonio, TX</i>		Phase I (877) 593-8945
PF-00562271	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-03084014	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-04554878	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PF-05212384 (PKI-587)	Pfizer <i>New York, NY</i>		Phase I (860) 732-5156
PRT062607	Portola Pharmaceuticals <i>South San Francisco, CA</i>		Phase I (650) 246-7000
QBI-139	Quintessence Biosciences <i>Madison, WI</i>		Phase I (608) 441-2950
SAR153192 (anti-DLL4 mAb)	Regeneron Pharmaceuticals <i>Tarrytown, NY</i> sanofi-aventis <i>Bridgewater, NJ</i>		Phase I (914) 345-7400 (800) 833-1610
SAR245409 (XL765)	Exelixis <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i>		Phase II (650) 837-7000 (800) 633-1810

## UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

Product Name	Sponsor	Indication	Development Status
SAR307746 (REGN910)	Regeneron Pharmaceuticals <i>Tarrytown, NY</i> sanofi-aventis <i>Bridgewater, NJ</i>		Phase I (914) 345-7400 (800) 833-1610
SB1578	S*Bio <i>Redwood City, CA</i>		Phase I (650) 730-2860
tasisulam	Eli Lilly <i>Indianapolis, IN</i>		Phase II (800) 545-5979
TL32711	TetraLogic Pharmaceuticals <i>Malvern, PA</i>		Phase I/II (610) 889-9900
V930/V932 (hTERT cancer vaccine)	Merck <i>Whitehouse Station, NJ</i> Vical <i>San Diego, CA</i>		Phase I completed (800) 672-6372 (858) 646-1100
VTX-2337	VentiRx Pharmaceuticals <i>San Diego, CA</i>		Phase I completed (858) 436-1530
XL999	Symphony Evolution <i>Rockville, MD</i>		Phase I <a href="http://www.symphonyevolution.com">www.symphonyevolution.com</a>
ZYC 300	Eisai <i>Woodcliff Lake, NJ</i>		Phase I (888) 422-4743

The content of this report has been obtained through industry sources and the Adis "R&D Insight" database based on the latest information. **Report current as of March 18, 2011.** The information may not be comprehensive. For more specific information about a particular product, contact the individual company directly or go to [www.clinicaltrials.gov](http://www.clinicaltrials.gov). The entire series of *Medicines in Development* is available on PhRMA's web site.

A publication of PhRMA's Communications & Public Affairs Department. (202) 835-3460

[www.phrma.org](http://www.phrma.org) | [www.innovation.org](http://www.innovation.org) | [www.pparx.org](http://www.pparx.org) | [www.buysafedrugs.info](http://www.buysafedrugs.info)

Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.

Copyright © 2011 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.

## GLOSSARY

**actinic keratoses**—Roughness and thickening of the skin caused by overexposure to the sun's ultraviolet rays. It can degenerate into a skin cancer called squamous cell carcinoma.

**adenocarcinoma**—Malignant tumor derived from a gland or glandular tissue.

**adjunctive treatment**—An auxiliary treatment that is secondary to the main treatment.

**adjuvant**—A substance or drug that aids another substance in its action.

**allogeneic**—Refers to having cell types that are distinct and cause reactions in the immune system.

**application submitted**—An application for marketing has been submitted by the company to the Food and Drug Administration (FDA).

**ascites**—Excess fluid in the space between the tissues lining the abdomen and abdominal organs (the peritoneal cavity).

**basal cell cancer**—Cancer of the lower layers of the skin.

**B-cell**—A class of white blood cells important to the body's immune system.

**biliary**—Relating to bile.

**carcinoma**—A malignant tumor that arises from epithelial tissues, such as skin.

**cervical**—Relating to the neck of the uterus.

**chemoprotection**—A therapeutic technique in which bone marrow cells are removed from an individual with cancer and are genetically modified to withstand higher doses of chemotherapy before being returned to the donor.

**cholangiocarcinoma**—A malignancy of the biliary duct system that may originate in the liver and extrahepatic bile ducts. More than 90 percent are **adenocarcinomas**, and the remainder are squamous cell tumors. Cholangiocarcinomas tend to grow slowly and to infiltrate the walls of the ducts. Each year, approximately 2,500 cases

occur, and the average incidence is 1 case per 100,000 people per year.

**cutaneous**—Pertaining to the skin.

**dysplasia**—Abnormal tissue development.

**gastric**—Of or relating to the stomach.

**GISTs**—Gastrointestinal stromal tumors are uncommon tumors of the GI tract. Not all GISTs are cancerous; some are benign. Although these cancers can arise anywhere in the GI tract, they occur most often in the stomach (60% to 70%) and less commonly in the small intestine (20% to 30%). The rest are found in the esophagus, large intestine, rectum, and anus. About 80% of people diagnosed with GIST are older than 50. It is slightly more common in men. Blacks are more likely to develop GISTs than whites.

**glioblastoma**—A fast growing and highly malignant type of brain tumor arising from glial (supporting) cells within the brain. There are about five to 10 new cases per million population per year in the United States, and the cause is unknown.

**glioma**—A type of brain tumor arising from the supporting glial cells within the brain. Gliomas make up about 60 percent of all primary brain tumors and are frequently malignant.

**graft-versus-host disease (GVHD)**—A complication in bone marrow transplants where immune system cells attack the transplant recipient's tissues.

**head and neck cancer**—The term given to a variety of malignant tumors that develop in the mouth, throat, paranasal sinuses, nasal cavity, larynx, and salivary glands. Many authorities also include skin tumors of the face and neck and tumors of the cervical lymph nodes. There are more than half a million survivors of oral, head, and neck cancer living in the United States today.

**hematological malignancies**—Cancers of the blood or blood-forming tissues, such as **leukemia**, **Hodgkin's** and **non-Hodgkin's lym-**

**phomas**, AIDS-related malignancies, **multiple myeloma**, myelodysplasia and myeloproliferative disorders.

**hepatocellular cancer/carcinoma**—A cancer that begins in the liver cells.

**hyperuricemia**—An abnormally high uric acid level in the blood.

**imaging agent**—A substance used to enhance x-ray images of organs and spaces in the body.

**intraepithelial neoplasia, anal (AIN) & cervical (CIN)**—AIN is a consequence of chronic human papillomavirus infection in the anal canal and appears to be driven by high viral loads of human papillomavirus. What is known of its natural history resembles that of cervical intraepithelial neoplasia. **Dysplasia** and cervical intraepithelial neoplasia (CIN) are different terms or names for the same condition—it is a precursor to **cervical cancer**. CIN may be mild, moderate or severe.

**Kaposi's sarcoma**—A rare, malignant skin tumor that occurs in some AIDS patients. It can be accompanied by fever, enlarged lymph nodes and gastrointestinal problems.

**leiomyoma**—A benign neoplasm derived from smooth muscle.

**leukemia**—A form of cancer in which abnormally growing white blood cells are scattered throughout the body and bone marrow. They can take over the marrow and prevent it from making enough normal blood cells (white, red and platelets), leaving the patient highly susceptible to serious infections, anemia and bleeding episodes. The cells can also spill into the blood, infiltrating and interfering with the function of other organs. The four main types of leukemia are: **acute lymphoblastic leukemia (ALL)**, **acute myeloid leukemia (AML)**, **chronic lymphocytic leukemia (CLL)**, and **chronic myeloid leukemia (CML)**. The acute types have a rapid onset, and overwhelming infection or blood loss can cause death. The chronic forms progress much more slowly.

**lung cancer**—The leading cause of cancer deaths in both men and

## GLOSSARY

women. There are several types of lung cancer, the most common being squamous cell carcinoma, small (oat) cell carcinoma, adenocarcinoma and large cell carcinoma. Each has a different growth pattern and response to treatment. The squamous cell, small cell and large cell types are all strongly associated with tobacco abuse.

**lymphoma**—Cancers in which the cells of lymphoid tissue, found mainly in the lymph nodes and spleen, multiply unchecked. Lymphomas fall into two categories: Hodgkin disease, characterized by a particular kind of abnormal cell, and **non-Hodgkin lymphomas**, which vary in their malignancy according to the nature and activity of the abnormal cells. **Mantle cell lymphoma** is a type of non-Hodgkin lymphoma.

**macroglobulinemia**—A disorder in which plasma cells produce an excessive quantity of macroglobulins (large antibodies) that accumulate in the blood. It results from a group of abnormal, cancerous lymphocytes and plasma cells. Men are affected more often than women, and the average age at onset is 65.

**mastocytosis**—A condition characterized by infiltration of mast cells into the tissues of the body. Mast cells are connective tissue cells which release chemicals including histamine that are very irritating and cause itching, swelling, and fluid leakage from cells.

**medullary**—Relating to the medulla (any soft marrow-like structure, especially the innermost part) or marrow.

**melanoma**—A cancer made up of pigmented (usually brown-colored) skin cells anywhere in the body.

**mesothelioma**—A tumor of the lining of the lung and chest cavity (the pleura).

**metastases/metastatic**—Areas of secondary cancer that have spread from the primary or original cancer site.

**mucositis**—The swelling, irritation, and ulceration of the mucosal cells that line the digestive tract. Mucositis

can occur anywhere along the digestive tract from the mouth to the anus. It can be a very troublesome and painful side effect of chemotherapy.

**multiple myeloma**—A malignant condition of middle to old age, characterized by the uncontrolled proliferation and disordered function of plasma cells in the bone marrow. The condition, which makes the patient particularly prone to infection, is rare, with about three new cases annually per 100,000 population.

**myeloablation**—A severe form of myelosuppression, a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets. It is a side effect of some cancer treatments.

**myelodysplastic syndromes (MDS)**—Blood disorders that ultimately are fatal. Patients usually succumb to infections or bleeding. The term “preleukemia” has been used to describe these disorders.

**neoadjuvant therapy**—Chemotherapy, radiation therapy, or hormone therapy given before the primary or main treatment. Neoadjuvant therapy, like chemotherapy and radiation therapy, is often given before surgery to reduce the size of a tumor or to make surgery less complicated.

**neuroblastoma**—A tumor of the adrenal glands or sympathetic nervous system (the part of the nervous system responsible for certain automatic body functions, such as the control of heart rate). Neuroblastomas are the most common extracranial (outside the skull) solid tumors of childhood.

**osteosarcoma**—Cancer of the bone that occurs predominantly in adolescents and young adults. It accounts for 5 percent of cancer in children

**peritoneal**—Relating to the peritoneum, the membrane that lines the abdominal cavity and covers most of the abdominal organs.

**Phase 0**—First-in-human trials conducted in accordance with FDA’s 2006 guidance on exploratory Investigational New Drug (IND) studies designed to speed up development of promising drugs by establishing very early on whether the agent behaves in human subjects as was anticipated from preclinical studies.

**Phase I**—Safety testing and pharmacological profiling of new drugs in small numbers of humans.

**Phase II**—Effectiveness testing and identification of side effects of new drugs in humans.

**Phase III**—Extensive clinical trials in humans to verify effectiveness and monitor adverse reactions of new drugs.

**prolactinoma**—A noncancerous pituitary tumor that produces a hormone called prolactin, which results in too much prolactin in the blood.

**refractory**—Resistant to treatment or cure.

**sarcoma**—A malignant tumor that arises from deep body tissues, such as muscle, bone or fibrous tissue.

**T-cell**—One of two main classes of white blood cells called lymphocytes, which are important to the body’s disease-fighting immune system.

**thrombocytopenia**—A reduction in the number of platelet cells in the blood, which causes a tendency to bleed, especially from the smaller blood vessels.

**thymoma**—Although rare, thymomas are the most common tumor of the thymus, a small organ located in the upper chest just below the neck that produces certain types of white blood cells (lymphocytes) before birth and during childhood. Thymomas arise from thymic epithelial cells, which make up the covering of the thymus. Up to 40 percent of thymomas are invasive. They affect men and women equally and are usually diagnosed between the ages of 40 and 60. Thymomas are uncommon in children.

**unresectable**—Unable to be removed (resected) by surgery.



## SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

### Overview<sup>1</sup>

- In 2010, more than 1.5 million new cancer cases were expected to be diagnosed. The National Cancer Institute estimates that approximately 11.4 million Americans with a history of cancer were alive in January 2006. The 5-year relative survival rate for all cancers diagnosed between 1999 and 2005 is 68 percent, up from 50 percent in the mid-70s.
- Men have a little less than a 1 in 2 lifetime risk of developing cancer, and for women, the risk is a little more than 1 in 3. About 78 percent of all cancers are diagnosed in people ages 55 and older.
- Scientific evidence suggests that about one-third of the cancer deaths expected this year will be related to overweight or obesity, physical inactivity, and nutrition, and thus could be prevented.
- Cancer is the second leading cause of death by disease—1 of every 4 deaths—in the United States, exceeded only by heart disease. This year, an estimated 569,490 are expected to die of cancer, more than 1,500 people a day.

### Costs<sup>1</sup>

- The National Institutes of Health estimates overall costs for cancer in 2010 at \$263.8 billion: \$102.8 billion for direct medical costs (total of all health expenditures); \$20.9 billion for indirect morbidity costs (e.g., cost of lost productivity due to illness); and \$140.1 billion for indirect mortality costs (cost of lost productivity due to premature death).

### Pain

- **Pain**, which can be caused by the disease itself or by treatments, is common in people with cancer, although not all people with cancer will experience pain. Approximately 30 percent to 50 percent of people with cancer experience pain while undergoing treatment, and 70 percent to 90 percent of people with advanced cancer experience pain.<sup>2</sup>
- Breakthrough **cancer pain** is common among people with cancer-related pain. It occurs in 50 percent – 90 percent of oncology inpatient settings, 89 percent of home care and inpatient hospice settings, 74 percent of U.S. pain clinics, and 33 percent of community-based oncology practices.<sup>3</sup>
- Breakthrough **cancer pain** is associated with higher costs for people who suffer from it compared to those who do not, for example, higher hospitalization rates (36.9 percent compared to 22.5 percent) and higher estimated annual costs of care (\$1.7 million compared to \$192,000).<sup>3</sup>

## SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

### New Cancer Cases/Deaths<sup>1</sup>

Cancer Type	Estimated 2010 New Cases	Estimated 2010 Deaths
All Sites	1,529,560	569,490
Male	789,620	299,200
Female	739,940	270,290
Acute Lymphocytic Leukemia	5,330	1,420
Male	3,150	790
Female	2,180	630
Acute Myeloid Leukemia	12,330	8,950
Male	6,590	5,280
Female	5,740	3,670



## SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

### New Cancer Cases/Deaths<sup>1</sup> (continued)

Cancer Type	Estimated 2010 New Cases	Estimated 2010 Deaths
Bladder Cancer	70,530	14,680
Male	52,760	10,410
Female	17,770	4,270
Bone Cancer (and joints)	2,650	1,460
Male	1,530	830
Female	1,120	630
Brain Cancer (and other nervous system)	22,020	13,140
Male	11,980	7,420
Female	10,040	5,720
Breast Cancer	209,060	40,230
Male	1,970	390
Female	207,090	39,840
Cervical Cancer/Uterine Cancer	55,670	12,160
Male	—	—
Female	55,670	12,160
Chronic Lymphocytic Leukemia	14,990	4,390
Male	8,870	2,650
Female	6,120	1,740
Chronic Myeloid Leukemia	4,870	440
Male	2,800	190
Female	2,070	250
Colorectal Cancer	142,570	51,370
Male	72,090	26,580
Female	70,480	24,790
Esophageal Cancer	16,640	14,500
Male	13,130	11,650
Female	3,510	2,850
Kidney Cancer (and renal pelvis)	58,240	13,040
Male	35,370	8,210
Female	22,870	4,830
Leukemia (all types)	43,050	21,840
Male	24,690	12,660
Female	18,360	9,180
Liver Cancer	24,120	18,910
Male	17,430	12,720
Female	6,690	6,190

## SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

### New Cancer Cases/Deaths<sup>1</sup> (continued)

Cancer Type	Estimated 2010 New Cases	Estimated 2010 Deaths
Lung Cancer (and bronchus)	222,520	157,300
Male	116,750	86,220
Female	105,770	71,080
Lymphoma (all types)	74,030	21,530
Male	40,050	11,450
Female	33,980	10,080
Lymphoma (non-Hodgkin's)	65,540	20,210
Male	35,380	10,710
Female	30,160	9,500
Melanoma-Skin Cancer	68,130	8,700
Male	38,870	5,670
Female	29,260	3,030
Multiple Myeloma	20,180	10,650
Male	11,170	5,760
Female	9,010	4,890
Ovarian Cancer	21,880	13,850
Male	—	—
Female	21,880	13,850
Pancreatic Cancer	43,140	36,800
Male	21,370	18,770
Female	21,770	18,030
Prostate Cancer	217,730	32,050
Male	217,730	32,050
Female	—	—
Stomach Cancer	21,000	10,570
Male	12,730	6,350
Female	8,270	4,220

#### Sources:

1. *Cancer Facts & Figures 2010*, American Cancer Society ([www.cancer.org](http://www.cancer.org))
2. Lesage P. and Portenoy RK. Cancer Control; *Journal of the Moffitt Cancer Center* 1999;6(2):136-145.
3. American Pain Foundation ([www.painfoundation.org](http://www.painfoundation.org))

## THE DRUG DISCOVERY, DEVELOPMENT AND APPROVAL PROCESS

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

		Clinical Trials			FDA	Phase IV
Discovery/ Preclinical Testing		Phase I	Phase II	Phase III		
Years	6.5	1.5	2	3.5	1.5	
Test Population	Laboratory and animal studies	20 to 100 healthy volunteers	100 to 500 patient volunteers	1,000 to 5,000 patient volunteers	Review process/ approval	Additional post-marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations	Determine safety and dosage	Evaluate effectiveness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use		
Success Rate	5,000 compounds evaluated	5 enter trials			1 approved	

## THE DRUG DEVELOPMENT AND APPROVAL PROCESS

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development, based on drugs approved from 1994 through 1998. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$1.3 billion to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are developed as follows:

**Preclinical Testing.** A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

**Investigational New Drug Application (IND).** After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

**Clinical Trials, Phase I.** These tests usually involve

about 20 to 100 normal, healthy volunteers. The tests study a drug's safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of its action.

**Clinical Trials, Phase II.** In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug's effectiveness and determine the early side effect profile.

**Clinical Trials, Phase III.** This phase usually involves 1,000 to 5,000 patients in clinics and hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events.

**New Drug Application (NDA)/Biologic License Application (BLA).** Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more. The average review time for the 25 new therapeutics approved by the FDA in 2009 was 13.3 months.

**Approval.** Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. Pharmaceutical companies invested an estimated \$67.4 billion in research and development in 2010.

## TRACKING THE BIOPHARMACEUTICAL RESEARCH PIPELINE

Today, more than 3,000 new medicines are in development in the United States. Many of these potential new medicines will fail in clinical trials, but some may represent tomorrow's new treatments. Bringing each new medicine to patients will require, on average, 10 to 15 years of testing and review.

PhRMA publishes several reports that track the biopharmaceutical research pipeline for many diseases, including the leading causes of death among Americans—heart disease, cancer, and stroke. The reports include medicines currently in clinical trials or at the U.S. Food and Drug Administration (FDA) for review. Below is a summary of our most popular reports.

- **Cancer**—There are few things that cause patients more fear and uncertainty as a cancer diagnosis. Yet today—because of a steady stream of new and improved medicines and treatments—cancer can increasingly be managed and even beaten. *The 2010 report found 887 medicines in the pipeline.*
- **Heart Disease and Stroke**—Keeping up the momentum of drug discovery that has helped cut deaths from heart disease and stroke in half in the past three decades, biopharmaceutical companies are working on new medicines for these diseases. *The 2011 report found 299 medicines in the pipeline.*
- **Diabetes**—Approximately 4,110 people are diagnosed with diabetes every day. To help fight this disease, pharmaceutical and biotechnology researchers are working on new medicines to treat it and related conditions. *The 2010 report found 235 medicines in the pipeline.*
- **Mental Illnesses**—Pharmaceutical and biotechnology researchers are testing many new medicines to help the more than 450 million people worldwide who suffer from some form of mental illness. *The 2010 report found 313 medicines in the pipeline.*
- **Biotechnology**—Millions of people have already benefited from medicines and vaccines developed through biotechnology, and a new report offers hope that many more will benefit in the future. *The 2008 report found 633 medicines in the pipeline.*
- **Children**—Biopharmaceutical researchers are testing medicines to meet the special needs of children. These medicines offer hope that the significant improvements achieved in children's health over the past few decades will continue and even accelerate. *The 2010 report found 234 medicines in the pipeline.*
- **Infectious Diseases**—Throughout history, infectious diseases have taken a devastating toll on the lives and well-being of people around the world. Today, vaccines and antibiotics have proven to be effective treatments in many cases, but infectious diseases still pose a very serious threat to patients. Infectious diseases may never be eradicated. But, new knowledge, new technologies, and a huge commitment of resources by America's biopharmaceutical research companies and the government can help meet the continuing—and ever-changing—threat from infectious diseases. *The 2010 report found 395 medicines in the pipeline.*



New Medicines. New Hope.®

Pharmaceutical Research and Manufacturers of America  
950 F Street, NW  
Washington, DC 20004

[www.phrma.org](http://www.phrma.org) | [www.innovation.org](http://www.innovation.org) | [www.pparx.org](http://www.pparx.org) | [www.buysafedrugs.info](http://www.buysafedrugs.info)